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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that 
leads to irreversible memory loss. An escalating burden of AD, with an ever 
growing aging population, will lead to an extensive increase in healthcare 
costs. AD is characterized by the presence of pathological features including 
intracellular neurofibrillary tangles, extracellular amyloid plaques, extensive 
neuroinflammation and neuronal/synaptic loss in selected areas of the brain. 
Although several studies have specified that neuroinflammation is associated 
with AD pathology, the exact mechanisms have not been fully elucidated. 
Moreover, a better understanding of the mechanisms behind the initiation and 
progression of AD pathology will guide future studies to develop effective 
treatment strategies.  
Deregulation of Cyclin-dependent kinase 5 (Cdk5) by production of its 
hyperactivator p25 (a fragment of its normal activator, p35), is involved in the 
formation of tau and amyloid pathology reminiscent of AD. Recent studies 
have shown that p25/Cdk5 hyperactivation is also associated with robust 
neuroinflammation. Therefore, the transgenic mouse that overexpresses p25 
has the potential to be used as a mechanistic model to investigate the 
neuroinflammation and associated neurodegenerative changes in vivo. 
Although several studies supported the role of Cdk5 in neurodegeneration, the 
actual mechanism behind the initiation of p25/Cdk5-mediated 
neuroinflammation and its role in the progression of neurodegeneration has 
not been clearly demonstrated. Hence, this thesis aims to investigate the 
p25/Cdk5-mediated neuroinflammatory mechanisms using in vitro p25 
overexpressing neurons and to translate this in vivo in the CamK2a-p25 
inducible transgenic (p25Tg) mice. The first half of this thesis deals with the 
characterization of the neuroinflammatory pathways regulated by p25 
overexpression and the second half covers the investigation of beneficial 
effects of early intervention of p25-mediated neuroinflammation in the 
progression of neurodegeneration in p25Tg mice using a potent natural anti-
inflammatory agent, curcumin.  
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Results showed the onset of neuroinflammation in p25Tg mice and the 
involvement of astrogliosis as an early event in the absence of microgliosis, 
tau and amyloid pathology. Subsequent in vitro characterization identified that 
neuronal cytosolic phospholipase 2 (cPLA2) upregulation-mediated 
production of a soluble lipid, lysophosphatidylcholine (LPC) was crucial for 
the initiation of p25 overexpression-mediated neuroinflammation and the 
progression of neurodegeneration. In addition, results from in vitro gene 
silencing experiments clearly showed that the inhibition of p25-induced 
neuroinflammation reduced the progression of tau/amyloid pathology and 
subsequent neurodegeneration. 
These novel findings were then validated further in vivo in p25Tg mice using 
curcumin, a multipotent natural compound that can cross the blood-brain 
barrier without any adverse side effects. Results showed an obvious reduction 
in the major events of inflammatory pathways including astrocyte activation, 
cPLA2 upregulation and LPC production. Moreover, this curcumin-mediated 
suppression of neuroinflammation efficiently limited the progression of p25-
induced tau/amyloid pathology and in turn ameliorated the p25-induced 
cognitive impairments.   
Together, results from this study have identified a novel pathway behind p25-
induced neuroinflammation and subsequent neurodegeneration. Data from this 
study could open exciting avenues of research to find effective therapeutic 
interventions against neuroinflammation and subsequent neurodegeneration 
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CHAPTER 1: Introduction 
 
1.1 Alzheimer’s disease (AD) 
Alzheimer’s disease (AD), the most common form of dementia, is a chronic, 
progressive and irreversible degenerative disorder of the brain that will 
eventually lead to memory loss. Dementia is a group of symptoms that is 
coupled with a decrease in mental abilities such as thinking, reasoning and 
memory. Even though the precise cause of AD is unknown, the possible risk 
factors are increasing age, life style factors, genetic predisposition and 
previous head injuries. AD is definitively diagnosed only after autopsy and 
there is currently no cure for AD. However, promising research is underway 
for early diagnosis and effective treatment of AD.   
1.1.1 History of AD 
The presence of dementia (Latin: “de mens”, without mind) in old people has 
been reported thousands of years ago by Greek and Roman scholars. 
Alzheimer’s disease was first discovered by a German neurologist and 
psychiatrist, Dr. Alois Alzheimer (1864–1915) in 1906 (Dahm, 2006). AD was 
first observed in a female patient, Auguste D. on November 26
th
 , 1901 and 
she displayed spatial and temporal disorientation, general confusion, anxiety, 
memory loss, impaired comprehension, psychosocial inaptitude and 
progressive aphasia (Maurer et al., 1997). Dr. Alzheimer followed her care for 
five years, until her death in 1906. Later, an autopsy was performed on her 
brain by Dr.  Alzheimer and his colleagues and they found a massive loss of 
neurons throughout the brain. Furthermore, they observed peculiar thick fibrils 
and deposits of an unidentified substance throughout the cerebral cortex. Dr. 
Alzheimer presented his results of the case of Auguste D. for the first time in 
the 37
th
 meeting of South-West German psychiatrists in Tübingen, Germany 
on November 3
rd
, 1906 and he published the Auguste D. case in 1911 
(Alzheimer, 1911). Dr. Alzheimer’s mentor, Dr. Emil Kraepelin, first renamed 
this presenile dementia as Alzheimer’s disease (AD) in a text book (Kraepelin, 
1910; Moller and Graeber, 1998). 
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1.1.2 Epidemiology of AD 
Currently, it is estimated that 6.8 million people in the United States have 
dementia. Nearly, two-thirds of total cases are women and 4% have younger-
onset AD. On average, the estimated annual incidence is approximately 170 
new cases per 1,000 people between the ages of 75 to 84. In addition, the 
aggregate payments for healthcare and long-term care for people with 
dementia in America are projected to increase from $203 billion in 2013 to 
$1.2 trillion in 2050 (Hebert et al., 2001; Hebert et al., 2013; Thies and Bleiler, 
2013).  
According to the World Alzheimer Report 2009, there are an estimated 35.6 
million people living with AD and other dementias worldwide. This number 
will nearly double and reach 66 million by the year 2030 and 115 million by 
2050. One new case of dementia is diagnosed every 4 seconds, or 7.7 million 
cases per year. Based on this global incidence report, more than 600 million 
people in the world are expected to live with this disease in the next 40 years. 
According to the World Alzheimer Report 2010, the estimated worldwide cost 
of dementia in 2010 was US$ 604 billion, nearly equivalent to the cost of the 
1% of the world’s gross domestic product figure (Wortmann, 2012).   
In Singapore, with the ever growing aging population, the escalating burden of 
AD and the others forms of dementia poses a huge problem for sufferers, 
families of patients and the healthcare industry. According to dementia 
statistics in the Asia pacific region in 2006, the prevalence of dementia in 
Singapore was approximately 22,000 in the year 2005 and this figure would 
reach 53,000 by 2020 (Alzheimer's Disease Association Singapore). A recent 
epidemiological study in Singapore reported that nearly 3-8% of people 
between the ages of 69-75 suffer from dementia and 60% of dementia cases 
over the age of 69 were AD (Sahadevan et al., 2008).  
1.1.3 Types of AD 
Sporadic or late onset AD is the most common form of AD, making up 90% of 
AD cases. It mainly affects people over 65 years of age and is caused by a 
chronic, nonlinear and dynamic pathophysiological cascade that leads to 
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neurodegeneration and late-stage clinical dementia (Hampel and Lista, 2012). 
Early-onset AD without a clear inheritance pattern, accounting for less than 
10% of all AD cases, is a rare form of the disease in which individuals are 
diagnosed before age 65. Early-onset AD is mainly caused by mutations in 
one of three genes: presenilin 1 (PS1), presenilin 2 (PS2) or amyloid 
precursor protein (APP) (Miyoshi, 2009). In addition, Familial AD (FAD), a 
form of entirely inherited disease, accounts for less than 1% of all cases of 
AD. It is extremely rare and has a much earlier onset, often starts in the 40s 
(Bateman et al., 2012). 
1.1.4 Risk factors for AD  
Advancing age is the best known risk factor for AD and the probability of 
developing AD doubles every five years after the age of 65. Many studies 
have investigated the factors that increase the risk of developing AD and some 
examples are gender (Vina and Lloret, 2010), genetic predisposition (Bertram 
et al., 2007), family history (Breitner et al., 1986), education (Addae et al., 
2003), hypertension (Kalaria et al., 2008), diabetes (Kroner, 2009) and a 
history of head trauma (Guo et al., 2000). Studies also reported that certain 
lifestyle factors can decrease the progress of AD and these include diet 
(Solfrizzi et al., 2011), happiness (Berger et al., 1999) and exercise (Larson et 
al., 2006). 
1.1.5 Diagnosis of AD 
Although a brain autopsy is a definitive method of diagnosing AD, 
comprehensive diagnostic workup such as mental and behavioral tests and 
physical examinations by skilled physicians can diagnose AD with 90% 
accuracy. A medical history taken from the patient and from an informant is 
important in identifying the rate of mental deterioration (McKhann et al., 
1984). In addition, physical and neurological examination should be 
conducted to rule out the other causes of symptoms such as chronic infection, 
vitamin deficiency, thyroid disorders and problems with the nervous system. 
Furthermore, recent studies suggested that combined measurements of tau 
protein, Aβ peptide species and inflammatory molecules from cerebrospinal 
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fluid (CSF) could provide detailed information on disease progression 
(Blennow and Zetterberg, 2009; Perrin et al., 2009). 
Recently, neuroimaging techniques such as magnetic resonance imaging 
(MRI) (Teipel et al., 2010), positron emission tomography (PET) (Jia et al., 
2011), single-photon emission computerized tomography (SPECT) & 
fluorodeoxyglucose-PET (FDG-PET) (Jagust et al., 2001; Herholz, 2011), 
functional MRI (fMRI) (Gountouna et al., 2010), amyloid-PET (Forsberg et 
al., 2008) and diffusion tensor imaging (DPI) (Beaulieu, 2002) have been 
widely applied to diagnose AD and discover early changes in brain structure. 
Additionally, neuropsychological tests may provide further information for the 
diagnosis of AD. Cognition tests including simple screening tests like the 
Mini-Mental State Examination (MMSE), the cognitive part of the 
Alzheimer’s Disease Assessment Scale (ADAScog), the Severe Impairment 
Battery, the Neuropsychiatric Inventory (NPI) and the scale for assessment of 
behavioral symptoms in AD (Behave-AD) were also conducted to investigate 
impairments in mental abilities (Folstein et al., 1975; Rosen et al., 1984; 
Khachaturian, 1985; Harrison et al., 2007; Ito et al., 2007).  
1.1.6 Clinical features of AD 
AD usually starts with slight memory loss that slowly reduces thinking skills 
and ultimately erodes the ability to perform daily tasks. Other major symptoms 
include problems with attention, confusion, impaired judgment, language 
disturbance, restlessness, hostility, withdrawal, irritability and impulsivity 
(Bird, 1993). Although the cause of spread of the disease is still poorly 
understood, the pattern of spreading has been studied extensively by several 
clinical studies (Locascio et al., 1995). Predicting the course of the disease is a 
key component that often forms the basis of treatment and healthcare 
decisions. The clinical features of AD are commonly classified into three 
stages: pre-clinical AD, mild cognitive impairment, and severe stage dementia. 
This is based on a set of criteria published by the working group of the 
National Institute on Aging (NIA) and the Alzheimer’s Association (AA) to 
define the progressive pattern of cognitive and functional impairments 
(Croisile et al., 2012). However, highly variable individual patterns of 
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cognitive decline may affect these predictions (Tandon et al., 2006; Komarova 
and Thalhauser, 2011).  
1.1.6.1 Pre-clinical or early stage AD 
The pre-clinical stage of AD refers to a period of cognitive decline that 
precedes the onset of clinical AD. The pre-clinical AD stage consists of a 
slight decline in cognitive abilities with moderate neuronal damage (Sperling 
et al., 2011). Pathological changes associated with AD begin in the entorhinal 
cortex and then proceed to the hippocampus which explains early symptoms 
such as failing short-term memory (Figure 1.1A). This mild stage usually lasts 
2 to 4 years and common symptoms include difficulty retaining new 
information, difficulty with problem solving or decision making, inappropriate 
use of words, mood swings, decreased motivation and attention, repeated 
questions or statements, trouble managing finances or other instrumental 
activities of daily living, personality changes, misplacing belongings or getting 
lost and difficulty navigating in familiar surroundings (Forstl and Kurz, 1999; 
Amieva et al., 2008). 
1.1.6.2 Moderate or mild cognitive impairment (MCI) stage AD 
The subsequent stage is the longest stage of the disease, lasting for 2 to 10 
years. This stage is referred to as mild cognitive impairment (MCI) due to AD 
and defined by the presence of clear memory impairment and biomarker 
evidence for AD (Albert et al., 2011). Brain damage has spread to most of the 
areas of the cerebral cortex that control language and memory (Figure 1.1B). 
Subsequently, atrophy of the affected areas of the cerebral cortex produces 
clinical symptoms that are more pronounced and widespread. Patients often 
experience greater difficulty with memory and may need help with daily 
activities. Symptoms reported during this stage are greater memory loss, 
difficulty completing complex tasks, increasing difficulty finding the right 
words, poor judgment, greater confusion, hallucinations, delusions, 
suspiciousness, restlessness, agitation, anxiety and sleep disturbances (Mariani 




1.1.6.3 Severe stage or dementia due to AD 
The final stage is conceptualized as dementia due to AD where brain damage 
is widespread and most of the vital areas of the brain have atrophied further 
(Figure 1.1C) (McKhann et al., 2011). Patients might not recognize their own 
family members or loved ones and are totally dependent on others for all of 
their care. This stage may last between 1 and 3 years. Common symptoms in 
this stage include the complete loss of ability to communicate, 
unresponsiveness to stimuli, weight loss, seizures, difficulty swallowing, 
oversleeping and loss of bladder and bowel control. Patients may be in bed 
much or all of the time and death is often the result of other illnesses. 
  A                                 B                                 C  
 
Figure 1.1: Stages of AD pathology  
In human AD, pathological accumulations including amyloid plaques and 
neurofibrillary tangles (shown in blue) start in the transentorhinal region (A), then 
spread to the hippocampus and amygdala (B) and finally to most of the areas of the 
neocortex (C). This pattern of spreading strongly coincides with AD clinical 
presentation and cognitive impairments. Adapted from: (Rodgers et al., 2002)  
 
 
1.1.7 Pathophysiology of AD 
AD is characterized by three pathological features: intracellular neurofibrillary 
tangles (NFT), extracellular amyloid plaques and neuronal death. Plaques and 
tangles, first discovered by Dr. Alois Alzheimer in 1906, are usually localized 
in the brain areas that correspond to the clinical symptoms (Dickson, 1997). 
The following sections discuss some of the principal theories thought to cause 




1.1.7.1 The amyloid hypothesis 
Amyloid-β plaques are thought to be major contributors to AD pathogenesis 
with severe and complicated pathophysiological processes. According to the 
amyloid hypothesis, generation and aggregation of amyloid is the principal 
causative factor behind the pathogenesis and progression of AD (Hardy and 
Selkoe, 2002). Amyloid beta precursor protein (APP), a ubiquitous 
transmembrane receptor-like protein has a critical role in neuronal growth and 
cell signaling (Thinakaran and Koo, 2008). Studies reported that APP is 
processed by three enzymes, i.e. β-secretase, γ-secretase and α-secretase 
(Chow et al., 2010). Under normal conditions, APP is cleaved first by α-
secretase, followed by γ-secretase and release a soluble 40 amino acid peptide 
(Aβ 1-40). In contrast, in the amyloidogenic pathway, APP is cleaved by β-
secretase first and then by γ-secretase and release an insoluble 42 amino acid 
peptide (Aβ 1-42) (Figure 1.2). Subsequently, amyloid-β (Aβ) monomers 
combined into dimers and oligomers, which in turn self-organized into fibrils 
and plaques (Zhang et al., 2011). The discovery of the three major genes 
(APP, PS1 and PS2) in the formation of Aβ in Familial AD gave additional 
support to the amyloid hypothesis. APP gene mutation is the first discovered 
mutation found to cause Familial AD and there are at least 20 known 
mutations in the APP gene studied so far, located on chromosome 21 (Goate et 
al., 1991). Subsequently, PS1 and PS2 mutations were found to be the most 




Figure 1.2: APP processing by secretases  
In the non-amyloidogenic pathway, amyloid beta precursor protein (APP) is 
processed first by α-secretase followed by γ-secretase and generates APP intracellular 
domain (AICD) and extracellular large APPs-α/p3 fragments. However, in the 
amyloidogenic pathways, a shorter APPs species (APPs-β) is secreted upon the first 
cleavage by β-secretase. The resulting C99 fragment is further cleaved by γ-secretase 
to produce Aβ and AICD which may be involved in nuclear signaling. Adapted from : 
(Kaether and Haass, 2004). 
 
PS1 and PS2 genes code for the catalytic subunit of γ-secretase and so far 140 
and 10 mutations have been studied in PS1 and PS2 genes respectively (Rohan 
de Silva and Patel, 1997). Apolipoprotein E (ApoE) is a cholesterol transport 
protein abundantly expressed in the liver and the central nervous system 
(Mahley, 1988). In 1993, the role for ApoE E4 allele in AD was first reported 
and ApoE E4 allele was found to be more than 3 times as common in AD 
patients as in age-matched, cognitively-intact controls (Strittmatter et al., 
1993). However, how ApoE affects the AD disease process is still unknown. 
Several studies indicated that ApoE binds directly to the Aβ peptide and 
promotes fibrillogenesis (Wisniewski et al., 1994; Castano et al., 1995). Aβ 
plaques were first observed in the temporal neocortex in the initial stage of 
AD and then progressively spread to the hippocampus and adjoining 
neocortical areas (Braak and Braak, 1991). The principle argument against the 
amyloid hypothesis has been the observation that neurofibrillary tangles 
10 
 
correlated more strongly with cognition scores than amyloid plaques 
(Arriagada et al., 1992; Giannakopoulos et al., 2003; Guillozet et al., 2003). 
However, other discoveries specified that soluble Aβ oligomers rather than the 
solid plaques are correlated to the clinical severity of disease and synapse loss 
(Naslund et al., 2000; Kirkitadze et al., 2002). 
1.1.7.2 The tau hypothesis 
Besides amyloid-β accumulation, many neurons in AD-affected brain regions 
also exhibit intracellular inclusions with bundles of abnormal fibers. These 
inclusions are neurofibrillary tangles (NFTs) which consist primarily of 
hyperphosphorylated tau (Kosik et al., 1986; Wang et al., 2007). Tau is a part 
of the microtubule associated protein (MAP) family, which is mainly 
implicated in microtubule stabilization (Kosik et al., 1986). Hence, tau protein 
is vital to crucial processes such as cytoskeletal organization, axonal transport 
and mitotic division (Cuchillo-Ibanez et al., 2008). There are six tau isoforms 
expressed by alternate splicing from the gene MAPT, found on chromosome 
17 (Lace et al., 2007). The well-described post-translational modification of 
tau is phosphorylation and a list of serine (Ser) and threonine (Thr) sites were 
reported previously (Buee et al., 2000). In addition, protein kinases such as 
glycogen synthase kinase (GSK-3β), cyclin-dependent kinase 5 (Cdk5) and 
MAP kinases that phosphorylate tau were also well documented previously 
(Mandelkow et al., 1995). Conversely, protein phosphatase 2A (PP2A) is the 
principle enzyme involved in the dephosphorylation of tau (Liu et al., 2005). 
Hyperactivation of protein kinases such as Cdk5 and significant reductions in 
PP2A activity were believed to be the reasons behind the tau pathology in AD 
(Wang et al., 2007). In AD, tau is hyperphosphorylated mainly at Ser 214 and 
Ser 202 sites and loses its ability to bind to microtubules. This in turn causes 
microtubule disassembly and defective axonal transport (Li et al., 2007). 
Additionally, the hyperphosphorylated tau is more prone to aggregate and 
form NFTs (Figure 1.3). Eventually, this microtubule disassembly and 
aggregation of NFTs leads to defective synaptic function and then neuronal 
death (Ihara et al., 1986; Kosik et al., 1986).  
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In human AD, the pattern of spreading of tau pathology strongly coincides 
with clinical presentations of AD and cognitive impairments (Braak and 
Braak, 1991). In contrast, the lack of genetic linkage to the tau pathology has 
weakened the hypothesis of hyperphosphorylation of tau as a primary process 
in AD. However, some prominent tau gene mutations was discovered to cause 
neurodegeneration in familial frontotemporal dementia with Parkinsonism 
linked to chromosome 17 (Spillantini et al., 2000). Hyperphosphorylated tau 
has been thought to be secondary to Aβ peptide accumulation in AD (Blurton-
Jones and Laferla, 2006; Iqbal et al., 2009). However, some studies reported 
that the tau protein is responsible for the initiation of the neurodegeneration, 
due to its ability to be predictive of dementia severity (Arriagada et al., 1992; 
Lace et al., 2007; Iqbal et al., 2009). Therefore, it is clear that the contributions 
of Aβ and tau to the progression of AD are closely linked and both should be 
considered in models of the disease.         
     
Figure 1.3: Tau pathology in AD 
Under normal condition, tau protein binds and stabilizes microtubules. This is 
important for axonal morphology and function. However, hyperphosphorylation of 
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tau by hyperactivated protein kinases reduces its ability to binds to microtubules and 
causes microtubule disassembly. Hyperphosphorylated tau eventually then aggregates 
to form paired helical filaments (PHF) and NFTs. This leads to microtubule 
disassembly, defective synaptic function and then finally neuronal death. Adapted 
from : (National Institute on Aging and Health and Human Services Department, 
2003) 
 
1.1.7.3 Potential molecular mechanisms in AD  
Cholinergic abnormalities are one of the oldest causal theories of AD where 
the number of cholinergic neurons and level of acetylcholine (Ach) are 
drastically reduced during the late stage of AD (Whitehouse et al., 1981; 
Arendt et al., 1983). Various studies indicated that the most viable therapeutic 
approach to increase the Ach levels in the brain is to inhibit the enzyme 
responsible for the degradation of Ach, acetylcholinesterase (AchE). Although 
currently available AchE inhibitors (donepezil and rivastigmine) effectively 
increase the level of Ach in AD brain, they failed to provide appreciable 
improvement in delaying clinical symptoms of the disease (Benzi and Moretti, 
1998; Bentham et al., 1999; Jacobson and Sabbagh, 2008). Thus, collective 
data suggest that cholinergic abnormalities are not the only pathway 
dysregulated in an AD brain and hence the focus of AD research has now 
diverged into other causal theories to aid the development of new treatment 
strategies (Doraiswamy, 2002). 
In addition, the endogenous systems for protection against reactive oxygen 
species (ROS) and oxidative stress are found to be insufficient in early AD. 
An augmented level of lipid peroxidation has also been observed in human 
AD brain (Pratico and Sung, 2004). Moreover, key antioxidant enzymes such 
as glutathione peroxidase and superoxide dismutase (SOD) are depleted in 
animal models of AD (Smith et al., 1991). Aβ peptides have been proposed as 
a source and a consequence of oxidative stress in an animal model of AD 
(Butterfield, 1997). It has been shown that an increased load of ROS is 
associated with amyloid plaques (McLellan et al., 2003). Furthermore, 
increased brain deposition of Aβ plaques was also reported in mice generated 
by crossing APP mutant mice with manganese SOD heterozygous knockout 
mice (Li et al., 2004). Studies also indicated that there is a close association 
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between oxidative stress and mitochondrial dysfunction at the early stages of 
AD (Lin and Beal, 2006).  
Programmed cell death (apoptosis) is an important biological process during 
development and under pathological conditions. Several different triggers of 
neuronal apoptosis have been documented in AD such as oxidative stress, 
excitotoxicity caused by an overstimulation of N-methyl-D-aspartate (NMDA) 
receptors, DNA damage and accumulation of damaged proteins (Lipton and 
Rosenberg, 1994; Yuan and Yankner, 2000). Amyloid-β exposure can lead to 
neuronal death through direct or indirect interaction with number of cellular 
signaling proteins. These include mainly the components of the apoptotic 
signaling pathways, such as activation of c-Jun N-terminal kinase (JNK), 
resulting in down regulation of anti-apoptotic proteins (Yao et al., 2005) and 
the activation of calpain and caspase-3 through an increase in intracellular 
Ca2+ concentrations (Kuwako et al., 2002). Studies also indicated that 
inflammatory processes with the simultaneous release of pro-inflammatory 
mediators contributed to neuronal death (Boje and Arora, 1992; Block et al., 
2007). Therefore, it is likely that a number of overlapping and interacting 
factors are involved in the mechanisms of neuronal cell loss in AD. 
1.1.8 Neuroinflammation in AD 
A wide variety of neurodegenerative diseases share a common conspicuous 
feature, neuroinflammation, which is a complex event of self-defensive 
response to injurious stimuli in the CNS (Saez et al., 2004). Pro-inflammatory 
mediators released by activated glial cells during brain inflammation have 
been proposed to contribute to neuropathology underlying cognitive deficits 
(Figure 1.4) (Frank-Cannon et al., 2009). Neuroinflammation in AD can be 
considered as a double-edged sword which has both beneficial effects by 
degrading toxic substances including Aβ and adverse effects by producing 
cytotoxic substances that contribute to disease progression (Akiyama et al., 
2000). Optimal activation of immune cells are important for phagocytosis of 
Aβ, whereas hyperstimulation may eventually lead to neuronal death 
(Koistinaho et al., 2004; Simard et al., 2006). Studies over several years have 
indicated that neuroinflammation is indeed associated with AD pathology. In 
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fact, Dr. Alois Alzheimer himself noticed and reported the sign of 
inflammatory changes in the demented brain. Studies have found that pro-
inflammatory cytokines are found at or near sites of pathological lesions in the 
AD brain (Johnston et al., 2011). Moreover, numerous epidemiological studies 
have found that the use of nonsteroidal anti-inflammatory drugs (NSAID) may 
be associated with reduced risk of AD development (Rogers et al., 1993; 
McGeer et al., 1996; Hirohata et al., 2008). Hence compelling evidences 
clearly suggest that there is a strong correlation between neuroinflammation 
and AD disease progression. However, the exact mechanism behind the link is 
not fully elucidated; whether it is a secondary process or directly involved in 
the initiation of the AD pathology is still unclear.   
   
Figure 1.4: Schematic diagram showing the pathogenesis of chronic 
neuroinflammation 
Chronic activation of resident immune cells (astrocytes and microglia) and 
macrophage recruitment by signals from injured neurons lead to the copious secretion 
of pro-inflammatory chemokines/cytokines which in turn causes neuroinflammation 
and subsequent neuronal cell death. Adapted from : (Reaux-Le Goazigo et al., 2013) 
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 1.1.8.1 Role of glia in AD 
1.1.8.1.1 Astrocytes 
Astrocytes are the most abundant non-neuronal cells in the brain and act as the 
main element of the homoeostatic system of the brain (Simard and 
Nedergaard, 2004). They protect the microarchitecture of the brain and 
regulate the blood-brain barrier (BBB). Astrocytes also control the 
microenvironment of the central nervous system and defend the nervous 
system against various insults (Zonta et al., 2003; Kofuji and Newman, 2004; 
Takano et al., 2006). Astroglial cells form the first line of brain defense by 
limiting the intrinsic excitotoxicity of the neurons and provide the main 
antioxidant system in the brain (Rothstein et al., 1996). At the same time, 
astroglial cells can contribute to neuronal damage when severe insults 
compromise astrocyte metabolism by the reversal of glutamate uptake system 
(Vesce et al., 2007). In addition, neurotoxic insults elicit a defensive glial 
reaction, known as reactive astrogliosis, which facilitates the remodelling of 
brain circuits in areas surrounding the damaged region with a permanent glial 
scar (Alonso and Privat, 1993; Pekny and Nilsson, 2005; Sofroniew, 2005). 
Astrogliosis is also characterized by the robust synthesis of glial fibrillary 
acidic protein (GFAP) intermediate filaments and several studies have shown 
that GFAP is a specific marker for astrocytic activation (Eng and Ghirnikar, 
1994; Jones et al., 1996). Prominent astrogliosis surrounding amyloid plaques 
is the main astroglial reaction found in the human AD brain (Nagele et al., 
2004). Interestingly, increases in GFAP-mRNA and immunoreactivity have 
also been observed previously in the human AD brain (Harpin et al., 1990; Le 
Prince et al., 1993). The role of astrogliosis in the development of AD 
pathology was also reported in several animal models of AD (Muyllaert et al., 
2008; Olabarria et al., 2010; Beauquis et al., 2012). In addition, reactive 
astrogliosis with altered GFAP expression was observed in other 
neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), 
Parkinson’s disease (PD) and Huntington’s disease (Maragakis and Rothstein, 
2006). Reactive astrogliosis in AD can be initiated by several factors, which 
include signals from damaged neurons as well as extracellular deposition of 
the amyloid-β peptide (Meda et al., 2001). The activated astrocytes in AD 
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brain are intimately involved in the progression of neuroinflammation through 
the release of cytokines, pro-inflammatory factors and nitric oxide/reactive 
oxygen species (Mrak and Griffin, 2005).  
It is still under debate whether astrogliosis has a role in the initiation of AD 
pathology or it is just a secondary event in AD pathology. Recent studies 
showed that the treatment of cultured glial cells with aggregated amyloid-β 
triggered reactive astrogliosis (Paradisi et al., 2004). The role of astrocyte 
responses in Aβ-induced neuronal loss was reported in another recent study 
using co-culture systems with rat primary astrocytes and neurons (Garwood et 
al., 2011). At the same time, studies also demonstrated that cytokines released 
from astroglia could trigger Aβ production through the activation of astrocytic 
β-site APP cleaving enzyme 1 (BACE 1) (Zhao et al., 2011). Moreover, 
astroglial BACE 1 was significantly increased in activated astrocytes 
surrounding Aβ plaques in several transgenic AD mice models, such as 
Tg2576 and the double mutated K670N-M671L APP model (Heneka et al., 
2005; Rossner et al., 2005). In summary, for a long time, astrocytes were 
thought to be merely “brain glue” and the role of astroglial activation in AD 
progression still remain largely unexplored. Hence, more studies are needed to 
unravel this mystery (Maragakis and Rothstein, 2006). 
1.1.8.1.2 Microglia 
Microglia are the primary innate immune cells in the CNS and represent 10% 
of all brain cells (Hughes, 2012). In addition, microglial cells show various 
phenotypes depending on the age and brain region (Hart et al., 2012). In their 
resting state, they display a ramified morphology with long and dynamic 
processes. The main role of resting microglia is to constantly move and scan 
the environment for harmful agents (Nimmerjahn et al., 2005). Upon 
activation, microglia proliferate, migrate to the site of lesion and undergo a 
drastic change to an amoeboid morphology with short processes (Ayoub and 
Salm, 2003). These reactive microglial cells then start to express surface 
antigens such as major histocompatibility complex (MHC)-II and 
subsequently release pro-inflammatory mediators including cytokines and 
complement factors (Heneka and O'Banion, 2007). The main role of this 
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process is to remove the toxic debris and protect neurons from damage 
(Schlachetzki and Hull, 2009). However, under chronic neurotoxic insults in 
various neurodegenerative disease states, prolonged release of inflammatory 
mediators is thought to cause neurodegenerative changes (Block et al., 2007). 
In particular, sustained neurotoxic insults in AD brains shift microglia towards 
a pro-inflammatory phenotype with reduced phagocytic abilities (Luo and 
Chen, 2012). However, it is still not clear why and when microglia switch 
from being beneficial to detrimental in the course of AD.  
Marked increases in reactive astrocytes and microglia, especially around Aβ 
plaques, have been observed in many AD mouse model studies (Frautschy et 
al., 1998). In addition, Aβ has been shown to attract and activate microglia 
leading to the clustering of microglial cells around Aβ deposits (Combs, 2009; 
Cameron and Landreth, 2010). Furthermore, studies suggested that clustering 
of activated microglial cells in the brains of mice with deposited amyloid is a 
phagocytic attempt to clear the Aβ deposits (Bornemann et al., 2001). 
Nevertheless, more studies are required to delineate the role of microglial 
activation in AD whether it is a primary trigger or a secondary consequence to 
the Aβ pathology (Lautner et al., 2011). Together, findings from several 
studies emphasized that proper understanding of the complex role of innate 
immune processes in neurotoxicity will help future therapeutic development. 
1.1.8.2 Role of inflammatory chemokines and cytokines in AD pathology 
The role of bi-directional communication between microglia and astrocytes 
through the release of inflammatory cytokines and chemokines in the course 
of AD has been well studied previously (Tuppo and Arias, 2005). Cytokines 
and chemokines are small, soluble signaling molecules secreted by microglia 
and astrocytes to mediate the immune response. Likewise, neurotoxic insults 
including Aβ are able to induce cytokine production through the stimulation of 
the nuclear factor-kappa B (NF-κB) dependent pathway (Combs et al., 2001). 
Upregulation of various chemokines and their receptors has been observed in 
the AD brain (Xia and Hyman, 1999). Detection of macrophage inflammatory 
protein-1α (MIP-1α) in reactive astrocytes near Aβ plaques strongly supported 
the role of astrocytes-mediated response in the pathological progression of 
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AD. In addition, an in vitro study found a remarkable increase in the 
expression of chemokines such as interleukin 8 (IL-8), monocyte chemotactic 
protein-1 (MCP-1) and MIP-1α from the astrocytes after treatment with Aβ 
(Lue et al., 2001; Smits et al., 2002). In the same manner, changes in levels of 
many cytokines have also been described in AD brains (Tuppo and Arias, 
2005). Based on their biological activity, cytokines are classified as pro-
inflammatory (IL-6, IL-1β and TNF-α) and anti-inflammatory (IL-4, IL-10 
and TGF-β) (Luster, 1998). In general, cytokines such as IL-1β (interleukin-
1β), IL-6 (interleukin-6), TNF-α (tumor necrosis factor-alpha), IL-8 
(interleukin-8) and TGF-β (transforming growth factor-β) seem to be up 
regulated during the course of AD (Akiyama et al., 2000). Moreover, neuron-
mediated production of IL-1 (interleukin-1), IL-6, and TNF-α under stress 
conditions has also been reported. Indeed, these neuronal cytokines act as 
messengers between neurons and glial cells. Both IL-1 and IL-6 were found to 
be effective in the induction of astrogliosis and activation of microglia (Castell 
et al., 1989; Mrak and Griffin, 2001). Clinical evidence showed that there was 
a tremendous elevation in levels of TNF-α, the “master regulator” of the 
immune response in the cerebrospinal fluid of AD patients (Tarkowski et al., 
2003). Additionally, the finding of TNF-α-mediated beta-amyloid-induced 
inhibition of long-term potentiation further supported the association of TNF-α 
with the memory impairment in AD (Wang et al., 2005). Various studies have 
determined that TNF-α contributes to neuronal dysfunction via its interactions 
with glutamate (Zou and Crews, 2005) and amyloid (Floden et al., 2005).   
In addition, anti-inflammatory cytokines like IL-4 (interleukin-4), IL-10 
(interleukin-10), TGF-β and IL-13 (interleukin-13) are also elevated in AD as 
a regulatory response to maintain homeostasis in the brain (Chao et al., 1994; 
Rota et al., 2006). These anti-inflammatory cytokines have been observed as 
inhibitory agents to the Aβ-induced neurotoxicity-mediated activation of 
microglial cells. In particular, IL-4 and TGF-β were found to reduce the 
expressions and activities of CD40 and class II major histocompatibility 
complex (MHC) (O'Keefe et al., 1999). More recently, decreased expression 
of TGF-β receptor and subsequent reduced neuronal TGF-β signaling were 
observed in both human AD cases and in AD mouse models (Das and Golde, 
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2006). In summary, it is crucial to preserve the balance between pro- and anti-
inflammatory cytokines/chemokines in the brain for the maintenance of 
optimal neuronal function. Chronic inflammation can result from imbalances 
between the levels of these inflammatory mediators (Lue et al., 2010).  
1.1.8.3 Peripheral leukocyte infiltration in neurodegenerative diseases 
Recent studies provide evidence that discrete populations of peripherally-
derived immune cells traffic to the CNS during disease states (Rezai-Zadeh et 
al., 2009). Although peripheral leukocyte migration and infiltration into the 
brain parenchyma is tightly regulated at the level of the BBB (Engelhardt, 
2008), neuroimmune surveillance by peripheral leukocytes does occur in 
instances of disease. Indeed, this peripheral leukocyte migration is influenced by 
inflammatory cytokines and chemokines such as MIP-1α and TNF-α (Ramos 
et al., 2005). The occurrence of brain infiltration of significant number of bone 
marrow-derived macrophages has been observed in murine models of AD. It 
has also been reported that these cells were effective in the clearance of Aβ 
accumulations from the brain (Stalder et al., 2005; Simard et al., 2006). 
Although there have been some concerns about the occurrence of brain 
infiltration of peripheral monocytes (Ajami et al., 2007; Mildner et al., 2007), 
two recent reports provided positive evidence that peripheral 
monocytes/macrophages can act to restrict amyloid-β plaques (Town et al., 
2008; Hawkes and McLaurin, 2009). Hence, further studies are required to 
clearly understand the role of peripheral leukocyte infiltration in the course of 
AD.  
1.1.9 Transgenic mice models of AD 
Multiple transgenic mouse models have been developed using familial AD 
mutations as a basis. Although these models do not completely replicate all 
aspects of the disease, they have been useful in understanding some of the 
mechanisms involved in the progression of AD (Spires and Hyman, 2005; 
Torres-Aleman, 2008). Mice are a particularly attractive model system due to 
their relatively easy genetic manipulation, short lifespan and ease of breeding. 
They can be engineered to develop specific pathological features which 
closely mimic aspects of human AD. However, there are a number of caveats 
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and limitations including ageing, environmental factors and genetic variability 
which must be considered (Jucker, 2010). Although mice models harboring 
mutations found in familial AD have led to the development of unique 
therapeutic strategies, none of the preclinical findings have translated into 
clinical success. This translational failure of promising animal studies is 
mainly due to the inadequate internal and external validity of preclinical 
studies. Hence, the external validity of mouse studies could be obtained by 
including more than one mouse model, testing at multiple sites and using 
adequately powered designs to confirm treatment effects (van der Worp et al., 
2010).  
1.1.9.1 Transgenic mice with Alzheimer’s-like amyloid pathology  
The first APP transgenic mouse (PDAPP) was generated with the Indiana 
mutation (V717F) using the platelet derived growth factor (PDGF) B chain 
promoter. This PDAPP mouse exhibited plaque pathology by 6-9 months and 
it is one of the few models with hippocampal atrophy (Games et al., 1995). 
Subsequent research done by various other groups using Morris water maze 
experiments reported age-dependent behavioral deficits in PDAPP mice (Chen 
et al., 2000). The next widely used APP model is the Tg2576 mice which 
expresses the APP 695 isoform with the Swedish mutation (K670N/M671L) 
using hamster PrP promoter. Tg2576 mice produced both Aβ (1-40) and Aβ 
(1-42) peptides and plaques usually developed at 12-18 months in both cortex 
and hippocampus (Hsiao et al., 1996). However, there was a lack of 
correlation between the late onset of deposition of amyloid plaques and 
memory deficits in these Tg2576 mice (Westerman et al., 2002). 
Subsequently, another APP 695 isoform expressing model (CRND8) was 
generated with both the K670N/M671L (Swedish) and V717F (Indiana) 
mutations and these mice developed early Aβ deposition (at the age of 3 
months) with premature mortality (Chishti et al., 2001). In addition, studies 
also reported prominent cognitive deficits, reduced basal synaptic transmission 
and increased long-term potentiation (LTP) in these mice (Jolas et al., 2002; 
McCool et al., 2003).  
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Presenilin mouse models have also been developed using various mutations in 
the PS1 gene (M146V, M146L, PS1exon 9 deleted, and A246E). Selective 
overexpression of Aβ 1-42 peptide without plaque or tangle pathology was 
reported in PS1 transgenic mice (Sudoh et al., 1998). However, these mice 
exhibited increased susceptibility to excitotoxicity via abnormal intracellular 
Ca2+ signaling (Guo et al., 1999; Stutzmann et al., 2006). Furthermore, the 
cross of APP transgenic mice (Tg2576) with the PS1 transgenic mice (PS1 
M146V) resulted in bi-transgenic mice (PSAPP) where accelerated Aβ 
pathology with robust elevated Aβ 1-42 levels were observed early at 3 
months due to the presence of the PS1 mutation (McGowan et al., 1999). 5X 
FAD Tg mice were made with multiple FAD mutations (Swedish, Florida and 
London) that additively increased Aβ production. Accordingly, 5X FAD mice 
represented a very aggressive amyloid deposition model that developed 
intraneuronal Aβ at 1.5 months, plaques at 2 months, memory deficits at 4 
months and neuron loss at 9 months of age (Eimer and Vassar, 2013). 
Interestingly, levels of the hyperactivation subunit of Cdk5, p25, were 
significantly elevated at 9 months in 5X FAD brain (Oakley et al., 2006). 
Transgenic mice expressing huBACE under the control of PrP promoter 
(SwAPP) or the neuron-specific mouse Thy1.2 promoter have also been 
developed to study the consequence of BACE overexpression on APP 
processing (Mohajeri et al., 2004; Ozmen et al., 2005). AD-like pathologies 
including Aβ production were massively increased in double transgenic mice 
expressing both BACE and SwAPP. At two months of age, early signs of 
extracellular Aβ deposition and reactive astrocytes were found in these double 
transgenic mice (Ozmen et al., 2005). 
1.1.9.2 Tau mutant transgenic mice 
Several transgenic models expressing familial tau mutations have been 
developed to study important aspects of AD pathology. JNPL3 mouse, which 
expresses the tau P301L mutation under the mouse PrP promoter, developed 
several features which mimic those observed in AD. Hyperphosphorylation of 
tau occurred at several AD-related epitopes, such as the AT8 epitope, and tau 
deposition was observed in the cortex, hippocampus and amygdala (Gotz et 
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al., 2001a). The JNPL3 mouse has also been used in the study of tau filament 
formation (Gotz et al., 2001a). In addition, tau transgenic mice have been used 
to investigate the interactions between Aβ and tau in AD research. For 
example, injection of Aβ fibrils exacerbated pathology in the JNPL3 mouse, 
resulted in a 5-fold increase in tangles in the amygdala (Gotz et al., 2001b). In 
another study, a cross between Tg2576 and the JNPL3 mouse resulted in an 
enhancement of neurofibrillary tangle pathology when compared to the tau 
mutants alone (Lewis et al., 2001), suggesting that Aβ overexpression can 
interact with tau protein to cause an enhancement of tangle pathology. 
Triple transgenic (3X Tg) mouse was generated by the microinjection of 
cDNA constructs with hAPP (K670N/M671L) Swedish mutation and P301L 
tau mutation into the embryos of homozygous PS1M146V mutant mice with 
Thy1.2 neuronal-specific promoter. Robust elevation of APP, intraneuronal 
Aβ 1-42 and tau proteins were observed in these 3X Tg mice compared to the 
respective single transgenic mice. Studies reported that 3X Tg mice developed 
extracellular Aβ plaques before tangle pathology, as in human AD (Oddo et 
al., 2003). In addition, recent studies detected increased phosphorylation of tau 
in multiple phospho-tau sites, AT100 (Thr 212/Ser 214), AT8 (Ser 202, Thr 
205) and AT180 (Thr 231) in the amygdala and cortex (Oh et al., 2010).  
1.2 Cyclin dependent kinase 5 (Cdk5) 
1.2.1 Discovery of Cdk5 
Cyclin-dependent kinases (Cdks) are a family of proline-directed protein-
serine/threonine kinases (30-35 kDa) with a well-established role in the timing 
of the various phases of cell cycle such as DNA synthesis phase (S), mitosis 
phase (M) and the two gap phases (G1 and G2) (Hengst et al., 1994; Morgan, 
1997). There have been 20 Cdk-related proteins studied so far and they are 
involved mainly in the regulation of proliferation, differentiation, senescence 
and apoptosis of many cells (Satyanarayana and Kaldis, 2009). In general, 
Cdks need to bind to regulatory subunits, called cyclins, in order to be 
activated. However, activities of Cdks are also regulated through various 
mechanisms like post-translational modifications such as phosphorylation and 
endogenous inhibition by Cdks inhibitors (Tannoch et al., 2000). Even though, 
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most Cdks have been associated with the regulation of the cell cycle, certain 
Cdks are involved in other important cellular processes. An important example 
is Cyclin-dependent kinase 5 (Cdk5), a peculiar member of the Cdk family of 
serine/threonine kinases. Cdk5 is neither activated by any known cyclins nor 
involved in cell cycle regulation (Dhavan and Tsai, 2001). Cdk5 was first 
isolated from bovine brain and named as neuronal Cdc2 like kinase (NCLK) 
because of its sequence homology (58%) to the human cell cycle regulatory 
kinase Cdc2 (Hellmich et al., 1992; Lew et al., 1992; Meyerson et al., 1992). 
Cdk5 is the fifth Cdk in the line of discovery and the nomenclature was first 
fixed in 1993. Human and mouse Cdk5 genes have been located on 
Chromosome 7 and 5 respectively and both encode for a 33 kDa protein with 
292 amino acids (Demetrick et al., 1994).  
1.2.2 Expression and activity of Cdk5 
Although Cdk5 is ubiquitously expressed in all mammalian tissues, its activity 
is mainly present in the central nervous system (CNS) and plays a crucial role 
in neuronal migration (Hellmich et al., 1994; Huang et al., 1999). However, 
studies have also reported the low level activity of Cdk5 in lens epithelial 
cells, Leydig cells of the testis and β-cells of the pancreas (Gao et al., 1997; 
Musa et al., 1998; Lilja et al., 2001). In neurons, Cdk5 is predominantly 
present in the cytoplasm and neurite terminals (Nikolic et al., 1996; Nikolic et al., 
1998). Cdk5 phosphorylates a large number of target proteins in post-mitotic 
neurons and the consensus phosphorylation site of Cdk5 is S/T-P-X-R/H/K (X 
can be any amino acid except Aspartate and Glutamate) (Beaudette et al., 
1993; Lew et al., 1995). Activation of Cdk5 requires association with 
neuronally-enriched binding partners p35 and p39 and therefore its function is 
mainly restricted to post-mitotic neurons (Dhavan and Tsai, 2001). It has been 
reported previously that the phosphorylation of activation loop is required for 
optimal activation of most of the Cdks. However the activation of Cdk5 is not 
associated with the phosphorylation of its activation loop and studies have 
shown that the binding of a regulatory subunit with Cdk5 is enough to stretch 
the activation loop into a fully extended active state (Russo et al., 1996; Poon 
et al., 1997; Brown et al., 1999; Tarricone et al., 2001). 
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1.2.3 Regulation of Cdk5 activation 
1.2.3.1 Cdk5 activators  
Cdk5 activity is mainly regulated by association with its activators p35 and 
p39. p35 (NCK5a, neuronal Cdk5 activator comprising of 307 amino acids 
with 35 kDa mass) is the first Cdk5 binding partner to be identified and has 
been well-studied. Studies determined that association of p35 itself is 
sufficient to activate Cdk5 (Tsai et al., 1994). p39 (NCK5ai, neuronal Cdk5 
activator isoform comprised of 367 amino acids with 39 kDa mass), another 
activator for Cdk5, was identified by its sequence homology (57% amino-acid 
identity) to p35 (Tang et al., 1995). Both p35 and p39 showed limited 
sequence homology to cyclins, suggesting that they belong to a non-cyclin 
family of Cdk5-activating proteins (Tang and Wang, 1996). 
Cdk5 null mice died just before or after birth and displayed massive 
disruptions in the cortical lamination (Gilmore et al., 1998; Ohshima et al., 
1999). In contrast, p35 knockout mice were viable, but have increased 
susceptibility to seizures (Kwon and Tsai, 1998). In addition, p35 knockout 
mice displayed moderate disruption in the organization of the CNS. Hence, it 
is clear from these studies that p39 could compensate to an extent for the 
absence of p35. Studies acknowledged that p39/p35 double knockout mice 
were phenotypically identical to Cdk5 knockout mice and further established 
that p35 and p39 are the primary activators of Cdk5 (Ko et al., 2001). Indeed, 
p35 and p39 display an overlapping, but distinct temporal and spatial pattern 
of expression in the synapse and neuronal growth cones (Delalle et al., 1997). 
Although there is no specific pattern of distribution of Cdk5, the sub-cellular 
distribution of Cdk5 and the choice of physiological substrates of Cdk5 are 
mainly dictated by the distribution pattern of p35/p39 (Pavletich, 1999).  
One of the most direct ways of regulating Cdk5 activity is to regulate p35 
levels in cells. p35 has been observed to be a short-lived protein with a half-
life of 20-30 minutes (Patrick et al., 1998). A possible mechanism for the 
degradation of p35 is the autophosphorylation by Cdk5 (Lew et al., 1994; Tsai 
et al., 1994). The possibility of a negative feedback regulation by Cdk5 was 
supported by previous studies where mutations of potential Cdk5 
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phosphorylation sites in p35 increased the stability of p35 (Patrick et al., 
1998).  
1.2.3.2 Transcriptional regulation of Cdk5 and p35 
Previous studies reported that chronic administration of cocaine to rats 
enhanced the expression of Cdk5. This cocaine-induced augmentation of Cdk5 
expression was mainly due to the increased expression of transcription factor 
δFosB, a member of the c-jun family of proteins (Bibb et al., 2001). 
Converging evidence from various studies revealed that Cdk5 activity can be 
altered through the transcriptional regulation of p35 protein by various factors 
like extracellular matrix glycoprotein laminin and neurotrophic factors 
(Paglini et al., 1998; Tokuoka et al., 2000). 
1.2.3.3 Binding with other partners 
Previous studies suggested that proteins such as casein kinase 2, DNA binding 
protein (dbpA) and the ribosomal protein L34 regulated Cdk5 activity by 
binding directly with Cdk5 or with p35 (Moorthamer and Chaudhuri, 1999; 
Ching et al., 2002; Lim et al., 2004). Furthermore, the involvement of a 
nuclear protein SET in the activation of p35/Cdk5 has also been reported (Qu 
et al., 2002).  
1.2.4 Physiological role of Cdk5 in central nervous system development 
The significant role of Cdk5 in the development and maintenance of the 
cytoarchitecture of the CNS has been well studied previously. Major neuronal 
functions of Cdk5 have been addressed by various experimental approaches 
including the production of transgenic knockout mice, in vitro studies using 
dominant negative constructs, and finally the identification of various 
substrates. Some of the major functions of Cdk5 are summarized in the 
following sections.  
1.2.4.1 Cdk5-mediated regulation of corticogenesis and neurite outgrowth  
The formation of cortical laminar structure, proper corticogenesis and viability 
of neurons require an optimal level of p35/Cdk5 kinase activity. Cdk5 
knockout mice studies suggested that Cdk5 activity was important for 
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neuronal survival during development. Cdk5 knockout mice exhibited lesions 
in the CNS, abnormal corticogenesis, inverted layering of cortical neurons and 
cerebellar defoliation that contribute to prenatal mortality (Ohshima et al., 
1996). Furthermore, p35 knockout mice studies suggested that p35 was the 
crucial activator for Cdk5 during corticogenesis. p35 null mice showed similar 
inverted layering of cortical neurons, with little disruptions in the 
hippocampus (Kwon and Tsai, 1998). Many studies have demonstrated the 
indispensable role of Cdk5 in cell motility and neurite outgrowth. In vitro 
inhibition of Cdk5 using Cdk5 dominant negative constructs prevented neurite 
outgrowth, whereas overexpression of p35/Cdk5 promoted the extension of 
neurites. Thus, evidence collectively suggested that Cdk5 activity is critical for 
neurite outgrowth (Nikolic et al., 1996; Xiong et al., 1997). Cdk5 induced 
hyperphosphorylation of PAK1 (p21 (Cdc42/Rac)-activated kinase) and 
subsequent downregulation of PAK1 kinase activity were likely to have an 
impact on the regulation of actin cytoskeleton dynamics in neurons and in turn 
promote neuronal migration and neurite outgrowth (Nikolic et al., 1998). 
Additionally, studies also reported that neurite outgrowth is regulated by the 
phosphorylation of Cdk5 by the nonreceptor tyrosine kinase c-Abelson (c-Abl) 
at Tyr 15 (Zukerberg et al., 2000).  
1.2.4.2 Modulation of axonal transport and microtubule dynamics  
It has been well-documented that Cdk5 regulates neuronal migration by 
phosphorylating numerous microtubule-associated proteins (MAPs). Cdk5-
mediated phosphorylation of the intermediate and heavy chain of 
neurofilaments especially at the carboxy-terminal KSP-rich domains 
influences the integration of neurofilaments into the cytoskeleton and also 
regulates its association with microtubules (Hisanaga et al., 1993; Grant et al., 
2001). In addition, Cdk5-mediated phosphorylation of microtubule-associated 
protein 1B (MAP1B) in cerebellar macroneurons was implicated in neurite 
extension (Paglini et al., 1998). Moreover, phosphorylation of tau protein by 
Cdk5 regulated the binding of tau to microtubules and in turn modulated the 
stability of microtubule assembly (Ahlijanian et al., 2000; Grant et al., 2001). 
Nudel is a cytoplasmic dynein-associated protein that is highly expressed in 
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the brain. It has been reported that Cdk5 regulates dynein-mediated axonal 
transport through the phosphorylation of Nudel (Niethammer et al., 2000).  
1.2.4.3 Role of Cdk5 in neurosignaling and neuronal survival 
Numerous studies have investigated the role of Cdk5 in the regulation of 
neuronal signal transduction pathways. Cdk5 altered the efficacy of dopamine 
signaling pathways through the phosphorylation of DARPP-32 (dopamine- 
and cAMP-regulated phosphoprotein, 32 kDa), a key player in dopamine 
signaling. The role of Cdk5 in the MAPK (mitogen-activated protein kinase) 
and JNK (c-Jun N-terminal kinase) pathways have also been extensively 
studied earlier. Cdk5 phosphorylates JNK-3 at Thr131 and inhibits the JNK-3 
activity to modulate neuronal apoptosis (Li et al., 2002). In addition, it has 
been reported that Cdk5 downregulates the MAPK signaling pathway via the 
phosphorylation of MAPK kinase 1 (MEK1) at Thr286. Subsequently, Cdk5-
mediated inhibition of MEK1 downregulates the activity of ERK1/2 (Sharma 
et al., 2002). Moreover, Cdk5 has recently been reported to be involved in Ras 
and Rac signaling pathways through the phosphorylation of Ras guanine 
nucleotide releasing factors (RasGRF1 and RasGRF2) (Kesavapany et al., 
2004; Kesavapany et al., 2006). Cdk5 activity was also found to be involved in  
the regulation of neuronal survival through the neuregulin/PI3-kinase/Akt 
signaling pathway (Li et al., 2003). Recent identification of B-cell lymphoma 
2 (Bcl-2) protein as a Cdk5 substrate suggested that Cdk5-mediated regulation 
of Bcl-2 is essential for the maintenance of neuronal survival (Cheung et al., 
2008). 
1.2.4.4 Cdk5-mediated regulation of synapses, neurotransmission and 
learning and memory  
Cdk5 plays a critical role in the regulation of neurotransmission through the 
modulation of synaptic vesicle exocytosis, endocytosis and neurotransmitter 
synthesis (Tomizawa et al., 2002; Bibb, 2003). Recent studies showed that 
Cdk5 regulates exocytosis by phosphorylating exocytosis-associated proteins 
like Pctaire 1, Munc18, Sept5 and Synapsin 1. In addition, Cdk5 also binds 
and phosphorylates endocytosis-associated proteins including synaptojanin 1, 
amphiphysin 1 and dynamin I at the synaptic terminals (Tan et al., 2003; 
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Tomizawa et al., 2003). Increasing evidence has pointed out that Cdk5 activity 
is associated with the regulation of cholinergic and glutamatergic 
neurotransmitter systems (Fu et al., 2001). In particular, p35/Cdk5 activity was 
found to be associated with acetylcholine receptor trafficking. The 
glutamatergic neurotransmitter system is also regulated by Cdk5 through the 
modulation of NMDA receptor activity (Fu et al., 2001; Hawasli et al., 2007). 
Cdk5 regulates the structural and functional plasticity of neurons through the 
phosphorylation of NMDA receptor subunit NR1 and NR2 (Li et al., 2001; 
Zhang et al., 2008). In addition,  Cdk5-mediated regulation of calpain-induced 
NR2B degradation has been reported previously (Lai and Ip, 2009). Recently, 
many studies have emerged to study the role of Cdk5 in the modulation of 
learning, memory and pain response. Elevated Cdk5 activity was observed 
during associative learning and fear conditioning (Fischer et al., 2002). In fact, 
long-term depression induction and spatial learning were both altered in p35 
knockout mice (Ohshima et al., 2005). Furthermore, p35 knockout mice 
exhibited abnormalities in pain signaling, where evident hypoalgesia was 
observed in response to thermal activation (Pareek et al., 2006). 
1.2.4.5 Role of Cdk5 in transcriptional regulation  
The localization of p35/Cdk5 in the nucleus and its role in transcriptional 
regulation has been recently investigated by various studies. Cdk5-mediated 
regulation of transcription factors including Egr-1 and signal transducer and 
activator of transcription 3 (STAT3) was identified previously and are mainly 
involved in dendrite outgrowth (Nikolic et al., 1996). In addition, Cdk5-
mediated regulation of p53 transcriptional activity has also been reported 
previously (Zhang et al., 2002). Members of the myocyte enhancer factor 2 
(MEF2) was recently identified as a Cdk5 substrate and phosphorylation of 
MEF2 by Cdk5 resulted in the inhibition of MEF2 transactivation activity 
(Gong et al., 2003). It has recently been reported that Cdk5 hyperactivation 
inhibits histone deacetylase 1 (HDAC1) which in turn impaired DNA integrity 





1.2.5 Cdk5 in neurodegeneration 
1.2.5.1 Mechanism behind Cdk5 deregulation 
Although Cdk5 activity is crucial for a proper CNS development, the 
deregulation of Cdk5 activity has been reported to be closely associated with 
the development of neurodegenerative processes in various neurodegenerative 
diseases (Nguyen et al., 2003; Tsai et al., 2004; Lopes et al., 2007; Alvira et 
al., 2008; Slevin and Krupinski, 2009). The tight regulation of Cdk5 is 
disrupted under many neurotoxic conditions like hydrogen peroxide exposure, 
ischemic brain damage, oxidative stress, excitotoxicity and Aβ exposure 
which lead to an abnormal increase in the intracellular Ca2+ levels (Lee et al., 
2000). Cdk5 deregulation is mainly caused by the calpain-mediated cleavage 
of Cdk5 activator, p35 which releases a C-terminal p25 fragment with 209 
amino acids and a small p10 fragment with 100 amino acids (Patrick et al., 
1999; Kusakawa et al., 2000; Lee et al., 2000; Camins et al., 2006). Calpain 
activity is more vulnerable to Ca2+ homeostasis changes which makes calpain 
an important element in numerous neurodegenerative disease including AD 
(Vosler et al., 2008; Araujo et al., 2010). In fact, both NMDA and AMPA (α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors were found 
to be involved in the abnormal influx of Ca2+ under neurotoxic insults 
(Alberdi et al., 2010). Calpain-mediated Cdk5 deregulation was further 
supported by recent findings where production of p25 was blocked by calpain-
specific inhibitors (Sato et al., 2008).  
The half-life of truncated Cdk5 activator p25 is considerably longer than that 
of their original precursor p35. Studies also indicated that the truncated Cdk5 
activator p25 was more resistant to phosphorylation-induced proteasomal 
degradation (Patrick et al., 1998). In addition, it has been shown that binding 
of p25 to Cdk5 displayed much stronger activation profile of Cdk5 compared 
to p35/Cdk5 or p39/Cdk5 (Amin et al., 2002). Furthermore, the p25 fragment 
(without amino-terminal myristoylation site) freely moved around the 
neuronal compartments and associated with Cdk5 to form a p25/Cdk5 
complex. This p25/Cdk5 complex exhibited abnormal subcellular localization 
and altered substrate specificity and eventually led to devastating effects for 
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cells such as destabilization of cytoskeleton, production of intra-cellular 
aggregates and finally modulation of nuclear function (Patrick et al., 1999; 
Kusakawa et al., 2000; Asada et al., 2008; Kim et al., 2008). A similar 
fragment, p29, produced from p39 cleavage has also been reported to move 
Cdk5 from its usual compartments, but p29/Cdk5 was detected mainly in the 
cell soma and the proximal neurites. However, the role of p29 in the 
progression of neurodegeneration has not been reported previously (Patzke 
and Tsai, 2002b).   
1.2.5.2 Altered Cdk5 substrate specificity 
p25-mediated altered Cdk5 substrate specificity might be the major event 
behind the neuropathological effects of Cdk5. Studies have shown that the 
expression of p25 in cortical neurons induced neurite retraction, microtubule 
collapse and apoptosis (Patrick et al., 1999). Although the mechanism behind 
this was not fully elucidated, p25 might mediate this through an altered Cdk5 
substrate specificity. An in vitro study using primary neuronal culture revealed 
that the p25/Cdk5 complex more efficiently phosphorylated tau than the 
p35/Cdk5 complex. Furthermore, in vivo evidence indicated that transgenic 
mice overexpressing p25 displayed robust hyperphosphorylation of tau, 
whereas p35 overexpressing mice did not exhibit increased tau 
phosphorylation (Takashima et al., 2001; Bian et al., 2002). This hyperactive 
p25/Cdk5 complex also caused aberrant hyperphosphorylation of various 
cytoskeletal components including neurofilaments (medium/heavy, NF-M/H) 
(Ahlijanian et al., 2000; Lee and Tsai, 2003; Noble et al., 2003). Even though 
several in vitro and in vivo studies confirmed that tau and NF-H were not the 
physiological substrate for Cdk5,  p25/Cdk5-mediated altered substrate 
specificity induces the hyperphosphorylation of Tau and NF-H, eventually 




Figure 1.5: p25/Cdk5 deregulation-mediated neurodegeneration 
Exposure of neurons to toxic insults activated the calcium-dependent protease 
calpain, which then cleaved the Cdk5 activator, p35, into p25 fragment. Deregulation 
of Cdk5 by the binding of p25 caused the hyperphosphorylation of tau and abnormal 
processing of APP, leading to the formation of intracellular neurofibrillary tangles 
and extracellular amyloid-β plaques. 
 
In addition, p25/Cdk5-meditated altered phosphorylation has also been 
reported to be involved in abnormal processing of the amyloid precursor 
protein (APP) (Iijima et al., 2000). In particular, elevated APP Thr668 
phosphorylation was found during increased p25/Cdk5 activity in transgenic 
mice (Cruz et al., 2003). p25/Cdk5 hyperactivation-mediated 
neurodegenerative changes are summarized in Figure 1.5. 
However, not all Cdk5 substrates were affected by p25/Cdk5 hyperactivation. 
For example, the phosphorylation levels of Nudel, mDab1 or PSD95 were not 
impaired during p25 overexpression (Cruz et al., 2003) possibly due to their 
cellular localization. Moreover, p25-mediated alteration in substrate 
specificity of Cdk5 is also partly due to its biochemical properties. Crystal 
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structure studies for p25/Cdk5 indicated that certain residues on p25 might be 
responsible for the altered substrate specificity (Tarricone et al., 2001). 
1.2.6 Role of p25/Cdk5 hyperactivation in neurodegenerative diseases 
Numerous studies have found that Cdk5 deregulation is associated with the 
development of neuropathology in various neurodegenerative diseases 
including AD, ALS, PD, cerebral ischemia and Huntington’s disease. The 
following sections summarize some of the key findings on the Cdk5-mediated 
neuropathological mechanisms underlying various neurodegenerative diseases. 
1.2.6.1 Role of Cdk5 in Alzheimer’s disease (AD) 
Substantial evidence now support a model in which the p25-mediated Cdk5 
deregulation is involved in the regulation of many of the signaling pathways 
that led to the development of AD-like neuropathology. Since Cdk5 
deregulation has a close connection with Aβ toxicity, tau pathology, and 
synaptic abnormalities, it may be an effective and novel therapeutic candidate 
for AD. Although there have been some controversy concerning the detection 
of p25 in postmortem samples of AD patients (Tandon et al., 2003), studies 
observed significant accumulations of p25 along with striking elevation of 
Cdk5 activity in the human AD cases compared to age-matched control brains 
(Patrick et al., 1999; Tseng et al., 2002). In addition, increased levels of active 
calpain were also observed in the human AD brains (Saito et al., 1993; Lee et 
al., 1999; Patrick et al., 1999; Tseng et al., 2002).  
1.2.6.1.1 Role of Cdk5 in Aβ accumulation 
Aβ has long been proposed as the toxic instigator of the cascade of 
pathological events that eventually leads to synaptic dysfunction and neuronal 
loss in AD. As mentioned earlier, Aβ peptide is formed from the sequential 
cleaving of APP by β-secretase (BACE1) and then by γ-secretase in the 
transmembrane region. Subsequently, senile plaques are formed due to an 
accumulation of Aβ aggregates (Shoji et al., 1992). The main link between 
Cdk5 and AD was supported by studies showing that hyperactivated Cdk5 
increased Aβ production through the phosphorylation-mediated abnormal 
processing of APP (Iijima et al., 2000; Lee and Tsai, 2003). Interestingly, 
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inhibition of Thr668 phosphorylation using Cdk5 inhibitors displayed marked 
reduction in Aβ peptides in cultured neurons (Lee et al., 2003). Additionally, 
elevated APP Thr668 phosphorylation has also been reported in p25 
transgenic mice compared to controls (Cruz et al., 2006). Studies also reported 
the role of Cdk5 deregulation in the alteration of presenilin (PS1) metabolism 
and stability (Kesavapany et al., 2001; Lau et al., 2002).  
Further studies specified that Cdk5-mediated phosphorylation of the 
transcription factor STAT3 resulted in elevation of transcription of BACE1, 
which then increased the generation of Aβ (Wen et al., 2008). Cdk5-mediated 
regulation of Aβ pathology was further supported by various studies where 
both in vitro and in vivo administration of Aβ peptide significantly elevated 
p25 levels (Patrick et al., 1999; Lopes et al., 2007, 2010). Moreover, studies 
have also shown that the direct or indirect inhibition of Cdk5 significantly 
reduced Aβ-mediated neurotoxicity (Lopes et al., 2007; Granic et al., 2010). 
These studies together strongly suggested that Cdk5 hyperactivation and 
subsequent abnormal processing of APP might be an early event in AD that 
led to the production of toxic Aβ peptide accumulation.  
1.2.6.1.2 Role of Cdk5 in Tau pathology 
Tau hyperphosphorylation and the presence of neurofibrillary tangles are 
among the major hallmarks of AD. Numerous studies showed that Cdk5 was 
co-purified with tau protein from microtubule preparations (Sobue et al., 
2000). Various studies using phosphoepitope-specific antibodies and mass 
spectrometric analysis revealed that the Cdk5-specific phosphorylation sites 
on tau (S202, T205, S396 and S404) were also hyperphosphorylated in AD 
brains (Flaherty et al., 2000). Moreover, immunohistochemical analyses on the 
human brains discovered the apparent co-localization of increased Cdk5 
immunoreactivity with both pretangle and NFT-bearing neurons (Yamaguchi 
et al., 1996). Results from in vitro studies indicated that p25/Cdk5 
hyperactivity is involved in the hyperphosphorylation of tau (Hashiguchi et al., 
2002). Likewise, p25 overexpressing mice displayed hyperphosphorylation of 
both neurofilaments and tau (Ahlijanian et al., 2000). Tau protein is thought to 
be degraded via the ubiquitin-proteasome mechanism (David et al., 2005; 
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Oddo, 2008). However, hyperphosphorylated tau is more resistant to this 
proteasome-mediated degradation and further causes the intracellular 
accumulation of tau fibers in neurons (Khatoon et al., 1992).  
Plenty of recent emerging evidence further supported the significance of 
Cdk5-mediated phosphorylation in tau pathology. An interesting study using 
triple-transgenic AD mice showed that knockdown of Cdk5 expression 
reduced the abnormal tau phosphorylation and neurofibrillary tangle formation 
(David et al., 2005).  Furthermore, Aβ-induced activation of Cdk5 was found 
to be responsible for the phosphorylation of tau that is missorted to the 
somato-dendritic compartment, which resulted in dissociation of tau from 
microtubules (Zempel et al., 2010). Cdk5 also facilitated tau phosphorylation 
by inhibiting phosphatase PP1 through phosphorylation (Lu et al., 2011). 
1.2.6.2 Role of Cdk5 in Amyotrophic Lateral Sclerosis (ALS) 
Amyotrophic lateral sclerosis (ALS), an adult-onset neurodegenerative 
disease, is mainly characterized by a selective loss of motor neurons in the 
spinal cord, brainstem and cerebral cortex, ultimately resulting in paralysis, 
respiratory failure, and death (Cleveland, 1999). ALS has been attributed to 
point mutations in the copper/Zinc superoxide dismutase (SOD1) gene that 
induce a series of neuropathological effects including excitotoxicity 
(Cudkowicz et al., 1997). An interesting discovery of elevated levels of p25 
expression and subsequent Cdk5 hyperactivation was the first evidence that 
supported the involvement of Cdk5 in ALS (Nguyen et al., 2003). This p25-
mediated Cdk5 hyperactivation induced hyperphosphorylation of the 
neurofilament H (NF-H) and made them insoluble. Subsequently, this 
insoluble hyperphosphorylated NF-H formed perikaryal aggregates, which 
disrupted axonal transport and eventually resulted in neuronal death (Nguyen 
et al., 2001; Patzke and Tsai, 2002a). In addition, co-localization of Cdk5 and 
NF-H aggregates was also noticed in the ALS patients’ brain (Bajaj et al., 
1999). The role of Cdk5 in ALS pathology was further supported by a recent 
study where minocycline treatment with mutant SOD1 mice drastically 




1.2.6.3 Role of Cdk5 in Parkinson Disease (PD) 
Parkinson’s disease (PD) is a progressive debilitating neurodegenerative 
disorder characterized by the selective loss of dopaminergic neurons in the 
substantia nigra (Dauer and Przedborski, 2003). The intracellular 
accumulation of α-synuclein aggregates named Lewy bodies is one of the 
major hallmark features of PD pathology  (Spillantini et al., 1997; Baba et al., 
1998; Venda et al., 2010). Interestingly, recent reports have shown the 
changes in level and activity of Cdk5 in the brain of PD patients (Alvira et al., 
2008). Moreover, elevated levels of Cdk5 activation along with the increased 
levels of p25 expression were reported during treatment with the neurotoxin, 
1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). This could be due to 
MPTP-induced glutamate toxicity and subsequent calpain activation (Smith et 
al., 2003; Alvira et al., 2006). In addition, another study demonstrated that 
MPTP-induced Cdk5-mediated phosphorylation of MEF2 contributed to 
neuronal death in dopaminergic neurons in the substantial nigra region of a PD 
mouse model (Smith et al., 2006). Moreover, MPTP-mediated Cdk5 
hyperactivation also induced the downregulation of peroxidase activity of 
Prx2 (peroxiredoxin) and in turn reduced the elimination rate of ROS (reactive 
oxygen species), which eventually led to neuronal loss (Qu et al., 2007). The 
involvement of Cdk5 in PD pathology is further supported by recent findings 
where MPTP-induced neuronal loss and behavioral deficits were effectively 
reduced by the inhibition of Cdk5 activity (Smith et al., 2003; Smith et al., 
2006; Qu et al., 2007). Findings of Cdk5-mediated phosphorylation of α-
synuclein and parkin further supported the critical involvement of Cdk5 in the 
pathogenesis of PD (Avraham et al., 2007; Rubio de la Torre et al., 2009).  
1.2.6.4 Role of Cdk5 in cerebral ischemia 
Cerebral ischemia (stroke) is a condition in which loss of brain function occurs 
as a result of  insufficient blood flow to the brain (Hou and MacManus, 2002). 
In particular, inflammatory reactions and excitotoxicity are the main events 
that contributes to neurodegeneration during cerebral ischemia (Mehta et al., 
2007; Nakka et al., 2008). Recent in vivo studies have clearly demonstrated 
that Cdk5 overactivation-mediated regulation of NMDA receptors (Wang et 
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al., 2004) and phosphorylation of tau (Wen et al., 2007) play a major role in 
the induction of neuronal death. 
1.2.6.5 Role of Cdk5 in Huntington’s disease  
Huntington's disease is an autosomal-dominant inherited genetic 
neurodegenerative disorder caused by a mutation in the huntingtin gene (HTT) 
that encodes for the protein, huntingtin (Htt) (Rubinsztein and Carmichael, 
2003). Numerous recent studies showed a protective role of Cdk5 in 
Huntington’s disease pathology, in contrast to the emerging detrimental role of 
p25/Cdk5 hyperactivation in various neurodegenerative diseases. Cdk5-
mediated phosphorylation of huntingtin was found to be neuroprotective 
against DNA damage and polyglutamine expansion (Anne et al., 2007). 
Moreover, reduced p35/Cdk5 levels and activity were observed in postmortem 
samples of Huntington’s disease patients (Anne et al., 2007) as well as in a 
Huntington’s disease mouse model (Luo et al., 2005). Furthermore, Cdk5 
phosphorylation at Ser434 abolished htt aggregation by reducing caspase-
mediated cleavage (Luo et al., 2005). Collectively, findings suggested that 
Cdk5 activity offered a protective role in Huntington’s disease by limiting the 
mutant htt toxicity.  
1.2.7 Modelling p25-induced neurodegeneration - p25 transgenic mice 
Several transgenic mouse lines overexpressing p25 have been generated and 
characterization of different p25 transgenic (p25Tg) mice lines has facilitated 
the investigation of mechanism behind p25/Cdk5-mediated neuropathology. 
However, these p25 transgenic mice lines exhibited variation in distribution 
pattern and expression levels of p25 and some are unsuitable for investigating 
the contribution of p25 formation in the development of AD-like pathology 
(Giese et al., 2005). For example, a mouse line developed with the platelet 
derived growth factor (PDGF) B chain promoter expressed relatively high 
amounts of p25 in the spinal cord. These mice exhibited profound dyskinesia, 
central axonal degeneration, but no neurofibrillary tangles. Moreover, this 
severe phenotype displayed semiparalysis of the hind limbs and early death 
occurred, preventing the investigation of memory formation and age-
dependent processes (Bian et al., 2002). In addition, even though  p25Tg 
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mouse generated using a cytomegalovirus promoter (pCMV) showed the 
accumulation of p25, neither hyperphosphorylation of tau nor neuronal death 
was seen (Takashima et al., 2001). Another p25Tg mouse generated using 
neuron-specific enolase (NSE) promoter exhibited hyperphosphorylation of 
tau/neurofilament, positive silver staining, and cytoskeletal disturbances that 
were similar to several neurodegenerative diseases including AD. In addition, 
mice displayed increased spontaneous locomotor activity compared to control 
mice (Ahlijanian et al., 2000). Furthermore, NSE p25Tg mice in a p35 
knockout background were generated by another group and results reported 
that p25 can compensate partially for p35/Cdk5 under some conditions during 
development (Patzke et al., 2003). Additional support for the effect of Cdk5 
on the progression of tau pathology comes from another study where NSE-
p25-P301L-tau bi-transgenic mice displayed elevated formation of 
neurofibrillary tangles compared to their parent mice (P301L-tau transgenic 
mice and NSE p25Tg mice) (Noble et al., 2003).  
Taken together, the variations in phenotypes as well as the spatial distribution 
of the p25 transgene in p25 overexpressing mice could be mainly due to the 
use of different promoters during the generation of transgenic mice. In 
addition, the intensity of p25 expression in these transgenic mice may possibly 
have a role in determining the rate of neurodegeneration (Cruz and Tsai, 
2004). Thus, it is critical to confine p25 expression to appropriate brain 
regions, such as the forebrain, to fully investigate the pathological role of p25 
production in AD. In addition, it is important to avoid the embryonic 
expression of p25 in order to prevent potential developmental consequences. 
Accordingly, mouse lines with the CaM kinase IIA promoter to drive p25 
expression fulfill these criteria. Importantly, this promoter is not active during 
the embryonic stage and expression of p25 is directed primarily to the 
hippocampus and cerebral cortex (Giese et al., 2005). Initially, p25 expressing 
transgenic mice were generated in the C57BL/6 background using the 
forebrain-specific CaM KIIA promoter in order to study whether and how p25 
formation affects learning and memory. This low level p25 expressing 
transgenic mice exhibited reduced contextual conditioning paired with 
enhanced tone conditioning in conjunction with improved reversal learning in 
38 
 
the Morris water maze (Angelo et al., 2003). In contrast, a later study 
indicated that low levels of p25 did not always improve learning (Mizuno et 
al., 2006). Absence of neurodegeneration with only slight increases in total tau 
protein was observed in these mice. Thus, results concluded that a high level 
of p25 expression was required to cause neuronal death. 
1.2.7.1 CK-p25 bi-transgenic mice 
To determine whether robust expression of p25 itself can trigger 
neurodegeneration, bi-transgenic p25 overexpressing mice (CK-p25Tg mice), 
that overexpress human p25 gene under the control of the CaM KIIA 
promoter,  were generated using tetracycline-controlled transactivator (tTA) 
system (Cruz et al., 2003). Initially, these CK-p25Tg mice were conceived and 
raised on a doxycycline supplemented diet. After normal development of the 
CNS (6-week postnatal), they were given a doxycycline-free diet to induce the 
expression of p25 specifically in the forebrain. Characterization of these CK-
p25Tg mice demonstrated that these mice exhibited progressive neuronal loss 
especially in the cerebral cortex, widespread astrogliosis, and prominent brain 
atrophy that strongly correlated with p25 expression pattern (Cruz et al., 
2003).  
Gradual progression of tau-associated pathology was observed in these CK-
p25Tg mice and p25-mediated hyperphosphorylation of endogenous tau at 
multiple epitopes emphasized the key role of p25/Cdk5 hyperactivation in the 
progression of neurofibrillary pathology in AD (Cruz et al., 2003). Subsequent 
characterization of these mice by the same group in 2006 demonstrated the 
occurrence of noticeable intracellular amyloid-β accumulations in the 
perinuclear regions within the forebrain (Cruz et al., 2006). They further 
claimed that apparent elevation of BACE 1 levels might be the mechanism 
behind the Aβ accumulation caused by the deregulation of Cdk5 in CK-p25Tg 
mice. However, these studies have not shed light on the precise molecular 





1.2.7.2 Behavioral studies in CK-p25Tg mice 
In order to investigate the effects of deregulated Cdk5 activity on learning and 
memory, in vivo behavioral studies were performed with CK-p25 mice and 
results showed that sustained p25 expression severely impaired hippocampal 
LTP and memory along with profound synaptic loss. In contrast, transient p25 
expression facilitated learning and memory with improved hippocampal LTP. 
Thus, these observations concluded that a sustained or prolonged p25 
expression could have the ability to modify the normal physiological function 
of Cdk5 into a pathological one (Fischer et al., 2007).  
1.2.7.3 Neuroinflammation in CK-p25Tg mice 
Recently, Muyllaert et al. generated a new p25 overexpressing transgenic 
mouse line using the same strategy as in CK-p25 inducible Tg mice to 
investigate further the mechanism behind the role of p25 production in 
neurodegeneration (Muyllaert et al., 2008). They observed extensive 
neurodegeneration with severe brain atrophy, as reported previously (Cruz et 
al., 2003; Cruz et al., 2006). However, neither an apoptosis-mediated neuronal 
death nor elevated phosphorylation of tau was noticed even in later stages. 
Conversely, neuroinflammation was observed as the most prominent event 
with considerable activation of microglia in and around the specific brain 
regions with p25-expressing neurons (Muyllaert et al., 2008).  
Collectively, findings from the characterization of inducible p25Tg mice 
(summarized in Table 1.1) delineated a novel pathological mechanism 
involving both neurofibrillary pathology and abnormal APP processing by 
aberrant p25/Cdk5 hyperactivity contributing to the development of AD 
pathologies. Although the occurrence of intense neuroinflammation was 
reported recently in these mice, the actual mechanism behind the p25-
mediated neuroinflammation and subsequent neurodegeneration was not yet 
fully elucidated. Hence, further investigation of Cdk5-mediated effects on 
many stress-induced signaling pathways including neuroinflammation will be 
necessary to fully elucidate the role of Cdk5 deregulation in 
neurodegeneration (Giese et al., 2005).  
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Table 1.1 Summary of characterization of various p25 transgenic mice  
 


















































































































































































































































































1.3 Objectives of this study 
AD is a complicated neurodegenerative disorder and the exact mechanism 
behind the disease pathology is not yet clear. Neuroinflammation is a 
prominent characteristic of AD pathology and is thought to induce 
neurodegeneration. However, the precise mechanism behind 
neuroinflammation and its significance in the initiation of the pathogenesis of 
AD has not been fully elucidated. Increase in p25 expression with subsequent 
deregulation of Cdk5 activity has been shown to be a key causative agent for 
AD pathogenesis. Even though there are many studies available addressing the 
role of p25/Cdk5 hyperactivation in neurodegeneration, there has not been 
clear evidence for the mechanism behind p25/Cdk5-mediated 
neuroinflammation and its significance in neurodegenerative disease 
progression. Hence, this study aims to elucidate the p25/Cdk5-mediated 
neuroinflammatory mechanism using the CamK2a-p25 transgenic (p25Tg) 
mice, a mouse model that exhibits pathological hallmarks seen in AD. The 
thesis is broadly split into two parts: firstly, characterization of the 
neuroinflammatory cascade in the p25Tg line, and secondly, determining the 
biological benefit when these mice are treated with curcumin, an anti-
inflammatory compound.  
The objectives for the first part of this thesis are: 
 To determine the onset of neuroinflammatory events such as 
astrogliosis, microgliosis and chemokine production in p25Tg mice. 
 To determine the role of brain infiltration of leukocyte in p25-mediated 
neuroinflammation in p25Tg mice. 
 To investigate the mechanism of p25-mediated robust increases in 
neuroinflammation in vitro. 
 To determine whether this p25/Cdk5-mediated neuroinflammation is 
the initial trigger for neurodegeneration. 
Disappointing failures of recent clinical trials of anti-inflammatory agents in 
neurodegenerative disorders has meant that a better understanding of the 
complex roles in the neuroinflammatory process is required to unravel its link 
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with neurodegeneration. Curcumin, a well-studied anti-inflammatory, 
antioxidant, anti-amyloidogenic and anti-oncogenic drug can be efficacious 
without any apparent side effects. However, its oral bioavailability is poor. To 
counter this, the laboratory of Sally Frautschy (UCLA) developed 
LONGVIDA-curcumin, a proprietary optimized formulation that showed 
promise in both human and animal studies with increased bioavailability in the 
brain as well as plasma (Begum et al., 2008; Frautschy and Cole, 2010). 
Hence, this study used this special formulation of curcumin to investigate 
whether early intervention to modulate inflammation will result in changes in 
later formation of pathological hallmarks in the p25 transgenic mice. 
The objectives of the second part of this thesis are: 
 To investigate the effect of curcumin on the p25-mediated 
neuroinflammation  
 To investigate whether inhibition of p25-mediated neuroinflammation 
by treatment with curcumin affects neuropathological progression (tau 
and amyloid pathology formation) in p25Tg mice. 
Taken together, data from this study will open avenues of research into 
inhibiting neuroinflammation in the AD paradigm and will also unveil 
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CHAPTER 2: Materials and methods 
 
2.1 Materials 
2.1.1 Materials used for animal maintenance  
 Doxycycline 
Doxycycline (Sigma, D9891) 
    Table 2.1: Doxycycline Preparation  
Stock solution Working dilution 
20 mg/ml  
1g of doxycycline in 50 ml of 
sterile ultra-pure water 
(18.2 MΩ·cm at 25°C, Arium 
611VF, Sartorius) 
200 µg/ml 
2 ml of stock solution was 




Sucrose (Sigma, S8501) 
    Table 2.2: Sucrose solution  
Stock solution Working dilution 
40% solution 
40 g of sucrose in 100 ml of 
sterile ultra-pure water  
 
1% solution 
5 ml of stock solution in 200 
ml of sterile ultra-pure water 
 
 Curcumin feed 
Longvida optimized Curcumin (Verdure Sciences) was mixed with 
regular rodent diet (Harlan, 4 g Curcumin/kg feed)    
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2.1.2 Genotyping  
2.1.2.1 Tail clipping 
 Ethyl chloride Spray  
 Ethyl chloride spray (Walter Ritter GmbH & co) was used before tail 
clip to reduce pain in mice. 
 Super clot  
Super clot (Synergy Labs) was used immediately after tail clip to stop 
bleeding in mice. 
2.1.2.2 Genomic DNA Extraction 
 DNeasy tissue kit (Qiagen, 69506) contains buffer ATL (Tissue lysis 
buffer), Proteinase K solution (> 600 mAu/ml), buffer AL (Lysis 
buffer), buffer AW1 & AW2 (Wash buffers) and buffer AE (elution 
buffer).  
 Absolute Ethanol (Fisher Chemicals, E/0650DF/17) 
2.1.2.3 PCR reagents 
 AccuPrime Pfx SuperMix  
AccuPrime Pfx SuperMix (Invitrogen, 12344-040) was used for p25 
transgene PCR. It contains 22 U/ml thermostable polymerase, 66 mM 
Tris-SO4 (pH 8.4), 30.8 mM (NH4)2SO4, 11 mM KCl, 1.1 mM 
MgSO4, 330 µM dNTPs and stabilizers.  
 GoTaq Green Master Mix  
GoTaq Green Master mix (Promega M712) was used for Camk2a 
transgene PCR. It contains GoTaq DNA polymerase, 400 µM dNTPs, 
3 µM MgCl2, reaction buffer (pH 8.5) and tracking dyes (Blue and 
yellow).     




Table 2.3: Primers for genotyping 
                 
      Primers 
                 
                       Primer sequences    
p25 transgene:  
p25 Forward 
p25 Reverse             
IC Forward  
IC Reverse 
                    
5’ CCATCGATCTAGTACAGCTCGTCCATGC 3’ 
5’ AGGGACGACGGCAACTAC 3’ 
5’ CAAATGTTGCTTGTCTGGTG 3’ 




Camk2a Reverse  
IC Forward  
IC Reverse  
 
 
5’ CGCTGTGGGGCATTTTACTTTAG 3’ 
5’ CATGTCCAGATCGAAATCGTC 3’ 
5’ CAAATGTTGCTTGTCTGGTG 3’ 
 5’ GTCAGTCGAGTGCACAGTTT 3’ 
IC – Internal control 
 Genomic DNA 
  1 µl with 10 ng of DNA extracted from mouse tail.  
 Water  
Nucleases, proteases and pyrogen free sterilized water (First Base,    
BUF-1180-1L). 
2.1.2.4   Agarose gel electrophoresis  
 1X TAE (Tris-Acetate-EDTA) buffer 
50X TAE (First Base, BUF-3000) buffer was diluted into 1X with 
distilled water.  
 1.5 % Agarose gel 
2.25 g of Agarose powder (Invitrogen, 15510-027) was dissolved in 
150 ml of 1X TAE buffer by heating in a microwave oven.  
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 GelRed (10,000X, Biotium, 41003-1)    
 Blue 6X loading dye (Promega, G190A) 
 1000 bp DNA ladder (Promega, G210A)  
2.1.3 Mammalian cell culture  
2.1.3.1 Primary Neuron culture 
 Neuron culture medium 
Neurobasal medium (Invitrogen, 21103-049)  
B27 supplement (1:50, Invitrogen, 17504-044)  
100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco, Life 
Technologies, 15070-063)  
2 mM glutamine (Gibco, Life Technologies, 25030-081) 
 Papain solution 
Papain (Worthington Biochemical Corp, 3176) in 5 ml Earle’s 
Balanced Salt Solution (EBSS, Sigma E2888) was mixed with 250 µl 
of 0.1% DNAse/EBSS (Worthington Biochemical Corp, LK003172). 
 Stop solution 
600 µl of Papain Inhibitor (Worthington Biochemical Corp, 
LK003182) with 5.4 ml of EBSS was mixed with 250 µl of 0.1% 
DNAse/EBSS.  
 10/10 solution 
 0.1 g bovine serum albumin (BSA) (Sigma, A2153) and 0.1 g Trypsin 
Inhibitor (Sigma, T9253) was dissolved in 10 ml of EBSS. 
 Poly-L-lysine (Sigma P6282) 
    Stock - 5mg in 2.5ml of sterile ultra-pure water (2 mg/ml) 
    Working - 1:100 in sterile ultra-pure water (20 µg/ml) 
2.1.3.2 Primary glia culture 
48 
 
 Glial cell culture media 
Dulbecco’s Minimal Essential Medium (DMEM) (GIBCO by Life 
Technologies, 12430-054)  
Fetal Bovine Serum (FBS) (GIBCO by Life Technologies, 10270-106)  
200 mM glutamine (GIBCO by Life Technologies, 25030-081)  
100 mM sodium pyruvate (GIBCO by Life Technologies, 11360-070)  
100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco, Life 
Technologies, 15070-063)  
 3.0 μm tissue culture inserts (Greiner bio-one, 657630) 
 Coverslips (25 mm, 0111650, Marienfeld GmBH) 
2.1.3.3 Mammalian cell line  
 Human Embryonic Kidney (HEK) FT cell line (Life technologies, 
Invitrogen, R700-07) 
 HEK FT cell culture medium 
 DMEM (GIBCO by Life Technologies, 12430-054)  
 Fetal Bovine Serum (FBS) (GIBCO by Life Technologies, 10270-106)  
200 mM glutamine (GIBCO by Life Technologies, 25030-081)  
10 mM non-essential amino acid (NEAA) solution (GIBCO by Life 
Technologies 1140050)  
100 mM sodium pyruvate (GIBCO by Life Technologies, 11360-070)  
Geneticin (G418 Sulphate, 500 µg/ml, GIBCO by Life Technologies, 
10131-035)  
 1X Trypsin-EDTA 
1X trypsin-EDTA solution was prepared from 10X stock (Biowest, 
X0930-100) using 1X Phosphate buffer saline (PBS) 
49 
 
 Freezing Media 
80% DMEM (GIBCO by Life Technologies, 12430-054) 
10% Dimethyl sulphoxide (DMSO) (MP Biomedicals, 191418) 
10% FBS (GIBCO by Life Technologies, 10270-106) 
2.1.4 Plasmids 
 p25-LV-CMV (a gift from Dr. Harish Pant (NINDS, NIH, USA) 
Carboxy terminal fragment (p25) of human cyclin-dependent kinase 5 
regulatory subunit 1 (CDK5R1) coding region was cloned after PCR 
into LV-CMV-link (third generation self-inactivating vector) between 
Asc1 and BsiW1 (Zheng et al., 2005). 
 EV-LV-CMV (a gift from Dr. Harish Pant (NINDS, NIH, USA) 
Empty Vector DNA-LV-CMV was constructed without the p25 coding 
region. 
2.1.5 Transformation and Plasmid DNA Scaling up 
 DH5α ultra competent cells (Invitrogen, 18265-017)  
 QIAprep Spin Miniprep Kit (Qiagen, 27106) 
 Luria Bertani (LB) broth (Novagen, EMD Millipore, 71753-5) 
25 g of LB powder was dissolved completely in 1 litre of ultra-pure 
water and sterilized by autoclaving (121°C, 15 psi for 20 minutes).  
 LB Agar (BD Difco-244520) 
40 g of LB agar powder was dissolved completely in 1 litre ultra-pure 
water and sterilized by autoclaving (121°C, 15 psi for 20 minutes). 
 Ampicillin 
Stock ampicillin solution was prepared by dissolving ampicillin 
powder (Sigma, A0166) in sterile water as 100 mg/ml, filter sterilized 
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and stored in aliquots at -20
o
C. This stock solution was mixed with LB 
broth or LB agar plates as 100 µg/ml concentration. 
 Glycerol stock 
Bacteria containing the plasmid of interest in LB-ampicillin broth were 
mixed with an equal volume of sterile glycerol (Invitrogen, 15514-011) 
solution to make glycerol stock and stored at -80
o
C. 
2.1.6 Transduction and lentivirus production 
 Lipofectamine 2000 (Invitrogen by Life Technologies, 11668-019) 
 ViraPower Lentiviral packaging mix (Invitrogen, K4975-00) 
 Syringe Filter 0.4 µM (Millex, Millipore, SLCR025NS) 
 Ultracentrifugation tube (Millipore, Amicon Ultra 100K, 
UFC910008) 
2.1.7 Factor removal experiments 
 DNAse (8 μg/ml) (Sigma, D4527) 
 RNAse (50 µg/ml) (Sigma, R5125) 
 Proteinase K (50 µg/ml) (Sigma, P2308) 
 Solid phase extraction column (SPE-C18 column, Waters, 186004620)  
2.1.8 Immunocytochemistry 
 Fixative 
 4% Formaldehyde solution was prepared from 37% Formaldehyde 
stock (Calbiochem, 344198) in 1X phosphate buffered saline (PBS). 
 1X Phosphate buffer saline (PBS) 
10X PBS ((First Base, BUF-2040) (137 mM sodium chloride, 2.7 mM 
potassium chloride and 10 mM phosphate buffer) solution was diluted 
into 1X with distilled water.   
 Permeabilizing solution  
0.1% Triton-X-100 (BDH, 306324N) in 1X PBS 
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 Blocking solution  
 5% FBS in 1X PBS 
 Antibody incubation solution  
5% FBS in 1X PBS 
 DAPI  
Stock DAPI (4’, 6-diamidino-2-phenylindole dihydrochloride) (Sigma, 
D8413) solution was prepared by reconstituting the content provided in 
water as per manufacturer’s instruction and used at a 1:1000 dilution. 
 Anti-fade fluor-mounting medium  
DAKO faramount aqueous mounting medium, S3025 
2.1.9 Immunohistochemistry 
2.1.9.1 Perfusion 
 Mouse Anesthesia 
A mixture of ketamine (75 mg/kg) and medepomidin (1 mg/kg) 
(provided by MD2 animal holding unit, Comparative Medicine, NUS). 
 Ringer’s Solution (in 1 litre of ultra-pure water) 
Sodium Chloride (NaCl) (First Base, Bio-1111) - 8.5 g,  
      Potassium Chloride (KCl) (BDH, 101985 M) - 0.25 g, 
      Calcium Chloride (CaCl2) (Sigma, C1016) - 0.3 g  
      Sodium Bicarbonate (NaHCO3) (Sigma, S6297) - 0.2 g  
 Fixative solution (for 1 litre) 
4% Paraformaldehyde (PFA) (Sigma, P6148)/1X PBS  
40 g of PFA powder was dissolved in 900 ml of ultra-pure water by 
heating slowly and pH was adjusted to 7.4 followed by addition of 100 
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ml of 10X PBS. The solution was allowed to cool before filtered 
through 0.2 µM filter and stored at 4
o
C.    
 Sucrose/1X PBS solution  
10%, 20% and 30% sucrose (Sigma, S8501) solutions were prepared in 
1X PBS.  
 Cryoprotectant for sectioning 
Shandon M1 Embedding Matrix (Thermo Scientific, APD1310) 
 Superfrost ultra plus adhesion slides (Thermo Scientific, 
1014356145) 
2.1.9.2 Staining Reagents 
 In situ cell death detection kit, TMR red (TUNEL kit) (Roche, 
12156792910) 
 Thioflavin solution 
0.05% thioflavin-S (Sigma, T1892) in 50% ethanol 
 Bielschowsky Silver staining 
20% Silver Nitrate (AgNO3) 
4 g of Silver Nitrate (Sigma, 209139) was dissolved in 20 ml of 
distilled water. 
      Ammoniacal Silver Nitrate Solution 
Ammonia solution (Sigma, 341428) was added to silver nitrate 
solution until the brown precipitate disappeared. 
Ammonia water solution 




2 ml of formaldehyde (37% formaldehyde, Calbiochem, 344198), 5 µl 
of concentrated nitric acid (Sigma, 258121) and 50 mg of citric acid 
(Sigma, 251275) in 10 ml of distilled water.     
Hypo solution 
5% Sodium thiosulphate (Sigma, 563188)  
 Absolute Ethanol (Fisher Chemicals, E/06050DF/17)  
 Xylene ( Sigma, 534056)  
 Shandon-Mount permanent mounting medium (Thermo Scientific, 
1900331) 
2.1.10 Western blot analyses   
 2.1.10.1 Protein quantification assay 
 Protein Standards  
1 mg/ml of bovine serum albumin (BSA) (98% pure Sigma, A7906) 
was serially diluted in lysis buffer.  
 BCA (Bicinchoninic acid) protein assay kit (Thermo Scientific, Pierce, 
23225)  
2.1.10.2 Buffers 
 Lysis buffer 
50 mM Tris pH 7.0 (First Base, 1415)  
150 mM Sodium Chloride (NaCl) (First Base, BUF-1112) 
1% Triton-X-100 (BDH, 28817.295)  
1 mM Ethylenediamine tetra acetic acid (EDTA) (First Base, BUF 
1052) 
1 mM Ethylene glycol-bis (β-amino ethyl ether)-N, N, N’, N’-
tetraacetic acid (EGTA) (Sigma, E8145) 
1 mM Sodium Fluoride (NaF) (Sigma, 201154) 
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  Protease inhibitor cocktail solution 
Complete EDTA-free protease inhibitor cocktail tablet (Roche, 
11873580001) was prepared as 50X solution in lysis buffer and stored 
in aliquots at -20
o
C freezer and used at 1X dilution. 
 Laemmli sample buffer (2X) 
4% Sodium dodecyl sulphate (SDS) (First Base, BUF-2051)  
20% glycerol (Invitrogen, 15514-011)  
125 mM Tris HCl pH 6.8 (First Base, BUF-1415) 
0.04% Bromophenol blue (Sigma, B6131) 
5% Beta-mercaptoethanol (BME) (BDH, 441435C) (add just prior to 
use) 
 1X Tris-glycine-SDS-running buffer  
10X Tris-glycine-SDS-running buffer (First Base, BUF-2030) (0.025 
M Tris, 0.192 M glycine and 0.1% SDS) was diluted to 1X with 
distilled water. 
 1X Tris-glycine-transfer buffer 
100 ml of 10X-Tris-glycine-buffer (First Base, BUF-2020) (0.025 M 
Tris and 0.192 M glycine) was mixed with 200 ml of methanol 
(Schedelco, M0106) and 700 ml of distilled water. 
 TBST (Tris buffered saline and Tween 20) (For  1 litre) 
50 mM Tris pH 7.0 (First Base, BUF-1415)  
150 mM NaCl (First Base, BUF-1112) 
1 ml of Tween 20 (Sigma, P1379) 
 Stripping buffer 
0.5% SDS (First Base, BUF-2051) 
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62.5 mM Tris pH 7.0 (First Base, BUF-1415) 
100 mM beta-mercaptoethanol (BME) (BDH, 441435C) 
 2.1.10.3 Blocking solution 
10% milk (blotting grade blocker, BioRad-170-6404) in TBST  
2.1.10.4 Antibody incubation solution 
5% milk in TBST  
2.1.10.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 Pre-cast gels 
Novex 4-20% Tris-Glycine mini gels, 1.0 mm, 10 well (Novex by Life 
technologies, EC6025) 
 Protein ladder  
See Blue plus pre-stained standard (LC5925, Life Technologies)  
 Nitrocellulose Membrane  
Amersham Hybond ECL, 0.45 µM (RPN68D, GE Healthcare) 
 Protein staining solution- Ponceau Red  
0.1% Ponceau (Sigma, P3504) was prepared in 5% glacial acetic acid 
(Merck Millipore, 100063). 
 Detection solution 
ECL detection kit (Amersham-ECL-prime-Western blot detection 
reagent, RPN 2232, GE Health care)  
 Film 





Antibodies used are listed in the following tables 
Table 2.4: Primary antibodies 
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Table 2.5:  Secondary antibodies 
Name Source & 
Catalogue 
number 

















































1:200 ICC and IHC 
HRP-Horseradish peroxidase, WB-Western blot analyses, IHC-
Immunohistochemistry and ICC-Immunocytochemistry 
2.1.12 Kinase assay  
 Protein A-Sepharose beads (Sigma P9424) 
 Kinase buffer 
20 mM Tris-HCL (pH 7.4) (First Base, BUF 1415) 
10 mM Magnesium chloride (MgCl2) (Sigma, M8266) 
1 mM EDTA (First Base, BUF-1052) 
10 μM Sodium fluoride (NaF, 131675.1210, Panreac) 
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1 μM Sodium orthovanadate (Na3VO4) (Alexis Biochemicals, A400-
032-G005) 
 5X kinase assay mixture 
100 mM Tris-HCl (pH 7.4) (First Base, BUF 1415) 
50 mM MgCl2 (Sigma, M8266), 
5 mM EDTA (First Base, BUF 1052) 
50 μM NaF (Panreac, 131675.1210) 
5 μM Na3VO4 (Alexis, 400-032-G005) 
5 mM DTT (Pierce, Thermo scientific, 20290) 
 5 μCi of (γ-32P)ATP (PerkinElmer, BLU002A100UC) 
 Histone H1 (Millipore, 14-155)   
 NF-H peptide (VKSPAKEKAKSPVK) (Sigma Proligo)  
 Trichloroacetic acid (Sigma 522082) 
 P81 phosphocellulose squares (Millipore, 20-134) 
 Bio-safe ІІ scintillation fluid (111195, Research Products 
International, Mount Prospect, IL) 
2.1.13 Real-Time PCR (RT-PCR) 
 Trizol (Invitrogen, 15596-018) 
 Chloroform (J. T. Baker – 9180-68)  
 70% ethanol  
70 ml of 100% ethanol (Ethanol-Fisher Chemicals, E/06050DF/17) in 
30 ml water  
RNeasy Mini Kit (Qiagen, 74106) 
 High capacity cDNA reverse transcription kit (Applied Biosystems, 
4368814) 




 Primers (Sigma Proligo) 
    Table 2.6: Primers used in RT-PCR 
           
               Primers 
                               
               Primer sequences 
 
MIP-1α Forward  
 
5’ TTGAGCCCCGGAACATTC 3’ 
MIP-1α Reverse 5’ GCAGCAAACAGCTTATAGGAGATG 3’ 
TNF-α Forward 5’ AGCACAGAAAGCATGATCCG 3’ 
TNF-α Reverse 5’ GGAGTAGACAAGGTACAACC 3’ 
TGF-β Forward 5’ CTTTAGGAAGGACCTGGGTT 3’ 
TGF-β Reverse 5’ CAGGAGCGCACAATCATGTT 3’ 
 IL-1β Forward 5’ ACCTGCTGGTGTGTGACGTTC 3 
IL-1β Reverse 5’ CAGCACGAGGCTTTTTTGTTGT 3’ 
iPLA2 Forward 5’ TAACCTGAAGCCACCGACTC 3’ 
iPLA2 Reverse 5’ TAGTGTTGATCTCTGATATG 3’ 
cPLA2 Forward 5’ CTGCAAGGCCGAGTGACA 3’ 
cPLA2 Reverse   5’ TTCGCCCACTTCTCTGCAA 3’ 
 
2.1.14 Radial Maze 
 Radial maze for mice: 5 cm lane width x 35 cm arm length x 9 cm 
wall height, Stoelting ANY-maze, IL, USA (60150) (Software: 
EthoVision 3.1) 
Novel food: Kellogg’s fruit loops 
2.1.15 Lipid Analyses 
 1-Butanol ( J.T. Backer, JT9189-01) 
 Chloroform (J.T. Baker, JT9180-68)  




  2.1.16 Cytosolic Phospholipase A2 (cPLA2) analyses 
 PLA2 Inhibitor studies 
0.3 µM of BEL (Bromoenol Lactone) (iPLA2 inhibitor) (Sigma, 
B1552)  
10 µM of AACOCF3 (Arachidonyl trifluoromethyl ketone) (cPLA2 
inhibitor) (Biomol, 149301-79-1) 
 cPLA2 silencing 
cPLA2 shRNA lentivirus (Santa Cruz Biotechnology, sc-35098-V) 
Polybrene (hexadimethrine bromide) (3 µg/ml) (Sigma, 107689)  
 cPLA2 activity Assay 
cPLA2 assay kit (Cayman Chemical, 765021) 
Ice cold buffer 
50 mM HEPES pH 7.4 (Thermo Scientific, SH 30237.01) 













2.2 Methods  
2.2.1 Animal Handling  
All animal procedures were carried out according to protocols approved by the 
Institutional Animal Care & Use Committee (IACUC) of the National 
University of Singapore (IACUC protocol number: 078/09). The animals were 
housed in standard cages (19.1 x 29.2 x 2.7 cm) with corncobs bedding at 
constant room temperature (22±1
o
C) and 46-48% relative humidity. They 
were under a regular light-dark schedule (lights on from 7AM to 7PM), had 
free access to food (Irradiated 18% protein rodent diet, Teklad global, 2918, 
Harlan) and water ad labitum. 
2.2.2 p25 transgenic mice 
Breeding pairs of p25 single transgenic mice (C57BL/6-Tg (tetO-
CDK5R1/GFP) 337Lht/J, Stock No: 005706) and CaM KIIα single transgenic 
mice (B6; CBA-Tg (Camk2a-tTA) 1Mmay/DboJ, Stock No: 007004) were 
obtained from The Jackson Laboratory (Bar Harbor, Maine, USA). All 
transgenics were heterozygous. p25 transgenic mice had the transgenic vector 
that encodes the carboxy terminal proteolytic fragment (p25) of human cyclin-
dependent kinase 5, regulatory subunit 1 (CDK5R1) sequence with a green 
fluorescent protein (GFP) tag under the control of a tetracycline-responsive 
promoter element (TRE; tetO). Transgenic construct in CaM KIIα mice was 
designed with mouse CaM KIIα promoter placed upstream of the tetracycline-
regulated transactivator (tTA) gene. p25 single transgenic mice were crossed 
with CaM KIIα mice to generate bi-transgenic offsprings (p25Tg mice) that 
inducibly overexpress human p25 gene under the control of the CaM KIIα 
promoter-regulated tet-off system. In this system, tTA binds to the TRE and 
activates transcription of the p25 gene in the absence of repressor 
(tetracycline-derivative, doxycycline). All mice in this study were conceived 
and raised in the presence of doxycycline in drinking water, for 6 weeks 
postnatal to avoid any potential developmental consequences from the 
expression of p25. Water containing doxycycline (200 µg/ml) was mixed with 
1% sucrose to reduce the bitter taste. p25 expression was induced by the 
removal of doxycycline in water and samples (brain/blood) were collected at 
63 
 
different weeks of p25 induction periods. p25Tg mice were initially 
characterized by Cruz et al., in 2003 and various studies suggested that p25Tg 
mice recapitulate most of the pathological features of AD including tau 
hyperphosphorylation, amyloid accumulation and neuronal loss. Wild-type 
littermates were used as control groups in all the experiments and mice of the 
same sex were used for comparison whenever possible.  
2.2.3 Curcumin treatment in p25 transgenic mice 
p25Tg mice were fed with a natural anti-inflammatory compound, curcumin, 
orally via in feed (4 g/kg of feed, Harlan). LONGVIDA, a novel curcumin 
formulation prepared under a novel method called SLCP (solid lipid curcumin 
particle) (Verdure Sciences), was used in this study which has greater 
bioavailability in both the brain and blood as compared to the unformulated 
curcumin powder (Gota et al., 2010). 
2.2.4 Genotyping 
The offsprings generated from mice under different breeding strategies were 
weaned and tails clipped to collect small pieces of tails (0.5 cm) at the age of 
21 days. Genomic DNA was isolated from these tails using DNeasy tissue kit. 
Mice tails were first digested with 180 µl of buffer ATL and 20 µl of 
Proteinase K at 56
o
C until the tissue was completely lysed. Digested tail 
samples were mixed with 200 µl of lysis buffer AL and 200 µl of 100% 
ethanol. This mixture was then transferred into mini spin column and washed 
with buffer AW1 and AW2. Finally, genomic DNA was eluted using the 
elution buffer AE. Purity as well as the concentration of the eluted DNA was 
assessed using NanoDrop (Spectrophotometer, ND 1000 Biofrontier 
Technology). Genotyping was done by independent PCRs with the extracted 
genomic DNA using primers specific for Camk2a-tTA and p25-GFP (see 
section 2.1.2.3). Details about the preparation of reaction mixtures and cycling 





Table 2.7: Detection of p25 transgene 
 
Table 2.8: Detection of Camk2a transgene 
   IC –Internal control 






















0.5 20 3 58 1 min - 
IC Reverse 
primer 
0.5 20 4 72 1 min Repeat 




11 - 5 72 2 min - 
water - - 6 10 - hold 





























in each cycle 
IC Reverse 
primer 
0.5 20 4 72 35 
sec 
Repeat steps 




6 - 5 94 20 
sec 
- 
water 6 - 6 58 30 
sec 
- 
  7 72 35 
sec 
Repeat steps 
5-7 for 12 
cycles 
 8 72 2 min - 
9 10 - hold 
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1.5% Agarose gel prepared in 1X Tris-acetate-EDTA (TAE) buffer was used 
to resolve the PCR products at 124 V for 1 hour. GelRedTM, a red fluorescent 
nucleic acid dye, added during agarose gel preparation step (1:10,000, 
Biotium) was used to visualize the bands under UV in Chemidox GelDoc XRS 
system (BioRad). Mice were labeled according to the genotyping results and 
separated in different groups as single and bi-transgenic mice to use for further 
experimental procedures.  
2.2.5 Mammalian Cell culture 
2.2.5.1 Primary mouse cortical neuron culture 
Cortices from the embryos of C57BL/6 wild-type or p25Tg mice at days 16-18 
(E16-18) were dissected out under the microscope. Cortices were then snipped 
into smaller pieces and digested in papain solution for 40 minutes at 37
o
C, 
followed by centrifugation at 201 x g (Eppendorf, 5810R) for 5 minutes at 
4
o
C. Pellet was resuspended in STOP solution to neutralize papain action and 
then filtered using 10/10 solution and centrifuge at 129 x g for 10 minutes at 
4
o
C to get the homogenous single cell cortical neurons (Eppendorf, 5810R). 
Cortical neurons were then cultured in different densities (100,000 cells per 
12-well plate, 1 x10
6
 cells per 6-well plate and 6 x10
6
 cells per 10 cm dish) in 
neurobasal medium with B27 supplement containing 100 IU/ml penicillin, 100 
µg/ml streptomycin and 2 mM glutamine in plates/dishes coated with poly-L-
Lysine. Coating was done by adding Poly-L-Lysine to the plates and kept at 
room temperature overnight. Plates were washed twice with sterile ultra-pure 
water and dried completely before plating the neurons. Cortical neurons from 
the p25Tg mice were cultured in neurobasal media with doxycycline (10 
µg/ml) until the neurons fully differentiated. Samples were collected after 5 
days induction of p25 expression by the removal of doxycycline from the 
media.  
2.2.5.2 Primary mouse glial cell culture 
Glial cells (mixed) were extracted from the pups at P0 (the day of birth)-P2 (2 
days old). The same procedure as primary mouse cortical neuron culture was 
followed except the final 10/10 filtration step. Glial cells were cultured in 
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DMEM supplemented with 2 mM penicillin streptomycin glutamine, 10% 
FBS and 10 mM sodium pyruvate at 37
o
C with 5% CO2.  
2.2.5.3 Human embryonic kidney FT (HEK-FT) cell line   
HEK-FT cells were cultured in DMEM containing 200 mM glutamine, 10 mM 
NEAA, 100 mM sodium pyruvate, geneticin (500 µg/ml) and 10% FBS at 
37
o
C with 5% CO2. Sub-culturing was performed by splitting the fully 
confluent cell culture flask into two or more flasks using 1X trypsin. Excess 
cells were frozen using freezing media. 
2.2.6 Transformation and plasmid DNA extraction 
Frozen DH5α (Douglas Hanahan bacterial strain 5α) ultra-competent cells 
were gently thawed on ice and 50 µl of the cells were transferred to a pre-
chilled sterile round-bottom tube (352059, BD Falcon). Subsequently, 1-2 µl 
of plasmid DNA (2-10 ng) was mixed gently with the cells and incubated on 
ice for 30 minutes. Cells were heat shocked at 42
o
C for 30 seconds and placed 
back on ice for 2 minutes. Cells were then mixed gently with 950 µl of pre-
warmed LB medium and incubated at 37
o
C for 1 hour with constant shaking at 
225 rpm. Later, 100 µl of transformed cells were spread onto LB/Ampicillin 
(100 µg/ml) plates using a plate spreader under sterile conditions. Petri dishes 
were dried for 10 minutes with cover and incubated overnight at 37
o
C. On the 
next morning, 4 ml of LB/Amp starter culture was inoculated with the 
colonies grown on the plates and incubated at 37
o
C for 4-5 hours with shaking 
at 225 rpm. At the end of the day, the starter culture was mixed with 100 ml of 
pre-warmed LB/Ampicillin media and incubated overnight at 37
o
C with 
constant shaking at 225 rpm. Plasmid DNA from these bacterial cultures was 
then extracted following the QIAprep Spin Miniprep Kit protocol. Eluted 
plasmid DNA was then quantitated using a NanoDrop (Spectrophotometer, 
ND 1000 Biofrontier Technology) and stored at -20
o
C until further use. 
2.2.7 Lentivirus production and transduction 
Lentiviruses of empty vector (EV-LV) and p25-LV enhanced green 
fluorescent protein (EGFP) plasmids were prepared as per protocol published 
previously with slight changes (Zheng et al., 2005). EV-LV/p25-LV plasmids, 
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Virapower Packaging mix and Lipofectamine 2000 complexes were prepared 
according to manufacturer’s instructions (Invitrogen, K4975-00) and added 
dropwise to HEK293-FT cells plated at 90-95% confluence in 10 cm dishes. 
Cells were incubated at 37
o
C with 5% CO2 for 48 hours. Cell-free viral 
supernatants were collected by centrifuging the media at 1811 x g (Eppendorf, 
5810R) for 15 minutes at 4
o
C followed by filtering with 0.45 µm filter and 
then concentrated using Amicon Ultra-15 centrifugal filter units at 1811 x g 
(Eppendorf, 5810R) for 20 minutes at 4
o
C. 7 days in culture (DIC) cortical 
neurons were treated with various dilutions of EV-LV/p25-LV virus to find 
out the optimal viral titre to get approximately 80% transduction efficiency. 
GFP-fluorescence was visualized and quantitated by counting the number of 
GFP positive cells (minimum 75 cells per field) and normalized against the 
number of DAPI signals in 10 independent fields. 
2.2.8 Co-culture and supernatant transfer experiments 
15 mm poly-L-Lysine-coated coverslips with the p25 overexpressing/control 
neurons (lentivirus-transduced neurons or primary neurons from 
p25Tg/control mice) were placed on tissue culture inserts (3.0 µm, Greiner 
bio-one, 657630). Inserts were then positioned inside the 6-well plates with 
the glial cells (plated either on the 18 mm coverslips or at the bottom of the 
plates) and co-cultured at 37
o
C with 5% CO2 for 48 hours. 
Alternatively, cell-free supernatants from p25 overexpressing neurons were 
collected by centrifugation (1811 x g (Eppendorf, 5810R) for 15 minutes) and 
then transferred directly onto the glial cells for 48 hours. Glial cells from co-
culture and supernatant transfer experiments were processed for 
immunocytochemistry and Western blot experiments. 
2.2.9 Factor removal experiments 
Media supernatants from EV-LV/p25-LV transduced neurons were treated 
individually with DNAse (8 µg/ml), RNAse (50 µg/ml) and Proteinase K (50 
µg/ml) for 60 minutes at 37
o
C. Subsequently these enzyme-treated 
supernatants were heated at 95
o
C for 10 minutes and then cooled to 37
o
C to 
arrest enzyme activity before adding onto glial cells. In parallel, major lipids 
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were removed from the untreated supernatants by passing through the solid 
phase extraction column and glial cells were also treated with these eluted 
supernatants. Finally, all the treated glial cells were processed further for 
Western blot analyses and immunocytochemistry after 48 hours. 
2.2.10 Immunocytochemical analyses 
Glial cells on 18 mm coverslips (300,000 cells/coverslip) were washed twice 
with 1X PBS for 5 minutes each and then fixed with 4% formaldehyde/1X 
PBS followed by permeabilization with 0.1% Triton-X-100/1X PBS for 20 
minutes each. Subsequently, cells were incubated with blocking solution (5% 
FBS in 1X PBS) for 30 minutes followed by the primary antibody GFAP 
(1:1000) in 5% FBS/PBS for 1 hour at room temperature. The cells were then 
washed 3 times for 5 minutes before and after incubation with appropriate 
secondary antibodies for 1 hour at room temperature in the dark. Later, cells 
were stained with DAPI (nuclei stain) (1:1000) and mounted on glass slide 
with anti-fade fluor-mounting medium. Confocal images were taken with 
Zeiss LSM-510 laser-scanning confocal microscope at 40X magnification.  
2.2.11 Histochemical studies  
2.2.11.1 Perfusion and brain sectioning 
Mice were anesthetized with mixtures of ketamine (75 mg/kg) and 
medepomidin (1 mg/kg) and placed on their backs on the paraffin block. 
Forelimbs were spread widely and each paw was secured with pins to the 
block. A cut was made along the sternum and on both sides of the diaphragm 
laterally to expose the heart. The mice were perfused first with Ringer’s 
Solution by inserting a cannula into the left ventricle and the right auricle was 
punctured to allow the escape of return circulation. Once the colour of the 
releasing circulation turned clear, fixative line clamp was opened to perfuse 
the mice with freshly made pre-chilled 4% PFA/PBS until the limbs, liver and 
the rest of the body hardened. Perfusion instruments were removed and brain 
samples were collected from mice heads. Perfused brains were then immersed 
in fixative overnight at 4
o
C. Subsequently, brain samples were placed in a 
series of sucrose/1X PBS solutions at 10%, 20% and 30%. In each solution, 
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brain samples had to sink to the bottom of the tube before transfer to the next 
solution. Brain samples were frozen in liquid nitrogen using the cryoprotectant 
Shandon M1 Embedding Matrix and sectioned into sagittal sections of 16 µm 
thickness using a cryostat (CM 3050S, Leica). 
2.2.11.2 Immunofluorescence staining 
Immunofluorescence staining was carried out by rinsing the brain sections 
with wash buffer (1X PBS with 0.1% Trition-X-100) two times at 5 minutes 
each, followed by incubation of the sections with blocking solution (5% FBS 
in 1X PBS) to prevent non-specific staining. Subsequently, sections were 
incubated with respective primary antibodies prepared in 5% FBS in 1X PBS 
overnight at 4
o
C and then rinsed three times at 5 minutes each with wash 
buffer to remove excess and unbound primary antibodies. Secondary 
antibodies prepared in 5% FBS in 1X PBS were added onto the sections for 1 
hour at room temperature and then sections were washed 3 times with 1X PBS 
for 5 minutes each. Nuclei were counter-stained with DAPI (1:1000 in 1X 
PBS) and washed two times with 1X PBS. Lastly, sections were mounted with 
Dako anti-fade fluor-mounting medium and allowed to dry in the dark until 
viewing with a confocal microscope.  
2.2.11.3 Thioflavin staining 
Thioflavin staining was performed according to the published protocol with 
some changes (Sun et al., 2002). Sections were incubated with 0.05% 
Thioflavin-S solution in 50% ethanol for 10 minutes in the dark followed by 
rinsing in 50 % ethanol two times for 10 seconds each and two washes with 
large volumes of water. Finally, sections were mounted with anti-fade fluor-
mounting medium and allowed to dry in the dark. Confocal images were taken 
at 40X magnification.  
2.2.11.4 Bielschowsky Silver staining    
Clean glass wares and all the reagents were cooled to 4
o
C before staining. 
Firstly, sections were incubated with 20% silver nitrate (AgNO3) solution and 
then with ammoniacal silver solution for 20 minutes each in the dark at 4
o
C, 
followed by washing with distilled water. Sections were then immersed 
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serially in ammonia water (2 minutes), developer solution (2 minutes) and 
distilled water (5 minutes). Staining was stopped by incubating with 5% 
sodium thiosulphate (hypo Solution) for 5 minutes and rinsed thoroughly with 
water. Finally, sections were dehydrated by immersing in graded series of 
ethanol solutions (50%, 95% and 100%) and then in xylene before mounting.   
2.2.11.5 TUNEL staining 
TUNEL staining was performed as per the instructions from the In situ cell 
death detection kit with some modifications. Briefly, slides with brain sections 
were rinsed twice in 1X PBS and then treated with 0.1% Trito-X-100/1X PBS 
solution for 2 minutes on ice. Slides were then washed immediately with 1X 
PBS twice for 5 minutes each and incubated with 50 µl of TUNEL mixture 
(mixture of 450 µl solution from Vial 2 and 50 µl of enzyme from vial 1) in a 
humidified chamber at 37
o
C for one hour. Lastly, sections were washed again 
with 1X PBS three times followed by nuclei DAPI staining. The slides were 
mounted and dried in a dark place until viewed with a confocal microscope. 
2.2.12 Western blot analyses 
2.2.12.1 Lysate preparation 
 Mice brain lysates  
Mice brain samples were homogenized in an ice cold lysis buffer using a 
Dounce homogenizer on ice. Homogenates were then kept on ice for 20 
minutes followed by centrifugation at 18,800 x g (Thermo Electron 
Corporation, Legend Micro21R) for 30 minutes at 4
o
C. Clear supernatants 
were then stored in aliquots at -80
o
C until further use.    
 Soluble cell lysates 
Cells were gently scraped into ice-cold 1X PBS, centrifuged at 18,800 x g for 
30 minutes at 4
o
C. Pellets were resuspended thoroughly in ice cold lysis 
buffer. Cell homogenates were kept on ice for 20 minutes followed by 
centrifugation at 18,800 x g for 30 minutes at 4
o
C. Clear supernatants were 
then stored in aliquots at -80
o
C before use.    
71 
 
2.2.12.2 Protein Quantitation/Bicinchoninic acid (BCA) Assay  
50 µL of each standard (range from 8 to 48 µg/ml of BSA in lysis buffer) and 
test samples (5 µl of lysate with 45 µl of lysis buffer) were mixed and 
incubated with 1 ml of working reagent mixture (Reagent A and B in the ratio 
50:1) at 37
o
C for 30 minutes. The intensity of the purple colour developed was 
read at 562 nm using a spectrophotometer (DU 800 Spectrophotometer, 
Beckman Coulter). Later, a standard curve plotted using the average blank-
corrected readings for each standard vs. its respective concentration (µg/ml) 
was used to calculate the protein concentration for unknown samples.  
2.2.12.3 Sample preparation 
An equal volume of 2X Laemmli sample buffer (with 5% BME) was mixed 
with brain/cell lysates and heated at 95°C for 5 minutes before loading onto 
the SDS-PAGE gels. Total cell lysates were prepared by scraping the cells 
directly in 2X sample buffer and heated at 95°C for 5 minutes.  
2.2.12.4 SDS-PAGE gel electrophoresis 
30 µg of lysates were separated on Novex 4-20% Tris-glycine mini gels at 120 
volts until the dye front reached the bottom of the gel and transferred onto the 
nitrocellulose membrane using the Novex XCell II blotting module with 1X 
Tris-glycine transfer buffer for 2 hours at 100 mA. Quality of protein transfer 
was confirmed by reversible staining of membrane using Ponceau S staining 
solution followed by adequate washing with Tris buffered saline and Tween 
20 (TBST) buffer. Blocking of non-specific binding of primary antibodies was 
achieved by incubating the membranes in blocking solution (10% milk in 
TBST) for 1 hour at room temperature. Membranes were then probed with 
respective primary antibodies (listed in table 2.1.1) overnight at 4
o
C followed 
by 3 washes with TBST buffer for 5 minutes each. Subsequently, membranes 
were incubated with horseradish peroxidase-conjugated mouse or rabbit 
secondary antibodies (listed in table 2.1.2) for 1 hour at room temperature and 
then washed 3 times with TBST for 5 minutes each. Immunoblots were 
developed using ECL (enhanced chemiluminescence) detection kit as per the 
instructions of the manufacturer. Membranes were finally stripped using 
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stripping buffer for 30 minutes at 50
o
C with agitation and then reprobed with 
other primary antibodies.  
2.2.13 (γ-32P) ATP Kinase Assay 
(This work was done in collaboration with Dr. Tej Kumar Pareek, Case 
Western Reserve University, Cleveland, OH, USA)    
Kinase assay was performed using 500 µg of brain/cell lysates in order to 
determine the changes in Cdk5 activity. Lysates were first pre-cleared with 
protein A-Sepharose beads slurry (50%) for 1 hour at 4
o
C. Subsequently, 10 
µg of rabbit polyclonal anti-Cdk5 (C8) antibody was added to the pre-cleared 
lysates and incubated for 3-4 hours with constant mixing at 4
o
C. Later, protein 
A-Sepharose beads slurry (50%) was added to this mixture prior to overnight 
incubation at 4
o
C. Immunoprecipitates were then washed 3 times with lysis 
buffer, once with kinase buffer and then resuspended in 30 µl of water 
followed by the addition of 10 µl of 5X kinase assay mixture, 10 µg of histone 
H1 and 0.2 µM of NF-H peptide. Later, immunoprecipitates were incubated 
with 5 μCi of (γ-32P) ATP for 30 minutes at 30°C and then 50% 
trichloroacetic acid was added to precipitate out the proteins, followed by 
centrifugation at 18,800 x g (Thermo Electron Corporation, Legend 
Micro21R) for 10 minutes at 4
o
C. 10 µl of trichloroacetic acid supernatants 
were added onto the P81 phosphocellulose paper squares and air-dried. These 
paper squares were washed 5 times with 75 mM phosphoric acid for 15 
minutes each and then once in 95% ethanol. Finally, these squares were 
transferred to vials containing bio-safe ІІ scintillation fluid for counting in a 
Beckman Coulter scintillation counter.      
2.2.14 Real-Time PCR 
RNA samples were extracted using the RNeasy mini kit as per instructions 
from the manufacturer. Briefly, brain samples/cell pellets were homogenized 
with 1 ml of Trizol and kept at room temperature for 5 minutes. Subsequently, 
this solution was mixed vigorously with 200 µl of chloroform and centrifuged 
for 15 minutes at 13,800 x g (Thermo Electron Corporation, Legend 
Micro21R) at 4
o
C. The upper aqueous phase was separated and mixed with 
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70% ethanol and then added to the mini columns followed by centrifugation at 
6,200 x g for 15 seconds at 4
o
C. Wash buffers RW1 and RPE were used to 
wash the columns before eluting the RNA with RNase free water. Later, RNA 
concentration was measured using Nanodrop (Spectrophotometer, ND 1000 
Biofrontier Technology). cDNA was synthesized from RNA samples using 
high capacity cDNA reverse transcriptase kit and quantitative real-time PCR 
was performed using ABI Prism 7900 HT Fast 9 detection system and results 
were analyzed using software AB 7500 version 2.0.5. 
2.2.15 Radial maze 
The radial arm maze paradigm was carried out as described previously (Zou et 
al., 1998; Schmitt et al., 2003) with some changes. The radial maze with 8 
arms extended radially from the central area was used and arms were 
numbered from 1 to 8. Visual cues (black and white images) were positioned 
at the end of the arms 2, 4, 6 and 8 and a video camera was placed just above 
the maze in the ceiling to capture the training and test session trials. Video 
images were sent to the computer equipped with EthoVision 3.1, software that 
can track the animal’s path and measures a number of useful parameters such 
as number of visits to each arm, time spent within each arm, number of 
attempts needed to finish the task and so on. EthoVision was used to specify 
different zones of interest from the video image of the test arena to 
automatically measure parameters related to these zones. In the training phase, 
mice were given 7 minutes to explore all the arms and allowed to consume the 
novel food (fruit loops) that were placed in only one arm in the order of 2, 4, 6 
or 8 each session. The apparatus was cleaned with 70% ethanol and dried in 
between trials. Novel food was also placed outside of all the arms to minimize 
the possibility of smell as a cue. During the test phase, all the four arms (2, 4, 
6 and 8) were baited and trial continued until all baits had been consumed or 
until 5 minutes had lapsed. Reference memory errors (entering a non-baited 
arm) and working memory errors (number of re-entry in baited arms) were 
calculated and analyzed between the groups. Mice were given a maximum of 
two test sessions per day, 6 days per week during the period of behavioural 
testing. The test and training sessions were conducted approximately at the 
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same time of the day in a moderately lit room with standard conditions of 
temperature and free from any stray noise. 
2.2.16 Lipid extraction from cell culture media 
Lipid extraction from cell culture media was performed using a protocol 
described previously with slight modifications (Bremer and Norum, 1982). In 
brief, the cell culture media/supernatant was incubated with 6 ml of 1-butanol 
with agitation at 4 x g (Eppendorf, 5424) for 2 hours at 4
o
C. After 
equilibration and phase separation, the upper layer of the butanol extract was 
saved and mixed with 5 ml of chloroform to facilitate the second extraction. 
Later, bottom phase of both the chloroform and the butanol extracts were 
mixed together and dried under the nitrogen stream and kept at -80
o
C. 
2.2.17 Lipid extraction from the brain samples 
Lipids were extracted from the brain samples according to the protocol 
described previously (Sharman et al., 2010). Briefly, approximately 26 mg of 
brain tissue was homogenized with 900 µl of Chloroform: Methanol (1:2) 
using a PRO 200 Homogenizer (PRO Scientific Inc) and incubated at 4
o
C with 
agitation at 4 x g (Eppendorf, 5424) for 2 hours. After incubation, 300 µl of 
chloroform and 300 µl of distilled water were added into the homogenates and 
mix thoroughly by vortex. Later, the homogenates were centrifuged at 7,800 x 
g (Thermo Electron Corporation, Legend Micro21R) at 4
o
C for 2 minutes to 
break phase and the bottom organic phase was collected into a new tube. Re-
extraction was carried out by adding another aliquot of 500 µl of chloroform 
and the organic phase obtained was pooled together, dried under a nitrogen 
stream and kept at -80
o
C. 
2.2.18 Lipids analysis using High-Performance Liquid            
Chromatography/Mass Spectrometry 
(This work was done in collaboration with A/Prof. Markus Wenk’s 
Lipidomics lab) 
Agilent 1200 high-performance liquid chromatography (HPLC) system and a 
3200 Q-trap mass spectrometer were used to quantify individual lipids 
extracted from brain/cell culture supernatants samples. The HPLC systems 
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contain an Agilent 1200 binary pump, an Agilent 1200 thermo sampler and an 
Agilent 1200 column oven. HPLC conditions are Luna 3u silica column 
(i.d.150x2.0 mm); mobile phase A (chloroform: methanol: ammonium 
hydroxide, 89.5:10:0.5), B (chloroform: methanol: ammonium hydroxide: 
water, 55:39:0.5:5.5); flow rate 350 µl/min; 5% B for 3 minutes, then linearly 
changed to 30% B in 24 minutes and maintained for 5 minutes, and then 
linearly changed to 70% B in 5 minutes and maintained for 7 minutes. Eluents 
were changed to the original ratio in 5 minutes and maintained for 6 minutes. 
Multiple Reaction Monitoring (MRM) transitions for individual lipid species 
such as phosphatidylethanolamine (PE), Phosphatidylcholine (PC), 
phosphatidylserine (PS), phosphatidylinositol (PI), ceramide (Cer) and 
sphingomyelin (SM) were set up for quantitative analyses.  PC-14:0/14:0, PE-
14:0/14:0, PS-14:0:14:0, ceramide, C12-SM and LPC 20:0 (4 µM) (Avanti 
Polar Lipids) were used as internal standards to quantitate the individual 
lipids.  
2.2.19 Stereotactic injection of lipids into mouse brain 
Mice were anesthetized and positioned in a stereotactic frame. Midline 
incision of the scalp was made and the vertex area was exposed. Later, a small 
hole was drilled according to the coordinates: caudal to bregma 2 mm, 2 mm 
lateral to the midline and 1.8 mm from the surface of the cortex. 1 µl of 
solution containing lipids (2 µM) was injected at a constant rate for 5 minutes 
using a microsyringe (Hamilton) inserted stereotactically through the opening. 
The needle was slowly withdrawn and the scalp sutured. After recovery from 
anesthesia, mice were returned to their cages and observed closely for normal 
food and water intake. Later, these mice were perfused with 4% PFA 48 hours 
post-injection and then brain samples were collected for sectioning and further 
immunostaining experiments.  
2.2.20 Phospholipase A2 (PLA2) Inhibitor studies 
 Inhibitor studies were performed by transducing the neurons with p25-LV 
together with 0.3 µM of BEL (iPLA2 inhibitor) or 10 µM of AACOCF3 
(cPLA2 inhibitor) for 48 hours at 37
o
C with 5% CO2. Later, cell-free 
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supernatants from these neurons were transferred to glial cells for 48 hours 
and glial cells were processed for further analyses.  
2.2.21 Cytosolic Phospholipase A2 (cPLA2) silencing 
Silencing of cPLA2 gene expression was performed in cortical neurons using 
shRNA lentivirus transduction. cPLA2 shRNA (mouse) lentiviral particles 
have a target-specific construct that encodes a 19-25 short hairpin RNA 
designed to knock-down cPLA2 gene expression (Santa Cruz Biotechnology, 
SC-35098-V). Cortical neurons plated on 6-well plates were incubated with an 
aliquot of p25-LV along with the cPLA2 shRNA lentiviral particles in 
neurobasal medium with polybrene (3µg/ml) for 48 hours at 37
o
C with 5% 
CO2. Subsequently, glial cells were treated with the cell-free supernatants 
from these cPLA2-silenced cortical neurons and then fixed with 4% 
formaldehyde after 48 hours for further analyses. 
2.2.22 cPLA2 activity assay 
cPLA2 activity was measured using cPLA2 activity assay kit according to the 
manufacturer’s instructions. Brain samples from different mice groups or cell 
pellets from neurons transduced with p25-LV/EV-LV were homogenized with 
ice cold buffer and lysates collected (10 µl) were diluted with 5 µl of assay 
buffer and added to the 96 well plate provide by the manufacturer. 15 µl of 
assay buffer was used as the blank and 10 µl of PLA2 standard (Bee venom 
included in the kit) diluted with 5 µl of assay buffer was added as a standard. 
Enzymatic reaction was initiated by incubating with 200 µl of substrate 
solution for 60 minutes. Subsequently, 10 µl of DTNB (5, 5’-dithiobis-(2-
nitrobenzoic acid) solution was added to stop the enzyme reaction and allow 
colour development. Finally, intensities of the reactions, a marker of activity, 
were read at 414 nm using a Tecan Infinite M200 microplate reader. cPLA2 
activity was calculated according to the formula suggested by the 
manufacturer and the results were normalized to total protein concentrations 






Data are expressed as the mean of at least three values ± standard error 
(s.e.m). Statistical significance was determined using student’s t-test (Chapter 
3 and Chapter 4), one-way analysis of variance (ANOVA) followed by post-
hoc tukey’s test (Chapter 5) and repeated measures ANOVA followed by post-
hoc tukey’s test (Behavioural studies in Chapter 5). P-value for statistical 





















                           
                        





















CHAPTER 3: Investigation of p25/Cdk5-mediated 
neuroinflammation using in vivo (p25Tg mice) as well as in 




Neuroinflammation is one of the key pathological features of many 
neurodegenerative diseases, including AD, and is thought to contribute to 
neurodegeneration (Aisen, 1996; Rogers et al., 1996; Tuppo and Arias, 2005). 
However, the exact mechanisms behind neuroinflammation and its 
significance in the initiation of AD pathogenesis are not completely 
understood (Zilka et al., 2006; Agostinho et al., 2010). 
Several studies suggested that Cyclin-dependent kinase 5 (Cdk5) 
hyperactivation could contribute to cytoskeletal abnormalities and neuronal 
death in AD (Pei et al., 1998; Patrick et al., 1999; Lopez-Tobon et al., 2011; 
Cheung and Ip, 2012). Although the potential role of Cdk5 deregulation by its 
hyperactivator p25 in the development of the pathogenesis of AD has been 
described by earlier studies (Ahlijanian et al., 2000; Yoo and Lubec, 2001; 
Cruz et al., 2003), the actual mechanisms behind the early changes in 
neuroinflammation that cause the progression of  neurodegeneration during 
p25 overexpression remains obscure. Therefore, the experiments detailed in 
this chapter aim to investigate the mechanisms behind p25-mediated 
neuroinflammation by employing in vivo (p25Tg mice) & in vitro (cortical 
neurons transduced with p25-LV virus) p25 overexpression systems and co-








3.2.1 p25 transgenic mouse model 
C57BL/6-Tg (tetO-CDK5R1/GFP) 337Lht/J mice (The Jackson laboratory) 
were crossed with B6; CBA-Tg (Camk2a-tTA) 1Mmay/J mice (The Jackson 
laboratory) to generate bi-transgenic mice (p25Tg mice) that inducibly 
overexpress human p25 transgene under the regulatory control of tetracycline 
analogue, doxycycline. Whenever possible, littermates of same sex mice were 
used for comparison. Brain samples were collected from p25 transgenic 
(p25Tg) mice at different induction periods of p25 expression such as 1, 4, 8 
and 12 weeks and processed differently for different experiments. 
3.2.2 Mammalian cell culture  
 3.2.2.1 Primary mouse cortical neuron culture 
Primary cortical neurons from wild-type (C57BL/6) and p25Tg mice embryos 
(E16-18) were cultured in different densities (100,000 cells per 12-well 
plate/coverslip, 1 x10
6
 cells per 6-well plate and 6 x10
6
 cells per 10 cm dish) 
in coverslip/plates/dishes coated with poly-L-Lysine.  
3.2.2.2 Primary mouse glia culture  
Glial cells were extracted from P0-P2 pups of (C57BL/6) wild-type mice and 
cultured at 37°C with 5% CO2.  
3.2.3 Lentivirus production and transduction 
Lentiviruses of empty vector (EV) and p25-enhanced green fluorescent protein 
(EGFP) were prepared from HEK293-FT cells using Virapower Packaging 
Mix and Lipofectamine 2000. Cortical neurons were treated with lentiviruses 
at optimal dilutions for 48 hours at 37
o
C with 5% CO2 to get approximately 80 
% transduction efficiency. 
3.2.4 Co-culture and supernatant transfer experiments 
EV-LV/p25-LV virus-transduced cortical neurons or primary neurons from 
p25Tg/control mice were co-cultured with glial cells using tissue culture 
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inserts in 6-well plates for 48 hours at 37
o
C with 5% CO2. In parallel, culture 
media supernatants from p25 overexpressing/control neurons were transferred 
onto glial cells for 48 hours at 37
o
C with 5% CO2. The glial cells from co-
culture and supernatant transfer experiments were then processed individually 
for immunocytochemistry and Western blot analyses. 
3.2.5 NMDA treatment 
9 DIC (days in culture) cortical neurons in 6-well plates (1x 10
6 
cells per well) 
were treated with NMDA + glycine (500 µM of NMDA (Tocris, 0114) and 
100 µM of glycine (Sigma, 50046), glutamate + glycine  (200 µM of 
glutamate (Sigma, G1251) and 100 µM of glycine) and NMDA + MK801+ 
glycine (500 µM of NMDA, 100 µM of glycine and 1 µM of MK801 (Tocris, 
0924) for 12 hours at 37
o
C with 5% CO2. Supernatants from these treatments 
were saved and transferred onto the glial cells in 6-well plates for 48 hours at 
37°C with 5% CO2. Cortical neurons were processed for Western blot 
analyses with anti-C19 antibody and glial cells were processed for both 
Western blot analyses and immunocytochemical staining experiments with 
anti-GFAP antibody.  
3.2.6 Immunocytochemistry 
Immunofluorescence staining was performed on glial cells from co-culture 
and supernatant transfer experiments using primary antibodies such as mouse 
anti-GFAP and anti-CD11b. Alexa Fluor 488 and Alexa Fluor 594 were used 
as secondary antibodies and nuclei were counterstained with DAPI. 
Immunofluorescence images were taken with Zeiss LSM-510 laser-scanning 
confocal microscope at 40X magnification.   
3.2.7 Immunohistochemistry 
16 μm brain sections collected from 1, 4, 8 and 12-week induced 
p25Tg/control mice were immunostained with primary antibodies such as 
mouse anti-GFAP, mouse monoclonal anti-GFP, mouse monoclonal  anti-
AT8, rabbit anti-beta-amyloid 1-42, mouse anti-CD11b, rabbit anti-tPA, 
mouse anti-CD4 and anti-CD8 antibodies. Later, sections were stained with 
Alexa Fluor 594 and 488 secondary antibodies followed by DAPI. Confocal 
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images were taken at 20X, 40X and 63X magnifications.  
3.2.8 Western blot analyses 
Brain lysates (from 1, 4, 8 and 12-week induced p25Tg/control mice), glial 
cell lysates (total cell lysates from co-culture and supernatant transfer 
experiments) and soluble cell lysates (from EV-LV/p25-LV virus-transduced 
cortical neurons and p25Tg/control mice neurons) were resolved on 4-20% 
polyacrylamide gels and transferred onto nitrocellulose membranes. 
Membranes were then immunoprobed with rabbit anti-GFAP, rabbit anti-Cdk5 
(C-8) and rabbit anti-p35 (C-19) antibodies.  
3.2.9 In vitro kinase assays 
Changes in Cdk5 activity were investigated with kinase assays using brain 
lysates from 1, 4, 8 and 12-week induced p25Tg/control mice and EV-
LV/p25-LV virus-transduced cortical neurons.  
3.2.10 Real-Time PCR 
Total RNA was extracted from 1, 4, 8 and 12-week induced p25Tg/control 
mice brains, EV-LV/p25-LV virus-transduced cortical neurons and 
p25Tg/control mice cortical neurons using RNeasy Mini Kit. cDNA was 
synthesized from RNA using High capacity cDNA reverse transcriptase kits 
and quantitative real-time PCR was performed with respective primers.  
3.2.11 Statistical analyses 
Data are expressed as the mean of at least three values ± standard error 
(s.e.m). Statistical significance was determined using student’s t-test and P-








3.3.1 p25 transgenic mice exhibit robust astrogliosis 
Astrogliosis, a hypertrophy of astrocytes, is commonly observed during 
neuroinflammation (Sofroniew, 2009). In an effort to determine the onset of 
neuroinflammation in p25Tg mice, astrogliosis was evaluated at various time 
points such as 1, 4, 8 and 12-week induction of p25 expression in p25Tg mice 
and in age-matched control mice. Immunohistochemistry was performed on 
brain sections using anti-GFAP antibody to determine when astrogliosis 
commences in p25Tg mice and increased GFAP immunoreactivity was used 
as an indicative feature of astrogliosis. A substantial increase in GFAP 
immunoreactivity was observed especially in 2/3 layer of cortex of 1 week 
induced p25Tg mice compared to control mice (Figure 3.1A). Likewise, 
progressive and significant increase in GFAP expression was observed in 4, 8 
and 12-week induced p25Tg mice. Moreover, a prominent increase in GFAP 
immunoreactivity was also observed in the CA3 region of hippocampus in 1-
12 week induced p25Tg mice compared to the respective age-matched 
controls (Supplementary Figure 1 in Appendices).      
Moreover, results from Western blot analyses using anti-GFAP antibody 
further confirmed immunohistochemistry results where robust elevation of 
GFAP expression levels was observed in brain lysates from 1 to 12-week 
induced p25Tg mice compared to the control mice (Figure 3.1B and 1C). In 
addition, kinase assay data and immunostaining experiments using anti-GFP 
antibody indicated a strong correlation between GFAP upregulation and 
p25/Cdk5 hyperactivation in 1 to 12-week induced p25Tg mice (Figure 3.1E 
and 1F). Cdk5 levels were found to be unaltered in all the time points of p25 











Figure 3.1: Astrogliosis is an early event in p25 transgenic mice  
(A) Representative immunofluorescence images of 2/3 layer of cortex from 1, 4, 8 
and 12-week induced p25Tg and their respective age-matched control (Ctrl) mice 
brain sections stained with anti-GFAP antibody (red) and nuclei were stained with 
DAPI (blue). (B)  Immunoblot analyses results for the brain lysates of 1, 4, 8 and 12-
week induced p25Tg/Ctrl mice using anti-GFAP antibody (top panel). Membranes 
were re-probed with anti-tubulin antibody (bottom panel) which acts as a loading 
control. (C) Quantification of immunoblot analyses in B by densitometric scanning 
(** p-value < 0.01 and *** p-value < 0.001). (D) Western blot analyses results from 
p25Tg/control mice using anti-Cdk5 (C8) antibody. (E) Representative in vitro kinase 
assay graph using active kinase (Cdk5) from p25Tg/control mice brain lysates (*** p-
value < 0.001 and * p-value < 0.05) (student’s t-test). Error bars indicate ± s.e.m. (F) 
Immunofluorescence images of the cortex from samples same as in A using anti-GFP 
antibody. Scale bars represent 50µm and images are representative of n=3 mice. 
 
 
RT-PCR analyses were performed to observe changes in 
chemokines/cytokines such as MIP-1α, TNF-α, TGF-β and IL-1β expression 
levels in brain samples from 1, 4, 8 and 12-week induced p25Tg/control mice. 
Results identified a remarkable increase in chemokines/cytokines expression 
levels in the brain samples from p25Tg mice compared to the controls (Figure 
3.2A-D). Specifically, MIP-1α, TGF-β and IL-1β expression levels peaked at 
4 weeks of induction, whereas TNF-α expression peaked at 8 weeks of 
induction of p25 expression.  
Together, these results determined that astrogliosis and the subsequent release 
of cytokines/chemokines were early events in the neurodegenerative process 










Figure 3.2: Chemokine/cytokine expression levels in p25 transgenic mice  
Real-time PCR results for (A) MIP-1α, (B) TNF-α, (C) TGF-β and (D) IL-1β 
expression levels in 1, 4, 8 and 12-week induced p25Tg/control mice (*** p-value < 
0.001 and * p-value < 0.05) (student’s t-test). Error bars indicate ± s.e.m. 
 
 
3.3.2 Reactive microgliosis is a late event in p25Tg mice  
To facilitate the study of microglial activation status in p25Tg mice, 
immunohistochemistry was carried out with the brain sections from 
p25Tg/control mice using a specific marker for activated microglia, anti-
Cd11b antibody. The results showed that microgliosis was absent at 1 week 
induction and only became evident after 4-week induction of p25 expression 
(Figure 3.3A). Thus, noticeable GFAP upregulation without microglial 
activation in 1 week induction of p25 expression (Figure 3.1) suggested that 
astrogliosis preceded microgliosis in p25-mediated neurodegenerative process 
in p25Tg mice.  
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Previous studies reported that the non-proteolytic action of tissue plasminogen 
activator (tPA) could mediate microglial activation and increases in tPA levels 
would be an indication for microglial activation during neurodegeneration 
(Siao and Tsirka, 2002; Pineda et al., 2012). To further confirm the findings 
about the onset of microgliosis in p25Tg mice, immunohistochemistry was 
performed and results using anti-tPA antibody were identical to the Cd11b 
findings (Figure 3.3B). Together, immunostaining results suggested that 




Figure 3.3: Reactive microgliosis in p25 overexpression-mediated 
neuroinflammation 
Representative immunofluorescence images of the cortex from 1, 4, 8 and 12-week 
induced p25Tg/control mice using (A) anti-Cd11b, (B) anti-tPA antibodies (red). 
Nuclei were stained with DAPI (blue). White arrows show the region that is 








3.3.3 p25Tg mice exhibit prominent infiltration of peripheral immune 
cells   
Infiltration of peripheral immune cells into the central nervous system (CNS) 
is a critical phase in the progression of several neurodegenerative diseases 
such AD, PD and ALS (Town et al., 2005; Chiu et al., 2008; Brochard et al., 
2009). However, the involvement of peripheral cell infiltration in p25-induced 
neuroinflammation has not been fully explored. Hence, the presence of 
peripheral immune cells in p25Tg mice brains was investigated using 
lymphocyte subset markers, CD4 and CD8. A dramatic increase in CD4 and 
CD8 immunostaining after 4 weeks of induction strongly suggested that 
peripheral cell infiltration was evident during p25-mediated 
neuroinflammation (Figure 3.4). 
  
 
Figure 3.4: CNS infiltration of leukocytes in p25Tg mice 
Confocal images of the cortex from p25Tg/control mice brain sections using (A) anti-
CD4 and (B) anti-CD8 antibodies (red). Nuclei were stained with DAPI (blue). White 
arrows show the region that is magnified in boxed insets. Scale bars: 20 µm (main 






3.3.4 Astrogliosis precedes amyloid-β/phospho-tau pathology in p25Tg 
mice 
The onset of neurodegenerative hallmarks such as hyperphosphorylated tau 
and intraneuronal amyloid-β accumulation in p25Tg mice were examined at 
different time points such as 1, 4, 8 and 12-week induction of p25 expression 
in order to determine whether the p25-mediated astrogliosis is triggered by 
amyloid-β or phospho-tau accumulation. Immunostaining analyses were 
performed using AT8 (marker for hyperphosphorylated tau) & Aβ 1-42 
antibodies and results indicated that phospho-tau production and amyloid 
accumulation were observed only after 4-week and 8-week induction of p25 
expression respectively (Figure 3.5). However, astrogliosis and 
chemokines/cytokines upregulation were found even in 1 week of p25 
induction (Figure 3.1 and 3.2). Thus, results identified that p25-mediated 
astrogliosis was not triggered either by phospho-tau or by amyloid-β 
pathology in p25Tg mice.   
 
 
Figure 3.5: Initiation of neuroinflammation is independent of amyloid-β and tau 
phosphorylation in p25 transgenic mice  
Confocal images of the cortex from p25Tg/control mice brain sections using (A) anti-
AT8 and (B) anti-Aβ (1-42) antibodies (red). Nuclei were stained with DAPI (blue). 
White arrows show the region that is magnified in boxed insets. Scale bars: 20 µm 
(main panel) and 10 µm (insets) (n=3).   
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3.3.5 p25-induced glial activation is mediated by a soluble factor  
Results from Figure 3.5 strongly suggested a possibility of an alternate trigger 
produced very early during p25 overexpression to mediate astrogliosis. 
Nonetheless, it was unclear what this trigger was. Hence, p25 overexpressing 
neurons and primary glial cells were used to investigate how p25 
overexpression mediates this astrogliosis. Glial cells in 6-well plates were co-
cultured with neurons transduced with p25-LV/EV-LV and primary neurons 
from p25Tg/control mice. Interestingly, immunostaining results indicated that 
GFAP immunostaining was significantly elevated in glial cells that were co-
cultured with neurons transduced with p25-LV and neurons from p25Tg mice 
compared to the respective controls. Thus, these results suggested a possibility 
of the involvement of soluble factors in p25 overexpression-mediated 
astrocytes activation, since neurons and glial cells were not in direct contact 
with each other in co-culture experiments (Figure 3.6A). Subsequently, 
Western blot analyses were carried out on lysates from glial cells that were co-
cultured with neurons transduced with EV-LV/p25-LV or neurons from 
p25Tg/control mice and results confirmed the findings of immunostaining 
results described above (Figure 3.6B).  
Furthermore, RT-PCR analyses were performed to determine changes in 
chemokines/cytokines levels during the p25 overexpression-mediated 
activation of glia in vitro. Significant increases in inflammatory 
cytokines/chemokines levels such as MIP-1α, TNF-α, TGF-β and IL-1β were 
observed in glial cells that were co-cultured with neurons transduced with 
p25-LV and neurons from p25Tg mice compared to the respective controls 
(Figure 3.6C and D). In addition, cell-free supernatant transfer experiments 
were carried out between p25-overexpressing neurons and glial cells and 
results from immunostaining and Western blot analyses supported the findings 
from the co-culture experiments where soluble signals from p25 
overexpressed neuron caused glial activation (Figure 3.7A and B). In parallel, 
kinase assays and Western blot analyses were carried out to determine the 
hyperactivation of Cdk5 in p25 overexpressing cortical neurons (Figure 3.7C 
and D).  
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In addition, to investigate the effects of p25-mediated soluble factor 
production on microgliosis, immunostaining using anti-Cd11b antibody was 
performed on glial cells that were incubated with cell-supernatants from p25 
overexpressing neurons and results showed that there were no significant 
changes in microglial numbers compared to controls (Figure 3.7E).   
 
Figure 3.6: Characterization of p25 overexpression-mediated glial activation 
using co-culture system 
(A) Immunofluorescence images from glial cells that were co-cultured with EV-
LV/p25-LV transduced neurons (top panel) and primary neurons from control/p25Tg 
mice (bottom panel) using anti-GFAP antibody (green) and DAPI (blue). Scale bars: 
20µm.  (B) Western blots with glial cell lysates that were co-cultured with EV-
LV/p25-LV transduced neurons and neurons from control/p25Tg mice using anti-
GFAP antibody. Bar graph below the blots shows GFAP expression level 
quantification (*** p-value < 0.001). RT-PCR results for the expression of MIP-1α, 
TNF-α, TGF-β and IL-1β in glia co-cultured with (C) p25 overexpressing cortical 
neurons and (D) primary cortical neurons from p25Tg/control mice (*** p-values < 





Figure 3.7: Characterization of p25 overexpression-mediated glial activation 
using supernatant transfer system 
 (A) Glial cells that received cell-free supernatants from EV-LV/p25-LV transduced 
neurons (top panel) and neurons from control/p25Tg mice (bottom panel) were 
immunostained with anti-GFAP antibody (green) and DAPI (blue). Scale bars: 20µm. 
(B) Western blots for samples same as in A using anti-GFAP antibody. Bar graph 
below the blots shows GFAP expression level quantification (*** p-value< 0.001). 
(C) Kinase assay results for cortical neurons transduced with EV-LV/p25-LV (** p-
values < 0.01) (student’s t-test). Error bars indicate ± s.e.m. (D) Western blot 
analyses results of cortical neurons transduced with EV-LV/p25-LV using anti-Cdk5 
(C8) antibody. (E) Confocal images of glial cells treated with supernatants from p25 
overexpressing /control neurons stained with anti-CD11b antibody (red) and DAPI 





3.3.6 Endogenously produced p25 induces astrogliosis through a soluble 
factor  
NMDA has previously been shown to produce p25 from p35 through the 
activation of the calcium-dependent protease calpain (Kerokoski et al., 2002; 
Wei et al., 2005; Hosokawa et al., 2006). To investigate the effects of 
endogenously produced p25 on neuroinflammation, cortical neurons were 
treated with NMDA in the presence and absence of NMDA blocker MK180. 
Results from Western blot analyses confirmed the production of significant 
amounts of p25 from p35 in the presence of NMDA alone, whereas no change 
in p35 levels were observed in the presence of NMDR blocker MK180 (Figure 
3.8A). Subsequently, cell-free supernatants from NMDA treated cortical 
neurons were transferred to glial cells and incubated for 48 hours. 
Immunocytochemical staining and Western blot analyses indicated that glial 
cells incubated with supernatants from cortical neurons with endogenously 
produced p25 were activated at about the same level as those incubated with 
supernatants from p25 overexpressed neurons (Figure 3.8B-E). Therefore, 
these data indicated that p25 caused neuroinflammation not only when 
overexpressed, but also when endogenously produced during neurotoxicity. In 
addition, results clearly demonstrated that endogenously-produced p25 also 




Figure 3.8: Endogenous p25 expression mimics the p25 overexpression induced 
effect on astrogliosis 
(A) Western blot analyses results from non-treated neurons (NT), neurons treated 
with glutamate (positive control), NMDA and NMDA+MK801 using C-19 antibody. 
(B) Representative immunostaining images from glial cells treated with supernatants 
from NT neurons or neurons treated with glutamate, NMDA and NMDA+MK801 
using anti-GFAP antibody. Scale bars represent 20µm. (C) Quantification of GFAP 
expression in B (*** p-value < 0.001). (D) Immunoblot analyses of lysates from glial 
cells treated with supernatants from NT neurons and neurons treated with glutamate, 
NMDA or NMDA+MK801 using GFAP antibody. (E) Quantification of Western blot 





Results from this chapter uncover novel aspects of the mechanism behind 
p25/Cdk5-mediated neuroinflammation. Results showed that p25-mediated 
astrogliosis was an early as well as amyloid-independent event in p25Tg mice. 
However, microgliosis was observed secondary to astrogliosis in these mice. 
In addition, results indicated for the first time that p25 overexpression initiated 
peripheral cell recruitment into p25Tg mice brain and exacerbated 
neuroinflammation. Additionally, co-culture and supernatant experiments 
results strongly suggested that p25 expression (either by endogenous 
production or by overexpression) in neurons induced the release of a soluble 
factor to mediate astrocyte activation. 
 Although various experimental animal models of AD have been available to 
study the pathological changes, p25 transgenic (p25Tg) mouse is one of the 
well-studied mouse model of AD which recapitulates most of the neurological 
deficits reminiscent of AD (Cruz et al., 2003; Cruz et al., 2006; Muyllaert et 
al., 2008). p25Tg mice overexpress human p25 in the forebrain under the 
control of an inducible CaM Kinase IIA promoter. Astrogliosis, neurofibrillary 
tangles with hyperphosphorylated tau and intraneuronal accumulation of 
amyloid-β were evidently observed in these mice (Cruz et al., 2003; Cruz et 
al., 2006). Interestingly, a recent study reported the occurrence of intense 
neuroinflammation and its association between neurodegeneration in inducible 
p25Tg mice (Muyllaert et al., 2008). However, the onset of neuroinflammation 
and the actual mechanism behind how p25 causes robust increases in 
neuroinflammation were not fully described. To date, very limited evidence is 
available to decipher the link between p25-induced neuroinflammation and 
neurodegenerative disease progression. This study adds on to current 
knowledge by delineating key aspects that regulate the early phase of p25-
mediated neuroinflammation and neurodegeneration. 
3.4.1 Astrogliosis is an early event in p25 transgenic mice 
Preliminary results from microarray analyses conducted by our group using 
brain samples of 4-week induced p25Tg mice suggested that 
neuroinflammation was an early incident in p25Tg mice (data not shown). 
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Inflammatory markers such as GFAP and pro-inflammatory cytokines 
expression were found to be robustly elevated in 4-week induced p25Tg mice. 
In addition, this interesting finding shed light on our further investigations to 
establish the mechanism behind the early changes in p25-mediated 
neuroinflammation. Results from immunohistochemistry, Western blot and 
RT-PCR analyses clearly demonstrated that GFAP expression and pro-
inflammatory chemokines/cytokines such as TNF-α, MIP-1α, TGF-β and IL-
1β levels were significantly increased even in 1 week induced p25Tg mice 
(Figure 3.1 and 3.2). The role of astrocytes in the progression of dementia was 
initially indicated by Dr. Alois Alzheimer himself (in 1910). Occurrence of 
reactive astrocytes in the animal models for AD, PD and ALS has also been 
reported previously (Nagele et al., 2004; Chiu et al., 2009; Ciesielska et al., 
2009). Although the presence of GFAP immunoreactive astrocytes has 
previously been reported in p25 transgenic mice (Cruz et al., 2003; Muyllaert 
et al., 2008), results from this study identified astrogliosis and inflammatory 
cytokines production as very early events occurring before any 
neuropathological changes in p25Tg mice. Our findings are consistent with a 
recent clinical study where prominent astrogliosis was found in the cortex at 
early stages of patients with frontotemporal dementia (Kersaitis et al., 2004). 
In another study, astrocytes activation was observed as the first event that 
occurred before any neurodegenerative changes (Wu et al., 2011). In 
summary, results collectively suggested that targeting astrocytes could be a 
potential early intervention strategy for the treatment of neuroinflammation-
associated neurodegenerative diseases including AD. Moreover, this 
interesting finding of early astrogliosis in p25Tg mice became a stepping stone 
for further investigations to understand the mechanism behind the p25/Cdk5 
hyperactivation-mediated neuroinflammation. 
3.4.2 p25-induced astrogliosis occurs prior to microgliosis in p25Tg mice  
Reactive microgliosis has long been implicated as a key aspect in the 
development of neuropathology in various neurodegenerative diseases 
(McGeer et al., 1988; Hall et al., 1998). Hence, the role of microgliosis in p25-
mediated neuroinflammation was studied using immunostaining experiments 
in 1, 4, 8 and 12-week induced p25Tg mice using anti-CD11b & anti-tPA 
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antibodies and results showed that reactive microgliosis appeared after 4 
weeks of induction of p25 expression in p25Tg mice (Figure 3.3). However, 
astrogliosis was found even at 1 week of induction (Figure 3.1). In addition, 
results from conditioned media transfer experiments between p25 
overexpressed neurons and glia further determined that astrocyte activation 
was observed primarily with substantially lower or no microglial activation 
(Figure 3.7E). Collectively, results showed that astrogliosis preceded 
microgliosis in p25-mediated neuroinflammation.  
Recently, astrocyte activation was reported as a first response to α-synuclein 
release from degenerating neurons in a transgenic mouse model of PD 
(Sekiyama et al., 2012). Reactive astrocytes-mediated microglial activation 
was also reported in another recent study using a cuprizone-induced rodent 
model of demyelination (Skripuletz et al., 2012). Furthermore, results from 
various studies suggested that activated astrocytes released inflammatory 
chemokines/cytokines (mainly MIP-1α or TNF-α) to attract microglia and 
contributed further to neuronal damage (Hurwitz et al., 1995; Janelsins et al., 
2005; Tuppo and Arias, 2005). Accordingly, findings of upregulated MIP-1α 
and TNF-α expression in 1 week induced p25Tg mice indicated that cytokines 
produced by p25-induced reactive astrocytes might be involved in the 
regulation of recruitment and activation of microglia and which might serve to 
further intensify neuroinflammation. 
3.4.3 Peripheral cell infiltration is evident in p25Tg mice 
Although, CNS recruitment of CD4+ and CD8+ T cells has been observed as a 
neuroinflammatory response in various neurodegenerative diseases (Brisebois 
et al., 2006; Brochard et al., 2009),
 
there have been no clear evidence about the 
involvement of these peripheral immune cells in p25-mediated 
neuroinflammation. Results from immunostaining experiments using brain 
sections from p25Tg mice determined that there was a significant level of 
CNS infiltration of CD4+ and CD8+ T cells in p25Tg mice after 4 weeks of 
induction of p25 expression (Figure 3.4). However, this finding of late 
leukocyte infiltration suggested that early astrogliosis and cytokines 
upregulation might have a role in the induction of leukocyte infiltration during 
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neurodegeneration. A number of reports have suggested that inflammatory 
mediators secreted by injured neurons or cytokines produced by activated 
astrocytes, especially MIP-1α and TNF-α could trigger peripheral cell 
infiltration (Ousman and David, 2001; Garcia-Ramallo et al., 2002).  
Recent studies on mouse models of neurodegenerative diseases suggested that 
CNS leukocyte traffic could be detrimental or beneficial depending on the 
disease state. Peripheral monocytes were found to be efficient in clearing 
amyloid-β plaques in a mouse model of AD (Town et al., 2008). CNS 
infiltration of CD4+ T lymphocytes promoted a neuroprotective 
microenvironment in a mouse model of ALS (Chiu et al., 2008). However, 
deleterious effects of CNS leukocyte traffic was also observed in a mouse 
model of multiple sclerosis (MS) and in experimental autoimmune 
encephalomyelitis (EAE) (Fletcher et al., 2010). Therefore, more studies are 
required to determine the significance of peripheral cell recruitment in p25-
mediated neuroinflammation. Proper understanding of the mechanisms behind 
the role of peripheral immune cells in p25-mediated neuroinflammation may 
lead to novel therapeutics in the future. 
3.4.4 p25-induced astrogliosis is an amyloid-β and phospho-tau 
independent event in p25Tg mice  
Amyloid accumulation was thought to be a major contributing factor for the 
induction of neuroinflammation in various neurodegenerative models (Combs 
et al., 2001; White et al., 2005). Moreover, induction of neuroinflammation by 
tau protein abnormalities has also been reported  earlier (Yoshiyama et al., 
2007). Therefore, the onset of phospho-tau production and amyloid-β 
accumulation in p25Tg mice was investigated to determine the role of 
phospho-tau and amyloid-β in the induction of astrogliosis during p25 
overexpression. Immunostaining results showed that phospho-tau and amyloid 
accumulation became evident after 4 and 8 weeks of p25 expression 
respectively (Figure 3.5). However, intense astrogliosis after 1 week of p25 
expression clearly suggested that astrogliosis was an amyloid-independent 
event in p25Tg mice (Figure 3.1). Our findings have been supported by a 
study using APP [V717I] mice where activated astrocytes were detected 
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before any amyloid deposition (Heneka et al., 2005). In another study, GFAP 
upregulation was identified before the onset of many pronounced AD  
neuropathologies (Zhu et al., 2008). Together, results found that there might 
be an alternate trigger for astrogliosis that occurs even before any evidence of 
amyloid and tau pathology in p25Tg mice. 
3.4.5 p25-induced astrocytes activation is mediated by a soluble factor 
Subsequently, in vitro co-cultures as well as conditioned media transfer 
systems were employed to uncover the mechanism behind p25-mediated 
astrocyte activation. Results identified a robust increase in GFAP expression 
in glial cells co-cultured with p25-LV transduced neurons or with p25Tg mice 
neurons compared to control neurons (Figure 3.6). Hence, this finding 
demonstrated that p25 overexpression was involved in neuroinflammation in 
vitro where a soluble signal secreted by the p25 overexpressed neurons 
activated glial cells. This soluble factor-dependent activation was further 
investigated using cell-free supernatants experiments, where there is no direct 
physical contact between glia and neurons. Significant increases in GFAP 
levels in glial cells that received the cell-free supernatants from p25-
overexpressed neurons further confirmed the findings from the co-culture 
experiments (Figure 3.7). Although studies indicated that signals from injured 
neurons could activate glial cells, (Salmina, 2009), the exact mechanism 












The onset of neuroinflammation in p25Tg mice was well documented in this 
study. Furthermore, astrocyte activation was found to be triggered by soluble 
factors secreted by the p25-overexpressed neurons. In light of our findings 
above, it is immensely important to elucidate the nature of these soluble 
factors and the pathway behind the production of these factors. Together, the 
novel findings from this chapter which has been published (Sundaram et al., 
2012) strongly indicated the need to establish the critical role played by the 
key inflammatory mediators so as to target them early to reduce 
neuroinflammation and subsequent neurodegeneration. As such, it is crucial to 
identify the nature of the soluble trigger in p25-mediated neuroinflammation 
























                             















Chapter 4: Identification of pathway involved in induction of 
p25/Cdk5 hyperactivation-mediated astrogliosis: its 
significance in initiation of neurodegeneration 
   
4.1 Introduction 
The results in Chapter 3 revealed the role of soluble factors secreted by p25 
overexpressing neurons in the induction of astrocytes activation. It is therefore 
important to elucidate the nature of these soluble factors and the pathway 
behind their production. Furthermore, identifying the mechanism as well as 
the trigger for neurodegeneration will help in early detection of 
neurodegenerative diseases and may provide novel therapeutic avenues to 
reduce the progression of neurodegenerative diseases where 
neuroinflammation is implicated in the pathogenesis.  
The first part of this chapter details the experiments conducted to identify the 
nature of the soluble factors involved in p25-mediated neuroinflammation 
using sequential factor removal strategies in coordination with high 
performance liquid chromatography-mass spectrometry (LC-MS). 
Additionally, confirmation of gene expression changes was made using Real-
time PCR and gene silencing experiments. The second part of this chapter 
focuses on the experiments conducted to determine whether the inflammatory 
mediators produced during p25 expression could initiate the progression of 
pathological changes in the brain. Together, results from this chapter identified 










4.2.1 Factor removal experiments 
Culture media supernatants from p25 overexpressing neurons (EV-LV/p25-
LV transduced neurons and p25Tg/control mice neurons) were treated with 
DNAse (8μg/ml), RNAse (50μg/ml) and Proteinase K (50μg/ml) (Sigma) for 
60 minutes at 37°C. In parallel, supernatants were passed through the SPE C-
18 (solid phase extraction) columns under vacuum in order to remove major 
lipids. Glial cells were incubated with enzyme-treated as well as lipid-free 
supernatants for 48 hours at 37°C. Later, glial cells were processed differently 
for Western blotting, immunocytochemistry and RT-PCR analyses. 
4.2.2 Lipid analysis using High-Performance Liquid 
Chromatography/Mass Spectrometry  
(This work was done in collaboration with Assoc Prof Markus Wenk’s 
Lipidomics lab)    
Individual lipids derived from the supernatants of EV-LV/p25-LV transduced 
cortical neurons and brain samples of p25Tg/control mice were separated and 
quantified using an Agilent 1200 high-performance liquid chromatography 
(HPLC) system and a 3200 Q-Trap mass spectrometer.  
4.2 3 Lipid treatment experiments 
Glial cells were incubated either with the lipids extracted from the cell-free 
supernatants of EV-LV/p25-LV transduced cortical neurons or with the 
commercially available LPC species 16:0, 18:0 and 18:1 (20 µM) for 24/48 
hours at 37°C. Lipids treated glial cells were then processed individually for 
Western blotting and immunocytochemistry analyses. 
4.2.4 cPLA2 activity assay 
cPLA2 activity was determined for the samples from EV-LV/p25-LV 
transduced neurons and p25Tg/control mice neurons using the cPLA2 activity 





4.2.5 cPLA2 gene silencing analyses 
cPLA2 gene silencing analyses were performed in p25-overexpressing cortical 
neurons using cPLA2 shRNA lentivirus and cortical neurons were then 
processed for RT-PCR and Western blot analyses to confirm the gene 
silencing. Subsequently, cell-free supernatants from these neurons were then 
transferred to glial cells and incubated for 48 hours at 37°C.  
4.2.6 Inhibitor studies 
Cortical neurons transduced with p25-LV/EV-LV were incubated with 0.3 µM 
of bromoenol lactone (BEL) (iPLA2 inhibitor) or 10 µM of arachidonyl 
trifluoromethyl ketone (AACOCF3) (cPLA2 inhibitor) for 48 hours at 37°C. 
Neurons were then fixed and processed for immunocytochemistry. 
4.2.7 Real-Time PCR 
RNA samples were extracted from the glial cells incubated with enzyme-
treated/lipid-free supernatants from p25 overexpressing neurons using RNeasy 
Mini Kit. Using high capacity cDNA reverse transcriptase kit, cDNA was 
synthesized from RNA and subsequently used for quantitative real-time PCR. 
4.2.8 Stereotactic injection of lipids into mouse brain 
1 µl of solution containing lipids (2 µM) were injected into anesthetized WT 
(C57BL/6) mice brains using a Hamilton microsyringe through a small hole 
drilled using the coordinates: caudal to bregma 2 mm, 2 mm lateral to the 
midline and 1.8 mm from the surface of the cortex at a constant rate for 5 
minutes. After 10 minutes, needle was withdrawn and the scalp was sutured.  
4.2.9 Immunohistochemistry 
16 μm of mice brain sections were immunostained with mouse anti-GFAP 
antibody overnight at 4°C. Sections were washed with PBS before and after 
incubation with Alexa Fluor 594 secondary antibody for one hour at room 
temperature and nuclei were counterstained with DAPI. Immunofluorescence 
images were taken with Zeiss LSM-510 laser-scanning confocal microscope at 
20X, 40X and 63X magnifications.  
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4.2.10 Immunocytochemical analyses 
Immunofluorescence staining was performed on glial cells using mouse anti-
GFAP (primary) and Alexa Fluor 488 (secondary) antibodies. Nuclei were 
counterstained with DAPI and fluorescent confocal images were taken at 40X 
magnification.  
4.2.11 Western blot analyses 
Total cell lysates (from glial cells) and soluble cell lysates (from EV-LV/p25-
LV virus-transduced cortical neurons and p25Tg/control mice neurons) were 
resolved on 4-20% polyacrylamide gels, blotted onto nitrocellulose 
membranes and then immunoprobed with rabbit anti-GFAP and mouse anti-
cPLA2 antibodies.  
4.2.12 TUNEL assay 
TUNEL staining was performed on 4% formaldehyde-fixed cortical neurons 
and 4% PFA-perfused mice brain sections using In Situ Cell Death Detection 
Kit, TMR red. 
4.2.13 Statistical analysis 
Data are expressed as the mean of at least three values ± standard error 
(s.e.m). Statistical significance was determined using student’s t-test and P-










4.3 Results  
4.3.1 p25-mediated neuroinflammation is caused by a lipid  
Findings from Chapter 3 strongly suggested that p25-overexpressing cortical 
neurons regulated astrogliosis by secreting a soluble mediator. It has 
previously been demonstrated that neurons regulate astrocytes differentiation 
and activation through soluble factors (Alvarez-Maubecin et al., 2000; Benz et 
al., 2004). However, the exact nature of the soluble factor was not well 
characterized. Hence, experiments in this chapter aimed to determine the 
biochemical nature of the secreted factor from the p25 overexpressing neurons 
based on the protocols published earlier (Lauber et al., 2003). 
To determine the possible factors that could be secreted during inflammation, 
supernatants of p25-LV/EV-LV transduced neurons were incubated with 
DNAse, RNAse and Proteinase K for 60 minutes at 37°C and then transferred 
onto glial cells for 48 hours. Later, glial cells were processed for 
immunostaining (Figure 4.1A and C) and Western blotting analyses (Figure 
4.1B and D) using anti-GFAP antibody in order to analyze the changes in glial 
activation during each enzymatic treatments. Results specified that there was 
no significant change in GFAP upregulation in glial cells incubated with 
supernatants treated with DNAse, RNAse and Proteinase K compared to the 
non-treated supernatants from the p25-LV transduced neurons. Thus, the 
above findings clearly demonstrated that the factor causing astrocyte 
activation was neither DNA/RNA nor protein in nature.  
In order to further characterize the soluble factor nature, the major lipids from 
the supernatants of p25 overexpressing neurons were removed by solid phase 
extraction column (SPE-C18) elution. Later, glial cells were treated with 
column-eluted supernatants of p25 overexpressing neurons and a change in 
glial activation was investigated using immunocytochemistry and Western 
blotting analyses. An interesting finding of marked reduction in GFAP levels 
in glial cells that received the SPE-C18 column-eluted supernatants 
demonstrated that the factor released during p25 overexpression could be lipid 









Figure 4.1: Elucidation of the nature of soluble factor secreted by p25-LV 
transduced neurons 
 
(A) Glial cells incubated with DNAse, RNAse and Proteinase K treated or SPE-C18 
column-eluted culture media supernatants from EV-LV/p25-LV transduced neurons 
were immunostained with anti-GFAP antibody (green) and DAPI (blue). Scale bars: 
20µm (n=3 for each group). (B)  Lysates of glia samples that were incubated with 
supernatants from same treatment as in A were resolved by SDS-PAGE and 
immunoprobed with anti-GFAP antibody (n=3 for each group). (C) Graph represent 
the percentage of GFAP expression in A (*** p-value < 0.001 and NS > 0.05). (D) 
Quantification of Western blots in B (*** p-value < 0.001 and NS > 0.05). RT-PCR 
results for the expression of (E)  MIP-1α, (F) TNF-α, (G) TGF-β and (H) IL-1β in 
glial cells incubated with supernatants from the same treatment as in A (*** p-values 
< 0.001, ** p-values < 0.01, * p-values < 0.05 and NS > 0.05). Error bars indicate ± 
s.e.m (student’s t-test). 
 
 
The results from RT-PCR analyses for chemokines/cytokines expression from 
the glial cells that were incubated with SPE-C18 column-eluted or DNAse, 
RNAse and Proteinase K treated supernatants from p25 overexpressing 
neurons further supported the above findings and a remarkable reduction in 
MIP-1α, TNF-α, TGF-β and IL-1β expression levels was observed in glial 
cells treated with SPE-C18-eluted supernatants (Figure 4.1E-H). In addition, 
these findings were further confirmed by the results from the same factor 
elucidation experiments carried out in neurons from p25Tg/control mice 
(Figure 4.2A-D). Together, these results determined that the soluble factor 







Figure 4.2: Elucidation of the nature of soluble factor secreted by neurons from 
p25Tg mice  
Immunostaining (A) and Western blot analyses (B) results for the glial cells 
incubated with DNAse, RNAse and Proteinase K treated or SPE-C18 column-eluted 
culture media supernatants from primary neurons of p25Tg/control mice. (C) Graph 
represent the percentage of GFAP expression in A (*** p-value < 0.001 and NS > 
0.05). (D) Quantification of Western blots in B (*** p-value < 0.001 and NS > 0.05). 
Error bars indicate ± s.e.m (student’s t-test). 
 
 
4.3.2 A lipid signal triggers the p25/Cdk5-mediated inflammatory cascade 
To facilitate further investigation to confirm the lipid nature of the factor 
behind p25-mediated astrogliosis, total lipid extraction was performed using 
supernatants of neurons transduced with EV-LV/p25-LV and extracted lipids 
were then transferred onto glial cells for 24 and 48 hours. Results from 
immunocytochemical staining (Figure 4.3A) and Western blot analyses 
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(Figure 4.3B and C) showed a significant increase in GFAP expression in the 
glial cells treated with the lipids from p25 overexpressing neurons. Moreover, 
these lipid treatment results were found indistinguishable from the supernatant 
transfer experiments results in Chapter 3 (Figure 3.7). Subsequently, lipids 
from p25-LV transduced neurons were stereotactically injected into WT mice 
brains in order to validate the above finding in vivo. Results from 
immunohistochemical analyses showed robust increases in GFAP staining in 
brain sections from mice that received an injection with lipids from p25-LV 
transduced neurons compared to control (Figure 4.3D). Together, both in vitro 
and in vivo results showed that the factor behind the p25-induced astrogliosis 
was a soluble lipid. 
 
 
Figure 4.3: p25 overexpressing cells secrete soluble lipids to mediate astrogliosis  
(A) Glial cells incubated with lipids from supernatants of EV-LV/p25-LV transduced 
neurons were stained with anti-GFAP antibody (green) and DAPI (blue). Scale bars: 
20µm (n=3 for each group). (B) Immunoblot analyses of lysates from glial cells 
received same treatment as in A using anti-GFAP antibody (C) Quantification of 
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immunoblots in B (*** p-value < 0.001). Error bars indicate ± s.e.m (student’s t-test). 
(D) Brain sections from mice received injection of lipids from supernatants of EV-
LV/p25-LV transduced neurons were immunostained with anti-GFAP (red) and 
DAPI (blue). Images in top panel: 20X magnification (scale bars: 50µm) and images 
in bottom panel: 40X magnification (scale bars: 20µm) (n=3 for each group).  
 
 
4.3.3 Lysophosphatidylcholine (LPC) is the lipid mediator involved in 
p25-mediated neuroinflammation 
To identity the particular lipid present in the supernatants of p25 
overexpressing neurons, lipidomic mass spectrometric analyses were carried 
out and results showed that lysophosphatidylcholine (LPC) levels were found 
to be significantly increased among the major lipids in supernatants from p25-
LV transduced neurons compared to the control neurons (Figure 4.4A). 
Although lysophosphatidylinositol (LysoPI) levels were also increased, the 
difference was not statistically significant (P value = 0.223). 
Likewise, LPC levels were again found to be significantly elevated among the 
major lipids in the brain samples from p25Tg mice compared to the controls 
(Figure 4.4B). Furthermore, progressive elevation of LPC levels from 1 to 12-
week induction of p25 expression clearly demonstrated a strong correlation 
with the progressive elevation of GFAP expression in p25Tg mice (Figure 
4.4C and Figure 3.1). Together, these data determined that LPC was the major 









Figure 4.4: p25 overexpression causes lysophosphatidylcholine (LPC) 
production to induce astrogliosis 
Results from mass spectrometric analyses using lipids from supernatants of (A) 
neurons transduced with EV-LV/p25-LV, (B) brain samples from 12-week induced 
p25Tg/control mice and (C) brain samples from 1, 4, 8 and 12-week induced 
p25Tg/age-matched control mice. Results were normalized against the internal 
standards of the respective lipids (*** p-values < 0.001, ** p-values < 0.01, * p-
values < 0.05 and NS > 0.05). Error bars indicate ± s.e.m (student’s t-test).  
 
 
4.3.4 LPC 18:1 is the more potent species that effectively causes 
astrogliosis 
LPC has many species based on variations in the acyl chain and potency of 
LPC is mainly determined by the acyl side chain (Ojala et al., 2007). To 
determine the role of different LPC species in the induction of astrogliosis, 
Lipidomics mass spectrometry analysis was carried out and results identified 
LPC 16:0, 18:0 and 18:1 as the main LPC species increased in p25-LV derived 
lipids compared to the control (Figure 4.5A). In addition, glial cells were 
treated with commercially available LPC species 16:0, 18:0 and 18:1 for 24 
and 48 hours in order to determine which LPC species was more effective in 
stimulating GFAP expression. Results showed greater GFAP elevation in glial 
cells treated with LPC 18:1 in both 24 and 48 hours incubation. In contrast, 
LPC 16:0 didn’t cause any changes in GFAP expression and LPC 18:0 effect 
was found only at 48 hour time point (Figure 4.5B-D). To further validate the 
above finding in vivo, commercial LPC 18:1 was stereotactically injected into 
WT mouse brains (Figure 4.5E) and results mirrored the in vitro experiment 
findings. Collectively, results determined that LPC 18:1 was one of the major 




Figure 4.5: p25 overexpression mediates astrocytes activation through LPC 18:1 
(A) Mass spectrometric analyses results for the lipids derived from supernatants of 
neurons transduced with EV-LV/p25-LV (** p-value < 0.01 and NS p-value > 0.05). 
(B) Glial cells incubated with media containing 20 µM of LPC species 16:0, 18:0 or 
18:1 were immunostained using anti-GFAP antibody (green) and DAPI (blue). Scale 
bars represent 20 µm (n=3 for each group).  (C) Representative Western blots of glial 
cells treated with 20 µM of LPC species 16:0, 18:0 or 18:1 using anti-GFAP antibody 
(n=3 for each group).  (D) Quantification of immunoblots in C (*** p < 0.001 and NS 
p-value > 0.05). Error bars indicate ± s.e.m (student’s t-test). (E) Brain sections from 
mice injected stereotactically with LPC 18:1/vehicle (chloroform/methanol) were 
immunostained with anti-GFAP (red) and DAPI (blue). Images in top panel: 20X 
magnification (scale bars: 50µm) and images in bottom panel: 40X magnification 






4.3.5 p25 overexpression upregulates cPLA2 expression and activity  
Lysophosphatidylcholine (LPC) is generated from phosphatidylcholine (PC) 
by phospholipase A2 (PLA2)-mediated hydrolysis (Steinbrecher et al., 1984). 
Recent studies have focused on characterizing the three major groups of 
PLA2: cytosolic PLA2 (cPLA2-IV), Ca
2+
-dependent PLA2 (iPLA2-VI) and 
secretory PLA2 (sPLA2-II) due to their important roles in inflammatory-
mediated neurodegeneration (Sun et al., 2010). To facilitate investigation of 
the role of these three major PLA2 enzymes in p25-mediated 
neuroinflammation, RT-PCR analyses were carried out on the p25-LV 
transduced neurons. CT values in RT-PCR using sPLA2 primers were found 
undetermined or not detected after 40 cycles of PCR and these results clearly 
indicated that the sPLA2-II mRNA is not present in an amount that is 
detectable in all the samples. In addition, results did not identify any obvious 
increase in iPLA2 expression between p25 overexpressing and control 
neurons. However, robust elevation of cPLA2 expression was observed in p25 
overexpressing neurons compared to controls (Figure 4.6A). Together, RT-
PCR results determined that only cPLA2 expression was significantly elevated 
among that of the three major PLA2 enzymes during p25 overexpression in 
neurons. Subsequently, the role of PLA2 isoforms in p25-mediated 
astrogliosis was investigated using bromoenol lactone (BEL) (iPLA2 
inhibitor) and arachidonyl trifluoromethyl ketone (AACOCF3) (cPLA2 
inhibitor). Obvious reductions in GFAP expression was observed in glial cells 
incubated with AACOCF3-treated supernatants compared to the BEL-treated 
supernatants from p25 overexpressing neurons (Figure 4.6B). Therefore, 
results confirmed that cPLA2 was the principal enzyme involved in p25-




Figure 4.6: p25-induced upregulation of cPLA2 causes LPC production 
(A) Graph represent the RT-PCR results of iPLA2 and cPLA2 gene expression from 
EV-LV/p25-LV transduced cortical neurons (NS p-value > 0.1 and *** p values < 
0.001). (B) Immunocytochemistry results from glial cells treated with supernatants 
from cortical neurons transduced with EV-LV, p25-LV, p25-LV+cPLA2 inhibitor 
(AACOCF3) and p25–LV+iPLA2 inhibitor (BEL) using anti-GFAP antibody (green) 
and DAPI (blue). Scale bars represent 20 µm. RT-PCR results of cPLA2 gene 
expression in (C) five days induced primary neurons from p25Tg/WT mice  and (D) 
1, 4, 8 and 12-week induced p25Tg mice/age-matched control mice (*** p values < 
0.001) (n=3 for each group). (E) Western blots for lysates from five days induced 
primary neurons from p25Tg/control mice (top panel) and neurons transduced with 
EV-LV/p25-LV (bottom panel) using anti-cPLA2 antibody (n=3). (F) Quantification 
of immunoblots in E (*** p-values < 0.001). (G) cPLA2 activity assay results for 
neurons transduced with EV-LV/p25-LV and lysates from primary neurons from 







Next, experiments focused on investigating cPLA2 expression in both in vitro 
(p25-LV transduced neurons and primary neurons from p25Tg mice) and in 
vivo (brain samples from p25Tg mice) p25 overexpression systems using RT-
PCR as well as Western blot analyses (Figure 4.6C-F). Results showed a 
significant increase in cPLA2 expression in p25-LV transduced neurons and in 
primary neurons from p25Tg mice (Figure 4.6A, C and E). Moreover, the 
finding of the progressive increases in cPLA2 expression from 1 to 12-week 
induced p25Tg mice brain samples supported the above in vitro results (Figure 
4.6D). Subsequently, cPLA2 activity assays were performed and results 
confirmed the robust elevation of cPLA2 activity in both in vitro and in vivo 
p25 overexpressing neurons (Figure 4.6G). Together, results suggested that 
p25 overexpression upregulated both cPLA2 expression and activity to 
produce LPC that in turn induced astrogliosis. 
4.3.6 cPLA2 knock-down reduces p25-induced glial activation  
To further define the role of cPLA2 activity on the glial activation, cPLA2 
gene silencing experiments were performed on the p25-LV transduced 
neurons using cPLA2 shRNA lentiviral particles. Silencing of the cPLA2 gene 
was confirmed by RT-PCR, Western blot analyses and cPLA2 activity assays 
where cPLA2 levels and activity were reduced in cPLA2-silenced p25 
overexpressed neurons compared to controls (Figure 4.7A-D). Later, mass 
spectrometric analyses were performed to determine the effect of cPLA2 gene 
silencing on p25 expression-stimulated LPC production. Results showed 
significantly decreased total LPC and specific LPC species 18:0 and 18:1 
levels from the p25-LV+cPLA2 shRNA transduced neurons compared to 
controls (Figure 4.7E). Thus, results clearly indicated that p25-mediated 
cPLA2 overexpression was crucial for the generation of the inflammatory 




Figure 4.7: shRNA-mediated silencing of cPLA2 gene reduces LPC production 
(A) RT-PCR results for cPLA2 expression and (B) cPLA2 activity assay results for 7-
DIC cortical neurons transduced with p25-LV+cPLA2 shRNA or p25-LV+control 
(ctrl) shRNA (*** p-values < 0.001 and ** p-values < 0.01). (C) Immunoblots for 
neurons transduced with p25-LV+cPLA2 shRNA or p25-LV+control shRNA using 
anti-cPLA2 antibody. (D) Quantification of immunoblots in C (*** p-values < 
0.001). (E) Mass spectrometric analyses results of lipids from the supernatants of 
p25-LV+control shRNA/p25-LV+cPLA2 shRNA transduced neurons (** p-value < 






To further investigate the role of cPLA2 knock-down in p25-mediated 
astrogliosis, glial cells were treated with supernatants from p25-LV+cPLA2 
shRNA/p25-LV+control shRNA transduced neurons and then processed for 
Western blot analyses to determine changes in GFAP expression levels. 
Dramatic reductions in GFAP immunostaining were observed in glial cells 
treated with the supernatants from p25-LV+cPLA2 shRNA transduced 
neurons compared to controls (Figure 4.8A-C). In addition, RT-PCR analyses 
were carried out with RNA samples extracted from glial cells treated with cell-
free supernatants from p25-LV+cPLA2 shRNA/p25-LV+control shRNA 
transduced neurons to detect for changes in chemokines/cytokines expression 
levels. Results showed a marked reduction in MIP-1α, TNF-α, TGF-β and IL-
1β expression levels in glia that received supernatants from cPLA2 silenced 
neurons compared to controls (Figure 4.8D). Subsequently, total lipids 
extracted from the supernatants of p25-LV+control shRNA or p25-
LV+cPLA2 shRNA transduced neurons were transferred onto the glial cells 
for 48 hours in order to further determine the significance of cPLA2 
expression in the induction of astrocytes activation. Immunostaining and 
Western blot analyses results showed approximately 4 to 5-fold reductions in 
GFAP expression in glial cells incubated with lipids from p25-LV+cPLA2 
shRNA transduced neurons compared to controls (Figure 4.8E-G).  
In order to perform in vivo validation of findings from the above in vitro 
studies, lipids from the supernatants of p25-LV+control shRNA and p25-
LV+cPLA2 shRNA transduced neurons were injected stereotactically into WT 
mice brains and immunohistochemical staining was performed with the brain 
sections using antibody specific to GFAP. Mice that received injection with 
lipids from p25-LV+cPLA2 shRNA transduced neurons exhibited reduced 
GFAP expression compared to controls (Figure 4.8H). Collectively, results 
from the cPLA2 gene silencing experiments strongly indicated that cPLA2 






Figure 4.8: cPLA2 gene silencing attenuates p25-induced astrocyte activation 
(A) Immunocytochemistry results on glial cells treated with supernatants of neurons 
transduced with p25-LV+cPLA2 shRNA or p25-LV+control shRNA using anti-
GFAP antibody (green) and DAPI (blue). Scale bars represent 20 µm. (B) 
Immunoblot analyses were performed on glial cells that received identical treatment 
as in A using anti-GFAP antibody. (C) Quantification of immunoblots in B (*** p-
values < 0.001). (D) RT-PCR results showing the expression of chemokines MIP-1α, 
TNF-α, TGF-β and IL-1β in lysates from glial cells treated with supernatants from 
neurons transduced with p25-LV+cPLA2 shRNA or p25-LV+control shRNA (***p 
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value < 0.001, NS- p value >0 .1). (E) Immunostaining images from the glial cells 
treated with lipids from the supernatants of neurons transduced with p25-LV+cPLA2 
shRNA or p25-LV+control shRNA using anti-GFAP antibody (green) and DAPI 
(blue). Scale bars represent 20 µm. (F) Western blot analyses using antibody specific 
to GFAP were performed on glial cells that received the same treatment as E. (G) 
Quantification of immunoblots in F (** p-values < 0.01). Error bars indicate ± s.e.m 
(student’s t-test). (H) Brain sections from mice injected stereotactically with lipids 
from the supernatants of neurons transduced with p25-LV+cPLA2 shRNA or p25-
LV+control shRNA were immunostained with anti-GFAP (red) and DAPI (blue). 
Images in top panel: 20X magnification (scale bars: 50µm) and images in bottom 
panel: 40X magnification (scale bars: 20µm) (n=3 for each group).  
 
 
4.3.7 The inflammatory mediator LPC produced during p25 
overexpression triggers amyloid and tau neuropathological changes  
To discover the significance of p25-mediated neuroinflammation in the 
induction of neurodegeneration, 7 DIC healthy cortical neurons were treated 
with conditioned media supernatants from glial cells that were incubated with 
lipids from EV-LV, p25-LV+control shRNA and p25-LV+cPLA2 shRNA 
transduced neurons. Results from immunostaining analyses using phospho-tau 
(AT8 and AT270) and amyloid-β (6E10 and Aβ 1-42) antibodies showed 
increases in neurodegenerative markers mentioned above in healthy cortical 
neurons that have been incubated with supernatants from glial cells activated 
by p25 overexpressed neurons, compared to controls (Figure 4.9A and B).  
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Figure 4.9: p25-mediated neuroinflammation is a trigger for neurodegeneration 
7 DIC healthy cortical neurons incubated with supernatants from glial cells treated 
with either lipids derived from p25+control shRNA/p25+cPLA2 shRNA transduced 
neurons or with LPC18:1/vehicle were immunostained with (A) phospho-tau 
antibodies AT8 & AT270 and (B) Aβ antibodies 6E10 & Aβ (1-42) (red). Brain 
sections from mice stereotactically injected with the above mentioned lipids were 
immunostained with (C) phospho-tau antibodies AT8 & AT270 and (D) Aβ 
antibodies 6E10 & Aβ (1-42) (red). The nuclei were stained with DAPI (blue) (n=3). 
Scale bars represent 20 µm. 
 
 
In addition, obvious reductions in phospho-tau and Aβ 1-42 staining 
intensities were observed in neurons treated with supernatants from glial cells 
that have been incubated with lipids derived from cPLA2 silenced p25 
overexpressing neurons and this finding strongly indicated the importance of 
cPLA2 activity in the initiation of p25-mediated neurodegeneration (Figure 
4.9A and B). In parallel, WT mice were stereotactically injected in the brain 
with lipids from EV-LV, p25-LV+control shRNA and p25-LV+cPLA2 
shRNA transduced neurons and results showed nearly identical findings 
corroborated with the above in vitro analyses (Figure 4.9C and D).  
TUNEL staining was performed in order to further investigate the role of p25-
mediated inflammatory mediators in the induction of neuronal cell death and 
results showed statistically significant increases in cell death in neurons 
incubated with supernatants from glial cells that have been treated with lipids 
from cPLA2-upregulated p25 overexpressing neurons compared to the 
cPLA2-silenced p25 overexpressing neurons (Figure 4.10A and B). In 
contrast, there was no significant increase in cell death found in the in vivo 
experiments (Figure 4.10C). This suggested that single dose of lipid injection 
may not be strong enough to induce neuronal death in mice. Together, the 
results confirmed that the inflammatory components released during p25-
mediated inflammatory events triggered the initiation of neurodegenerative 





Figure 4.10: p25-mediated neuroinflammation is a trigger for neuronal cell 
death 
(A) TUNEL staining images of cortical neurons incubated with supernatants from 
glial cells treated with vehicle, LPC 18:1 and lipids extracted from EV-LV, p25-
LV+control shRNA/p25-LV+cPLA2 shRNA treated neurons. Scale bars: 20 µm. (B) 
Percentage cell death in panel A was determined by counting the number of TUNEL 
positive cells  and normalized against DAPI signals from 10 independent fields (*** 
p-value < 0.001). Error bars indicate ± s.e.m (student’s t-test). (C) TUNEL staining 
images from brain sections of WT mice injected with lipids samples same as in A. 








4.4 DISCUSSION  
The previous chapter (Chapter 3) described the finding of soluble factors 
triggering neuroinflammation. This chapter focuses on the identification of the 
factor as well as the pathways involved in its production. It is crucial to 
investigate the above-mentioned knowledge gaps to understand the 
mechanism behind p25/Cdk5 hyperactivation, neuroinflammation and 
subsequent neurodegeneration. Results from this chapter demonstrated that the 
overexpression of cPLA2 regulated glial activation through the production of 
LPC, a soluble lipid factor. The results further determined that the lipids from 
p25 overexpressing neurons could trigger neuropathological disease 
progression both in vivo and in vitro. Furthermore, results suggested that 
inhibition of cPLA2 early in the process of neurodegeneration could be a 
possible therapeutic target to decrease or slow down neurodegeneration.  
4.4.1 p25-induced neuroinflammation is mediated by a soluble lipid 
factor, Lysophosphatidylcholine (LPC)   
Biochemical characterization of the supernatants from p25 overexpressed cells 
determined the soluble signal secreted by p25 overexpressing cells to glial 
cells to be lipid in nature (Figure 4.1 and 4.2). This finding was further 
validated by in vitro as well as in vivo treatments of glial cells with lipids 
extracted from p25 overexpressing neurons (Figure 4.3). Although the 
involvement of lipids in neurodegeneration has been reported previously 
(Wells et al., 1995; Bassett et al., 1999; Grimm et al., 2005), the exact changes 
in lipid profiles during neuroinflammation were not fully studied. Hence, mass 
spectrometry analyses were carried out on the total lipids extracted from p25 
overexpressing neurons and results showed that the neuroinflammation 
induced by p25 overexpression was caused by a polar phospholipid, 
Lysophosphatidylcholine (LPC) (Figure 4.4). Moreover, the progressive 
increase in LPC levels from 1 to 12 weeks of induction of p25 expression in 
mice hinted at the role of LPC in the induction of astrogliosis, T cell 
infiltration and further progression of neurodegeneration in p25Tg mice. A 
possible mechanism behind the induction of neuroinflammation by LPC was 
reported earlier where LPC treatment activated resident astrocytes via a Rho 
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kinase-mediated inflammatory response (Sheikh et al., 2009). In addition, G-
protein coupled receptor, G2A has been recognized as the receptor for LPC, 
through which LPC functions as a chemo-attractant for T cells and 
macrophages (Radu et al., 2004). It has been reported earlier that LPC could 
regulate the expressions of various inflammation-related genes that encode 
chemokines, adhesion molecules, growth factors and pro-inflammatory 
enzymes in macrophages and T cells (Cieslik et al., 1998).  
To further characterize the particular subtype of LPC responsible for p25-
mediated astrogliosis, mass spectrometry analyses were performed using 
internal standards of individual LPC species and results identified that LPC 
16:0, 18:0 and 18:1 were robustly increased when p25 was overexpressed. 
However, further studies on glial cells treated with commercially available 
LPC species indicated that LPC 18:1 was the most effective species in causing 
cause GFAP upregulation and astrogliosis (Figure 4.5). Previous studies 
already suggested that the effect of LPC might differ based on the unsaturation 
of acyl chain. Another important factor that can modify LPC effects is the 
capability to generate active micelles (Lauber et al., 2003; Ojala et al., 2007). 
Hence, it is understandable that the unsaturated nature of the LPC species 18:1 
aids in the formation of active micelles compared to the other saturated 
species. This could be the reason behind the increased potency of LPC 18:1 in 
the activation of astrocytes. Although increased levels of LPC have been 
observed previously during neuropathological changes (Andreoli et al., 1973; 
Wender et al., 1988), the actual mechanism behind the role of LPC in the 
induction of neuroinflammation was not fully described. This study is the first 
to link p25/Cdk5 hyperactivation with LPC production and subsequent 
neuroinflammation. 
4.4.2 p25 overexpression induces LPC production through the 
upregulation of cytosolic PLA2 (cPLA2) 
LPC is produced from phosphatidylcholine by the action of phospholipase A2 
(PLA2) (Steinbrecher et al., 1984). Previous studies indicated that increased 
PLA2 activity and PLA2-generated pro-inflammatory mediators play a major 
role in the induction of inflammatory changes in numerous neurological 
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disorders such as ischemia, AD, PD, and MS (Stephenson et al., 1996; Tariq et 
al., 2001; Yagami et al., 2002; Kalyvas and David, 2004; Farooqui et al., 
2006). So far, cytosolic PLA2 (cPLA2-IV), Ca
2+
-independent PLA2 (iPLA2-
VI) and secretory PLA2 (sPLA2-II), the three main PLA2 types, have been 
studied extensively due to their significant role in inflammation-associated 
neurodegeneration (Sun et al., 2010). However, sPLA2-II is absent in our 
primary neuron culture and our mice model, because of a naturally-occurring 
frame shift mutation in the C57BL/6 inbred mice strain (Kennedy et al., 1995). 
Undetermined Ct values from RT-PCR studies using sPLA2-II primers further 
confirmed the absence of sPLA2-II mRNA in our experimental system. In 
addition, studies have suggested that sPLA2 action might be dependent on an 
active cPLA2 (Balsinde et al., 1998). Therefore, cPLA2 is likely to be the key 
enzyme for lysophospholipid metabolism even when sPLA2 is present. This 
essential role of cPLA2 in lysophospholipid signaling pathways was 
emphasized by a study using cPLA2 knock-out mice where the rate of 
inflammatory mediators release was significantly reduced (Uozumi et al., 
1997). The iPLA2 subtype is one of the common housekeeping enzymes that 
usually maintain constant membrane phospholipids contents. Activity of 
iPLA2 has been reported previously to be involved in the process of vascular 
smooth muscle contraction and apoptosis (Guo et al., 2003). RT-PCR data 
from this chapter confirmed that there was no obvious difference in iPLA2 
levels between the control and the p25 overexpressing neurons (Figure 4.6A). 
It has been found earlier that AACOCF3 is a more potent inhibitor for cPLA2 
(500-fold higher) than for sPLA2,  and BEL is 1,000-fold more selective for 
iPLA2 than for cPLA2 (Riendeau et al., 1994; Jenkins et al., 2002; Farooqui et 
al., 2006). Results from experiments in this chapter using AACOCF3 and BEL 
further determined that the p25 overexpression did not affect iPLA2 levels, but 
increased cPLA2 expression and activity (Figure 4.6). Together, these results 
identified a robust increase in cPLA2 gene expression, protein level and 
activity in various p25 overexpression systems including p25 overexpressing 
transgenic mice model, primary neurons from the p25 transgenic mice and the 
neurons transduced with p25-LV.  
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In order to study whether the reduction of p25-induced cPLA2 overexpression 
could ameliorate the progression of pathological changes, cPLA2 gene 
silencing experiments were carried out and the results demonstrated a dramatic 
reduction in LPC 18:1 level as well as the expression of downstream 
neuroinflammatory markers (Figure 4.7 and 4.8). Previous studies have 
reported the involvement of cPLA2 in neurodegeneration and cPLA2 
expression has been shown to be abundant in AD brains especially in the 
hippocampal regions (Stephenson et al., 1996; Farooqui et al., 1997; 
Colangelo et al., 2002; Farooqui et al., 2003). Elevated cPLA2 expression 
levels have also been observed in injured cervical neurons and dorsal root 
ganglia (Hornfelt et al., 1999). In addition, studies also reported that NMDA 
infusion into rat hippocampus caused striking increases in cPLA2 activity 
(Pepicelli et al., 2002). Moreover, increased levels of cPLA2 activity were 
observed in hAPP mice (Sanchez-Mejia et al., 2008). However, the 
neuroinflammatory role of cPLA2 was not fully investigated yet. Findings 
from this chapter strongly suggest that cPLA2 activity has a critical role in the 
p25/Cdk5 hyperactivation-mediated neuroinflammation and 
neurodegeneration. 
Previous studies reported an association between the Aβ toxicity and increased 
cPLA2 activity in AD brains (Stephenson et al., 1996; Farooqui et al., 1997; 
Kriem et al., 2005). However, findings from this chapter suggested that 
cPLA2 upregulation might occur before the induction of tau 
hyperphosphorylation or amyloid accumulations (Figure 4.6 and Figure 3.5). 
Thus, there must be an alternate trigger for this upregulation of cPLA2. The 
next important question to be answered is how p25 regulate this cPLA2 
expression. p25/Cdk5 activity has been observed earlier in the nuclei of 
neurons (Patrick et al., 1999; O'Hare et al., 2005; Saito et al., 2007). In 
addition, it was reported that p25/Cdk5 complex may interact with nuclear 
machineries to modulate gene transcription (Yin et al., 2005). Therefore, 
evidence from various studies led to a hypothesis that p25/Cdk5 
hyperactivation may possibly mediate this effect through the transcriptional 
regulation of cPLA2 gene expression. Previous studies showed that cPLA2 
gene expression could be regulated by the transcription factors p300 and NF-
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B (Luo et al., 2006; Lee et al., 2010; Lee et al., 2011). Furthermore, AKT-
mediated phosphorylation was found to be critical for the regulation of p300 
and NF-B activity (Kane et al., 2002; Huang and Chen, 2005). p25/Cdk5-
mediated AKT activation (Liu et al., 2008) has also been reported previously. 
However, more studies are needed to understand the actual mechanism behind 
the p25/Cdk5 hyperactivation-mediated cPLA2 upregulation. Although the 
occurrence of neuroinflammation during p25 overexpression has been reported 
previously (Cruz et al., 2003; Muyllaert et al., 2008), this is the first study to 
not only provide a crucial link between the two processes, but also identify the 
pathway behind the initiation of neuroinflammation where upregulation of 
cPLA2 caused the production of LPC.  
4.4.3 p25-mediated neuroinflammation triggers neurodegenerative 
changes 
Astrocytes can respond to factors released by neurons at the synaptic cleft by 
releasing glutamate back to neurons (Sonnewald et al., 2002). To investigate 
the involvement of p25-induced production of inflammatory mediators in the 
initiation of neurodegeneration, conditional media transfer experiments were 
performed between activated glial cells and healthy cortical neurons. The 
results showed noticeable increases in neurodegenerative markers, phospho-
tau and intracellular Aβ (1-42) accumulation in neurons treated with 
supernatants from glial cells that were previously incubated with lipids from 
p25 overexpressing neurons and commercially obtained LPC 18:1. The above 
finding was further confirmed by in vivo injection of mice brain with lipids 
from p25 overexpressing neurons and commercially obtained LPC18:1. Thus, 
results collectively indicated that p25-mediated inflammatory changes could 
trigger the initiation of neurodegeneration (Figure 4.9). TUNEL staining 
experiments further suggested a significant increase, compared to control, in 
cell death when neurons treated with supernatants from glial cells that have 
been treated with lipids from p25 overexpressing neurons. In contrast, there 
was no TUNEL staining in the in vivo experiments (Figure 4.10). This could 
be due to the single dose injection of lipids and following clearance of lipids. 
Moreover, one-time injection of lipids into mice was just sufficient to trigger 
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the pathological hallmark production, but subsequent induction of the neuronal 
death cascade might require sustained LPC levels. In addition, marked 
reduction in the expression of neurodegenerative markers with cPLA2 knock-
down condition supported strongly the above findings.  
Together, results indicated that cPLA2 is elevated when p25 is produced, 
resulting in subsequent neuroinflammation and neurodegeneration. Findings 
from this study are supported by various studies conducted on other 
neurodegenerative models where CDP-choline (a cPLA2 inhibitor) protected 
neurons from excitotoxicity (Mir et al., 2003). Moreover, AACOCF3, a potent 
inhibitor of cPLA2, reduced the release of arachidonic acid metabolites in 
MPP
+
-mediated neurodegeneration, an in vitro model of PD (Yoshinaga et al., 
2000). 
We proposed a model based on the findings from this chapter to understand 
the mechanism behind p25-induced neuroinflammation-mediated 
neurodegeneration (Figure 4.11). p25/Cdk5 hyperactivation causes increases 
in cPLA2 expression and releases extracellular soluble LPC from PC which 
activate glial cells to produce chemokines/cytokines such as MIP-1α, TNF-α, 
TGF-β and IL-1β. This results in the CNS recruitment of peripheral immune 
cells which then instigates the next phase of neuroinflammatory response, 





Figure 4.11: Schematic representation of neurodegeneration caused by 
p25/Cdk5-mediated neuroinflammation  
Neurotoxic insults cause abnormal Ca2
+ 
influx and intense calpain activation. Calpain 
in turn cleaves Cdk5 activator, p35 into p25. p25 has increase stability and potential 
to hyperactivate Cdk5. p25/Cdk5 hyperactivation leads to intra cellular tangle 
formation and extra cellular Aβ plaque deposition through hyperphosphorylation of 
tau and APP. Moreover, p25/Cdk5 hyperactivation causes increase in cPLA2 
production and activation which in turn releases extracellular soluble LPC from PC. 
LPC activate glial cells to produce chemokines such as MIP-1α, TNF-α, TGF-β and 
IL-1β. Furthermore, LPC and chemokines production cause microglial activation and 
CD4+/CD8+ lymphocytes infiltration, the main indicators for severe 












 In conclusion, findings from this chapter demonstrated that LPC was a 
soluble molecular signal released from stressed neurons to induce the 
activation of glial cells and the subsequent release of diverse inflammatory 
mediators that have been implicated in the progression of AD-like 
neuropathology in p25Tg mice. Results also identified cPLA2 and LPC 
species 18:1 as being responsible for the pathological effects caused by 
p25/Cdk5 hyperactivation. Thus, results suggested that targeting cPLA2 
activity might be a viable therapeutic target to halt neurodegeneration caused 
by p25/Cdk5 hyperactivation. Development of a specific cPLA2 inhibitor for 
human clinical use could be a valuable therapeutic tool to treat 
neuroinflammation-associated neurodegenerative diseases. 
Although some studies have explained the role of anti-inflammatory drugs in 
the amelioration of neurodegenerative changes (Jantzen et al., 2002; Sastre et 
al., 2006), there have so far been no optimal approaches supporting the 
treatment of AD (Imbimbo, 2009). Hence, it is crucial to investigate the effect 
of various anti-inflammatory agents on the p25 overexpression-mediated 
cPLA2 upregulation and subsequent neurodegenerative disease progression. 
The next chapter will focus on the investigation of the effect of curcumin, a 
naturally occurring anti-inflammatory molecule on p25-mediated 
neuroinflammation and neurodegeneration. Moreover, the results from these 
studies will provide comprehensive evidence to uncover the mechanism 
behind the inflammatory-mediated neurodegenerative disease progression in 





                                                          





















Chapter 5: Curcumin (a natural polyphenol) blocks the 
neuroinflammatory cascade, attenuates neuropathological 
progression and offers neuroprotection against p25/Cdk5-
mediated neurodegeneration  
5.1 Introduction 
The results in Chapter 3 and Chapter 4 revealed that the p25/Cdk5-mediated 
neuroinflammation was an early event and not a secondary consequence of 
amyloid or tau pathology in p25Tg mice. In addition, results indicated that the 
cPLA2 upregulation and the subsequent LPC production were the critical 
events that regulated the initiation of neuroinflammation as well as the 
progression of neurodegeneration in p25Tg mice. Hence, the most obvious 
next step is to extend the investigation on the p25-mediated 
neuroinflammation using reported anti-inflammatory agents such as curcumin 
and study their effects on the p25-mediated neuropathological changes 
including amyloid and tau pathology in p25Tg mice. Curcumin, the main 
component of turmeric (a spice present in Indian curries) is well known for its 
antioxidant, anti-amyloid, anti-inflammatory and anti-oncogenic properties 
(Menon and Sudheer, 2007; Sa and Das, 2008; Monroy et al., 2013). 
Moreover, recent studies indicated that this natural and inexpensive dietary 
supplement can cross the blood-brain barrier and offer neuroprotection 
(Garcia-Alloza et al., 2007). However, the major limitation in the use of 
curcumin is its low bioavailability due to poor oral adsorption (Anand et al., 
2007). Fortunately, our collaborator in UCLA has formulated a novel 
curcumin formulation with solid lipid curcumin particle (SLCP) preparation, 
called “LONGVIDA”, which effectively increased free curcumin levels in 
plasma as well as in brain (Begum et al., 2008; Gota et al., 2010; Dadhaniya et 
al., 2011). Therefore, it would be interesting to investigate the effect of 
curcumin (LONGVIDA) on the p25-mediated neuroinflammation and the 
subsequent neuropathology in p25Tg mice.  
The first part of this chapter focuses on the experiments to determine the 
effects of curcumin on p25-mediated neuroinflammatory changes including 
135 
 
glial activation, cPLA2 upregulation and LPC production. The second part 
details the study on the neuroprotective ability of curcumin against p25-
mediated neurodegenerative changes including tau and amyloid pathologies. 
Together, results from this chapter showed that early inhibition of p25-
mediated neuroinflammation prevented the robust progression of 
neurodegeneration and provided neuroprotection against p25/Cdk5 






















5.2.1 Curcumin treatment in p25 transgenic mice 
LONGVIDA, a novel curcumin formulation prepared using a novel method 
called SLCP (solid lipid curcumin particle) (Verdure Sciences), was used in 
this study under collaboration. p25Tg mice were treated with this special 
curcumin formulation orally via their feed (4 g/kg of feed, Harlan). 
5.2.2 Western blot analyses 
Brain lysates from 4 and 12-week induced p25Tg/control mice (with and 
without curcumin treatment) were resolved on 4-20% polyacrylamide gels, 
blotted onto nitrocellulose membranes and then immunoprobed with mouse 
anti-GFAP, mouse anti-GFP, mouse anti-CD11b, mouse anti-cPLA2, rabbit 
anti-NF-κB and mouse monoclonal anti-PHF-tau antibodies (clones AT8 and 
AT100).  
5.2.3 In vitro kinase assays  
(This work was done in collaboration with Dr. Tej Kumar Pareek, Case 
Western Reserve University, Cleveland, OH, USA)    
Cdk5 activity levels were analyzed using kinase assays with brain lysates from 
4 and 12-week induced p25Tg/control mice (with and without curcumin 
treatment).  
5.2.4 Real-Time PCR 
RNA samples were extracted from 4 and 12-week induced p25Tg/control mice 
brains (with and without curcumin treatment) using RNeasy Mini Kit. 
Quantitative real-time PCR for chemokines/cytokines expression levels was 
performed with cDNA synthesized from RNA using High capacity cDNA 
reverse transcriptase kits.  
5.2.5 Immunohistochemistry 
16 μm brain sections from 4 and 12-week induced p25Tg/control mice (with 
and without curcumin treatment) were immunostained with primary antibodies 
137 
 
such as mouse anti-GFAP, mouse monoclonal anti-GFP, mouse anti-CD11b, 
rabbit anti-tPA, mouse anti-CD4, mouse anti-CD8, mouse monoclonal anti-
PHF-tau antibodies (clones AT8 and AT100), rabbit anti-beta-amyloid 1-42, 
mouse monoclonal anti-beta-amyloid 1-16 (6E10) and rabbit anti-cleaved 
caspase-3 antibodies. Secondary fluorescence-conjugated antibodies used 
were Alexa Fluor 488 and Alexa Fluor 594. Confocal images were taken at 
40X magnification.  
5.2.6 Thioflavin staining 
Thioflavin staining was performed as described in section 2.2.11.3 using brain 
sections from 12-week induced p25Tg/control mice (with and without 
curcumin treatment) and confocal images were taken at 40X magnification.  
5.2.7 Bielschowsky silver staining    
Bielschowsky silver staining was performed as described in section 2.2.11.4 
using brain sections from 12-week induced p25Tg/control mice (with and 
without curcumin treatment) and images were taken at 20X magnification.  
5.2.8 cPLA2 activity assay 
cPLA2 activity was analyzed using the brain samples from 4 and 12-week 
induced p25Tg/control mice (with and without curcumin treatment) using the 
cPLA2 activity assay kit.  
5.2.9 Lipids analysis using High-Performance Liquid 
Chromatography/Mass Spectrometry  
(This work was done in collaboration with A/Prof Markus Wenk’s Lipidomics 
lab, NUS)    
Lysophosphatidylcholine (LPC) levels were quantified from the total lipids 
extracted from brain samples of 4 and 12-week induced p25Tg/control mice 
(with and without curcumin treatment) with an Agilent 1200 high-
performance liquid chromatography (HPLC) systems and a 3200 Q-Trap mass 




5.2.10 Behavioural studies  
The radial arm maze study was carried out using the 8 arm radial maze 
according to the protocol described in detail in section 2.2.15.  The number of 
reference memory errors (entering a non-baited arm) and working memory 
errors (entering a baited arm but previously entered) were measured and 
analyzed for 12-week induced p25Tg/control mice groups (with and without 
curcumin treatment). 
5.2.11 Statistical analyses 
Data are expressed as the mean of at least three values ± standard error 
(s.e.m). Statistical significance was determined using one-way ANOVA 
followed by post-hoc tukey’s test and repeated measures ANOVA followed by 
post-hoc tukey’s test (Figure 12: reference memory errors). P-value for 

















5.3.1 Curcumin reduces p25-mediated astrocyte activation in p25Tg mice 
In order to investigate the effect of curcumin on p25-mediated 
neuroinflammation and the subsequent neurodegeneration, p25Tg mice were 
fed with curcumin-enriched feed for 4 and 12 weeks after the induction of p25 
expression. There were no obvious side effects including weight loss and 
behavioural abnormalities observed after 4 and 12-week curcumin treatment. 
Curcumin-treated control mice were in good health with normal 
exploratory/foraging behaviours, smooth coat, and stable weight growth. 
Firstly, equivalent levels of p25 expression were confirmed in the curcumin-
treated as well as non-treated p25Tg mice groups for both 4 and 12-week time 
points using immunohistochemistry (Figure 5.1A and B) and Western blot 
analyses with anti-GFP antibody (Figure 5.1C and D).  
Subsequently, the effect of curcumin on p25-mediated astrocyte activation was 
investigated using anti-GFAP antibody. Results from immunohistochemistry 
analyses revealed that the intensity of GFAP staining was greatly reduced in 
the cortex as well as the hippocampus of 4 and 12-week induced curcumin-
treated p25Tg mice group compared to the non-treated p25Tg mice group 
(Figure 5.2A and B).  
Furthermore, Western blot analyses were performed to quantitate the rate of 
reduction of p25-mediated glial activation by curcumin treatment using anti-
GFAP antibody and approximately 2-3 fold reduction in GFAP expression 
levels were observed in both 4 and 12-week induction groups in the forebrain 
of curcumin-treated p25Tg mice compared to the non-treated group (Figure 
5.2C and D). Collectively, these results suggested that curcumin effectively 




Figure 5.1: Expression levels of p25 in p25Tg mice  
Representative confocal pictures of frontal cortex (layer 2/3) (top panels) and CA3 
region of hippocampus (bottom panels) from the (A) 4-week and (B) 12-week 
induced p25Tg mice with normal feed (NFBT), p25Tg mice with curcumin feed 
(CFBT), respective age-matched WT mice with normal feed (NFWT) and WT mice 
with curcumin feed (CFWT) (n=3). Immunofluorescence staining was performed on 
the brain sections using anti-GFP antibody (green) and DAPI (blue). Scale bars 
represent 20 µm. Western blot results of the brain lysates from (C) 4-week and (D) 
12-week induced NFBT, CFBT, NFWT, CFWT mice using anti-GFP antibody (top 





Figure 5.2: Reduced astrocyte activation in curcumin-treated p25Tg mice 
Immunofluorescence images from the cortex (layer 2/3) (top panels) and 
hippocampus (CA3 region) (bottom panels) of the brain sections from (A) 4-week 
and (B) 12-week induced p25Tg mice with normal feed (NFBT), p25Tg mice with 
curcumin feed (CFBT), respective age-matched WT mice with normal feed (NFWT) 
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and WT mice with curcumin feed (CFWT) (n=3) using anti-GFAP antibody (red) and 
DAPI (blue). (C) GFAP levels were analyzed by immunoblot analyses with brain 
lysates from 4-week (top panel) and 12-week (bottom panel) induced p25Tg/control 
mice with/without curcumin treatment using anti-GFAP and anti-tubulin antibodies. 
(D) Quantification of immunoblots in C by densitometric scanning (*** p-value < 
0.001, ** p-value < 0.01 and NS p-value > 0.05) (one-way ANOVA followed by 
post-hoc tukey’s test). Scale bars represent 20 µm. Error bars indicate ± s.e.m. 
 
 
To further investigate the role of curcumin on p25-mediated glial activation, 
chemokine/cytokine expression levels were analyzed using RT-PCR studies 
with RNA samples from curcumin-treated and non-treated p25Tg/control mice 
for both 4 and 12-week induction periods. p25-mediated upregulation of 
expression levels of pro-inflammatory chemokines/cytokines such as MIP-1α, 
TNF-α and IL-1β were significantly abolished by curcumin (Figure 5.3A, B 
and D). However, TGF-β levels were found to be unaltered by curcumin 
treatment in p25Tg mice (Figure 5.3C). 
 





Figure 5.3: Chemokine/cytokine expression levels in curcumin-treated p25Tg 
mice 
Real-Time PCR results for (A) MIP-1α, (B) TNF-α, (C) TGF-β and (D) IL-1β 
expression in 4-week/12-week induced p25Tg mice with normal feed (NFBT), p25Tg 
mice with curcumin feed (CFBT), respective age-matched WT mice with normal feed 
(NFWT) and WT mice with curcumin feed (CFWT) (n=3) (*** p-value < 0.001, ** 
p-value < 0.01, * p-value < 0.05 and NS p-value > 0.05) (one-way ANOVA followed 




5.3.2 Curcumin inhibits p25/Cdk5 hyperactivation in p25Tg mice  
In order to investigate whether curcumin has any effect on p25/Cdk5 
hyperactivation, kinase assays and immunoblots analyses were performed and 
results indicated that there was no obvious change in Cdk5 protein levels 
between the curcumin-treated and non-treated p25Tg mice groups in both 4 
and 12-week induction groups (Figure 5.4A-C). However, p25-mediated Cdk5 
hyperactivity was reduced significantly by curcumin treatment especially in 
the 12-week induced p25Tg mice (Figure 5.4D). Endogenous p35 and 
exogenous p25 expression levels were also determined using C19 antibody 
and results showed that there was no significant change in endogenous p35 
expression levels in p25Tg mice with and without curcumin treatment 
(Supplementary Figure 2 in Appendices). 
   
 
Figure 5.4: Reduced Cdk5 hyperactivity in curcumin-treated p25Tg mice 
Western blot results of brain lysates from the (A) 4-week  and  (B) 12-week induced 
p25Tg mice with normal feed (NFBT), p25Tg mice with curcumin feed (CFBT), 
respective age-matched WT mice with normal feed (NFWT) and WT mice with 
curcumin feed (CFWT) using anti-C8 antibody (n=3). (C) Quantification of 
immunoblots in A & B by densitometric scanning. (D) Kinase assay results of the 
brain lysates from the samples same as in A and B (*** p-value < 0.001, * p-value < 
0.05 and NS p-value > 0.05) (one-way ANOVA followed by post-hoc tukey’s test). 
Error bars indicate ± s.e.m.  
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5.3.3 Curcumin regulates p25-induced microgliosis 
In order to extend the investigation of curcumin effects on the p25-mediated 
neuroinflammation, the role of curcumin on p25-mediated microgliosis was 
examined by immunohistochemical studies and Western blot analyses using 
microglial activation markers anti-Cd11b and anti-tPA antibodies. Cd11b 
immunostaining was markedly decreased in both cortical and hippocampal 
regions of curcumin-treated 4-week induced p25Tg mice brain sections 
compared to those in the non-treated p25Tg mice (Figure 5.5A). However, 
there was only a moderate reduction in Cd11b staining in the 12-week induced 
curcumin-treated p25Tg mice (Figure 5.5B). Western blot results were 
identical to the immunostaining results and reduction in Cd11b expression 
levels were significant in 4-week induced curcumin-treated samples compared 
to 12-week induced curcumin-treated p25Tg mice brain samples (Figure 5.5C 
and D). Together, these results showed that the curcumin-mediated reduction 
in microglial activation was more significant in 4-week induced p25Tg mice 





Figure 5.5: Reduced microgliosis in curcumin-treated p25Tg mice 
Immunofluorescence images from the cortex (layer 2/3) (top panels) and 
hippocampus (CA3 region) (bottom panels) of brain sections from (A) 4-week and 
(B) 12-week induced p25Tg mice with normal feed (NFBT), p25Tg mice with 
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curcumin feed (CFBT), respective age-matched WT mice with normal feed (NFWT) 
and WT mice with curcumin feed (CFWT) (n=3) using anti-Cd11b antibody (red) and 
DAPI (blue). (C) Cd11b levels were analyzed by immunoblot analyses with brain 
lysates from 4-week (top panel) and 12-week (bottom panel) induced p25Tg/control 
mice with/without curcumin treatment using anti-Cd11b antibody. (D) Quantification 
of immunoblots in C by densitometric scanning (*** p-value < 0.001, ** p-value < 
0.01, * p-value < 0.05 and NS p-value > 0.05) (one-way ANOVA followed by post-
hoc tukey’s test). Scale bars represent 20 µm. Error bars indicate ± s.e.m. 
 
 
As mentioned in Chapter 3 (section 3.3.2), tissue plasminogen activator (tPA) 
upregulation is an indicator for inflammatory-microglial activation (Siao and 
Tsirka, 2002; Pineda et al., 2012). In addition, results in Chapter 3 showed that 
tPA levels were elevated in p25Tg mice compared to the controls (Figure 
3.3B) and it is important to study the changes in tPA levels after curcumin 
treatment in p25Tg mice. Interestingly, results from this chapter identified that 
tPA immuostaining was almost completely abolished in both 4 and 12-week 
induced curcumin-treated p25Tg mice brain sections compared to the non-
treated p25Tg (Figure 5.6A and B). Thus, results collectively revealed that the 
pro-inflammatory state of microglial activation was efficiently blocked by 





Figure 5.6: Reduced pro-inflammatory microglial activation in curcumin-
treated p25Tg mice 
Confocal images from the cortex (layer 2/3) (top panels) and hippocampus (CA3 
region) (bottom panels) of the brain sections from (A) 4-week and (B) 12-week 
induced p25Tg mice with normal feed (NFBT), p25Tg mice with curcumin feed 
(CFBT), respective age-matched WT mice with normal feed (NFWT) and WT mice 
with curcumin feed (CFWT) (n=3) using anti-tPA antibody (red). Nuclei were stained 








5.3.4 Curcumin induces temporal change in the rate of peripheral cells 
brain infiltration in p25Tg mice 
Results in Chapter 3 showed that the infiltration of CD4- and CD8-positive 
peripherally-derived lymphocytes was very prominent in the p25Tg mice brain 
(Figure 3.4). Hence, experiments in this chapter were focused on studying the 
effects of curcumin on this event, using immunohistochemical staining. The 
results suggested that there was a noticeable reduction in CD4 (Figure 5.7A) 
and CD8 (Figure 5.7C) staining in 4-week treatment of curcumin in p25Tg 
mice. However, this curcumin-mediated reduction of peripheral cell 
infiltration was only moderate in 12-week induced p25Tg mice (Figure 5.7B 
and D). Moreover, these results were found almost identical to the effect of 
curcumin on microgliosis. Thus, these results suggested that curcumin was 
unable to effectively block the CNS infiltration of peripheral immune cells 






Figure 5.7: Peripheral cell infiltration in curcumin-treated p25Tg mice 
Representative confocal images from the cortical (layer 2/3) (top panels) and 
hippocampal (CA3 region) (bottom panels) regions of the brain sections from p25Tg 
mice with normal feed (NFBT), p25Tg mice with curcumin feed (CFBT), respective 
age-matched WT mice with normal feed (NFWT) and WT mice with curcumin feed 
(CFWT) (n=3). Immunofluorescence staining was performed using anti-CD4 (red) 
(A: 4-week and B: 12-week) and anti-CD8 (red) (C: 4-week and D: 12-week) 









5.3.5 Curcumin blocks p25-mediated neuroinflammatory cascade in 
p25Tg mice 
Chapter 4 results concluded that cPLA2 upregulation and the subsequent LPC 
production are the crucial events behind p25-mediated neuroinflammation and 
neurodegeneration. Hence, experiments were next focused on analyzing the 
role of curcumin on the p25-mediated increase in cPLA2 expression and LPC 
production. Results from Western blot analyses using anti-cPLA2 antibody 
revealed approximately 3-fold reductions in p25-mediated cPLA2 
upregulation in both the 4 and 12-week induced curcumin-treated p25Tg mice 
(Figure 5.8A top panel and B). In addition, cPLA2 activity was also 
significantly reduced in curcumin-treated p25Tg mice brain samples compared 
to the non-treated samples (Figure 5.8D). Furthermore, mass spectrometry 
analyses results specified that p25-mediated LPC production was markedly 
decreased by curcumin treatment in p25Tg mice (Figure 5.8E). Recently, it 
was shown that cPLA2 expression and activation were regulated by NF-κB 
(Cheng et al., 2009; Lee et al., 2010; Lee et al., 2011). The activation of NF-
κB (transcription factor), the master switch of the inflammatory cascade,  
plays a  critical role in the  pathogenesis of many chronic inflammatory 
diseases (Salminen et al., 2008). Western blot results from this chapter 
determined that NF-κB expression levels were augmented during p25 
overexpression in p25Tg mice. In addition, results further identified that 
curcumin effectively abolished the p25 overexpression-mediated NF-κB 
upregulation in both the 4 and 12-week induced p25Tg mice brain samples 
(Figure 5.8A second panel and C). Hence, the results collectively indicated 
that p25-mediated increases in cPLA2 levels/activity and LPC production via 






Figure 5.8: Curcumin effectively blocks the cPLA2/LPC pathway in p25Tg mice 
(A) Immunoblots for brain lysates from 4-week (left) and 12-week (right) induced 
p25Tg mice with normal feed (NFBT), p25Tg mice with curcumin feed (CFBT), 
respective age-matched WT mice with normal feed (NFWT) and WT mice with 
curcumin feed (CFWT) (n=3) using anti-cPLA2 (top panel) and anti-NF-κB (second 
panel) and anti-tubulin (bottom panel) antibodies. Quantification of (B) cPLA2 
immunoblots and (C) NF-κB immunoblots were performed by densitometric 
scanning. (D) cPLA2 activity assay results for the mice groups same as in A. (E) 
Mass spectrometric analyses results for lysophosphatidylcholine (LPC) levels in the 
forebrain samples from the mice groups same as in A (*** p-value < 0.001, ** p-
value < 0.01, * p-value < 0.05 and NS p-value > 0.05) (one-way ANOVA followed 





5.3.6 Curcumin attenuates p25-mediated neurodegenerative pathology in 
p25Tg mice  
To facilitate the investigation of the role of curcumin on p25-medited tau 
hyperphosphorylation, immunohistochemistry and Western blot analyses were 
performed using phospho-tau antibodies AT8 and AT100. Results showed that 
immunostaining intensities for both AT8 (Figure 5.9A and B) and AT100 
(Figure 5.10A and B) antibodies were reduced in curcumin-treated p25Tg 
mice compared to non-treated p25Tg mice. This immunostaining finding was 
further confirmed by Western blot analyses where approximately 2-fold 
reductions in AT8 (Figure 5.9C and D) and AT100 levels (Figure 5.10C and 
D) were observed in curcumin-treated p25Tg mice compared to the non-









Figure 5.9: Curcumin attenuates p25-mediated tau hyperphosphorylation (AT8) 
in p25Tg mice 
Immunofluorescence staining images from the cortex (layer 2/3) (top panels) and 
hippocampus (CA3 region) (bottom panels) of the brain sections from (A) 4-week 
and (B) 12-week induced p25Tg mice with normal feed (NFBT), p25Tg mice with 
curcumin feed (CFBT), respective age-matched WT mice with normal feed (NFWT) 
and WT mice with curcumin feed (CFWT) (n=3) using phospho-tau antibody AT8 
(red) and DAPI (blue). (C) Phospho-tau levels were analyzed by immunoblot 
analyses with brain lysates from 4-week (top panel) and 12-week (bottom panel) 
induced p25Tg/control mice with/without curcumin treatment using anti-AT8 
antibody. (D) Quantification of immunoblots in C by densitometric scanning (** p-
value < 0.01, * p-value < 0.05 and NS p-value > 0.05) (one-way ANOVA followed 











Figure 5.10: Curcumin reduces p25-mediated tau hyperphosphorylation 
(AT100) in p25Tg mice  
Immunofluorescence staining images from cortex (layer 2/3) (top panels) and 
hippocampus (CA3 region) (bottom panels) of the brain sections from (A) 4-week 
and (B) 12-week induced p25Tg mice with normal feed (NFBT), p25Tg mice with 
curcumin feed (CFBT), respective age-matched WT mice with normal feed (NFWT) 
and WT mice with curcumin feed (CFWT) (n=3) using phospho-tau antibody AT100 
(red). (C) Phospho-tau levels were analyzed by immunoblot analyses with brain 
lysates from 4-week (top panel) and 12-week (bottom panel) induced p25Tg/control 
mice with/without curcumin treatment using anti-AT100 antibody. (D) Quantification 
of immunoblots in C by densitometric scanning (*** p-value < 0.001, ** p-value < 
0.01 and NS p-value > 0.05) (one-way ANOVA followed by post-hoc tukey’s test). 
Error bars indicate ± s.e.m. Scale bars represent 20 µm. 
 
 
Subsequently, immunofluorescence, thioflavin and Bielschowsky silver 
staining experiments were performed in order to examine whether curcumin 
treatment had any effects on p25-stimulated amyloid-β accumulation in p25Tg 
mice. Results identified remarkable reductions in 6E10 and Aβ (1-42) 
immunostaining in curcumin-treated p25Tg mice compared to the non-treated 
p25Tg mice (Figure 5.11A and B). Moreover, thioflavin and silver staining 
results were identical to the immunohistochemical staining findings (Figure 
5.11C and D). Together, the results demonstrated that curcumin efficiently 
abrogated the progression of p25-induced tau hyperphosphorylation and 






Figure 5.11: Robust amyloid accumulation reduction in curcumin-treated p25Tg 
mice 
Brain sections from the 12-week induced p25Tg mice with normal feed (NFBT), 
p25Tg mice with curcumin feed (CFBT), respective age-matched WT mice with 
normal feed (NFWT) and WT mice with curcumin feed (CFWT) (n=3) were 
immunostained with (A) 6E10 (Aβ 1-16)  and (B) Aβ (1-42) (red). Nuclei were 
stained with DAPI (blue). (C) Thioflavin-S staining and (D) Bielschowsky silver 
staining images from the brain sections of the mice groups same as in A. Scale bars 
represent 20 µm.  
 
 
5.3.7 Curcumin reduces p25-mediated neuronal apoptosis and 
neurocognitive deficits in p25Tg mice 
It has been shown previously that neuronal apoptosis and forebrain atrophy are 
significant between 8-12 weeks of p25 expression in p25Tg mice  (Cruz et al., 
2003). Hence, the next set of experiments was designed to detect whether 
curcumin has any effect on p25-induced neuronal death. Cleaved caspase-3 
immunostaining was performed and results showed a noticeable increase in 
cleaved caspase-3 immunostaining in 12-week induced p25Tg mice, which 
were reduced after curcumin treatment (Figure 5.12A).  
To further examine whether curcumin treatment has any beneficial role on p25 
overexpression-stimulated neurocognitive deficits in p25Tg mice, spatial 
memory tasks were performed using the radial arm maze. Results confirmed 
that curcumin-treated p25Tg mice exhibited better performance compared to 
non-treated p25Tg mice. Working memory errors were reduced almost to 
normal levels (Figure 5.12B) and reference memory errors decreased robustly 
in curcumin-treated p25Tg mice (Figure 5.12C). Together, these results 
demonstrated that curcumin has the capability to restore p25-induced 




Figure 5.12: Curcumin rescues neuronal apoptosis and ameliorates cognitive 
deficits in p25Tg mice 
 (A) Immunofluorescence staining images using anti-cleaved caspase-3 antibody 
(green) and nuclei were stained with DAPI (blue) (n=3). Scale bars represent 20 µm. 
Eight-arm radial maze performance was analyzed for 12-week induced NFBT (n=5), 
CFBT (n=6), NFWT (n=5) and CFWT (n=6) mice. (B) Working memory errors 
(average of 10 sessions) (** p-value < 0.01) (one-way ANOVA followed by post-hoc 
tukey’s test) and (C) reference memory errors (the average of sessions per day (10 
sessions in 6 days)) (* p-value < 0.05 compared to NFWT mice, 
#
 p-value < 0.05 
compared to CFWT mice and 
±
 p-value < 0.05 compared to CFBT mice) (repeated 









5.4 Discussion  
Results from Chapter 3 and Chapter 4 facilitated the elucidation of the actual 
mechanism behind early changes in p25-mediated development of 
neurodegeneration where p25 overexpression induced neuroinflammation and 
triggered neurodegeneration via cPLA2 upregulation and LPC production. In 
addition, results from in vitro studies clearly demonstrated that the inhibition 
of early events of neuroinflammation could reverse the progression of p25-
mediated neuropathology. Hence, the obvious extension of this study is to 
carry out in vivo investigation using p25Tg mice to explore the effects of 
inhibiting p25-mediated inflammatory triggers on the progression of the later 
events of neurodegeneration. To achieve this essential objective, p25Tg mice 
were treated with naturally available anti-inflammatory agent, curcumin, and 
results from 4-week treatment of curcumin in p25Tg mice showed an obvious 
reduction in the major events of p25-mediated inflammation. In particular, 
curcumin efficiently reduced p25 overexpression-induced astrocyte activation, 
chemokine/cytokine release, cPLA2 upregulation and LPC production. 
Moreover, results from curcumin-treated 12-week induced p25Tg mice 
revealed that the curcumin-mediated inhibition of neuroinflammation reversed 
the progression of p25-induced neurodegenerative changes including tau and 
amyloid pathology and rescued neurocognitive deficits.    
5.4.1 Overview of therapeutic properties of curcumin  
To date, there is no effective approach to treat neurodegenerative diseases 
including AD, using anti-inflammatory drugs (Imbimbo, 2009). Although 
some epidemiological studies have suggested that the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) could reduce AD incidence (McGeer et al., 
1996), there have been numerous failures in clinical trials with NSAIDs in 
AD/MCI patient cohorts (Aisen et al., 2003; Pasqualetti et al., 2009). NSAIDs 
exert their anti-inflammatory properties through the inhibition of COX-2 
(Masferrer et al., 1996). COX-2 is an inducible form of cyclooxygenase 
(COX), which catalyzes the initial step in the synthesis of pro-inflammatory 
arachidonic acid metabolites including prostaglandins (O'Banion, 1999). 
Although studies have suggested that COX-2 activity is upregulated in AD 
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brain and may contribute to the development of pathogenesis of AD (Ho et al., 
2001), multiple failures of clinical trials with COX-2 inhibitors in human 
AD/MCI patients have brought up doubts about the involvement of COX-2 in 
Alzheimer’s disease (Imbimbo, 2009). Moreover, studies indicated that these 
NSAIDs may be effective only in normal brains to prevent the production of 
Aβ (1-42) and may not be effective in AD/MCI patients where Aβ deposition 
have already begun (Imbimbo, 2009). In addition, long term use of NSAIDs 
may cause adverse side effects like gastrointestinal, cardiovascular and kidney 
toxicity (Armstrong and Blower, 1987; Al-Saeed, 2011).  
Thus, there is a need for more studies to investigate potential for clinical use 
of natural compounds that do not overtly display severe side effects. One such 
potential candidate is curcumin (Diferuloylmethane), a natural polyphenolic 
component of the rhizome of the turmeric (Curcuma longa) plant that grows 
naturally in southeast Asia (Ammon and Wahl, 1991). Turmeric powder is a 
spice present in Indian curries and has also been used for thousands of years in 
Indian and Chinese medicine (Prasad and Aggarwal, 2011). Curcumin is well-
known for its antioxidant, anti-arthritic, anti-ischemic, anti-amyloid, anti-
inflammatory and anti-oncogenic properties (Ammon and Wahl, 1991; Menon 
and Sudheer, 2007; Mishra and Palanivelu, 2008; Sa and Das, 2008; Monroy 
et al., 2013). Clinical trials with curcumin for many inflammation-associated 
diseases including ulcerative colitis, suggested that the use of curcumin is 
relatively safe and even in larger quantities does not cause any severe side 
effects to humans (Hanai et al., 2006). Moreover, curcumin exerts beneficial 
effects in many diseases including cancer (Basnet and Skalko-Basnet, 2011), 
diabetes, atherosclerosis (Jagtap et al., 2009), arthritis (Chandran and Goel, ; 
Funk et al., 2006), stroke, peripheral neuropathy, inflammatory bowel, and 
brain trauma (Aggarwal et al., 2007; Begum et al., 2008).  
However, the major limitation in the use of curcumin for treatment of 
neurodegenerative diseases is the low bioavailability of curcumin due to its 
low solubility in water and poor oral adsorption (Anand et al., 2007). 
Pharmacokinetic studies of curcumin showed that after administration, 
curcumin rapidly biotransformed into curcumin sulfate and curcumin 
glucuronide (Pan et al., 1999). Curcumin was also reduced to an unconjugated 
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active metabolite tetrahydrocurcumin. Moreover, evidence suggested that 
curcumin is able to cross the BBB mostly in unconjugated form. However, 
unconjugated curcumin is highly unstable with a shorter half-life and hence 
goes mostly undetected in clinical trials with regular unformulated curcumin 
(Baum et al., 2008). Numerous approaches have been undertaken to improve 
the bioavailability of curcumin and some of them have been successful. The 
laboratory of Sally Frautschy in UCLA has formulated a novel curcumin with 
solid lipid curcumin particle (SLCP) preparation, called “LONGVIDA”. 
Studies with this new formulation showed increased concentration of 
curcumin in plasma as well as in brain compared to unformulated curcumin 
(Begum et al., 2008; Gota et al., 2010; Dadhaniya et al., 2011). A study with 
chronic administration of SLCP curcumin (4 months, 500-2000 ppm) to an 
AD mouse model (APPsw Tg2576) detected significant levels of 
unconjugated curcumin in plasma ((parent curcumin-0.095-0.465 µM) and 
(tetrahydrocurcumin-0.023-0.115 µM)) as well as in brain ((parent curcumin-
1.276-1.428 µM) and (tetrahydrocurcumin-0.264-0.143 µM)) (Begum et al., 
2008). In healthy volunteers, SLCP curcumin administration (650 mg) showed 
substantial levels of free curcumin in plasma compared to the 95% 
curcuminoids extracts. This enhanced bioavailability of SLCP curcumin could 
be either due to increased absorption or due to reduced conversion of free 
curcumin to conjugated products (Gota et al., 2010). Hence, in this study, 
p25Tg mice were fed with this special formulation in the form of curcumin 
supplemented feed pellets (1000 ppm) (SLCP-Longvida) after the induction of 
p25 expression (withdrawal of doxycycline water 6-week postnatal). Brain 
samples were collected at early (4-week) as well as late (12-week) time points 
of p25 expression for various analyses.  
5.4.2 Curcumin counteracts p25-mediated neuroinflammation in p25Tg 
mice      
Results from this chapter (Figure 5.2) clearly suggested that GFAP 
upregulation and astrogliosis were significantly reduced by curcumin 
treatment in p25Tg mice. It has been shown previously that curcumin reduces 
astrocytic activation in amyloid-β induced primary astrocytes (Wang et al., 
2010), in APPsw mouse model (Lim et al., 2001), a hemiparkinsonian mouse 
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model (Tripanichkul and Jaroensuppaperch, 2013) and in an AD rat model 
(Wang et al., 2013). However, the exact mechanism behind this curcumin-
mediated inhibition of astrocyte activation has not yet been clearly defined. 
Results in Chapter 4 identified that p25-induced glial activation was mediated 
through the upregulation of cPLA2 and LPC production. The results from this 
chapter (Figure 5.8) showed that curcumin significantly reduced the cPLA2 
levels/activity and also significantly decreased LPC levels. Therefore, this 
curcumin-mediated reduction of p25-induced cPLA2 upregulation could be 
the reason behind the inhibition of glial activation in the curcumin-treated 
p25Tg mice. 
The next important question to be answered was how curcumin regulates 
cPLA2 activity. Of late, it was shown that cPLA2 expression and activation 
are regulated by NF-κB (Cheng et al., 2009; Lee et al., 2010; Lee et al., 2011). 
Results from immunoblot analyses using NF-κB (p65) antibody showed that 
NF-κB expression was significantly elevated in p25Tg mice; however, this 
p25-mediated elevated NF-κB expression was reduced to WT/control levels 
by curcumin treatment in p25Tg mice (Figure 5.8). Inhibition of NF-κB is 
believed to be a central pathway behind the anti-inflammatory effects of 
curcumin (Jin et al., 2007). NF-κB (transcription factor), is thought to be a 
master switch controlling the inflammatory cascade and play a critical role in 
the inflammatory pathogenesis of many chronic diseases (Salminen et al., 
2008). In 1995, Singh and Aggarwal reported this curcumin-mediated 
suppression of NF-κB (Singh and Aggarwal, 1995). It has previously been 
shown that curcumin blocked NF-κB activation via its inhibitory effects on 
IқB kinase, which subsequently resulted in the inhibition of the NF-κB gene 
products (Aggarwal and Sung, 2009). 
Results from chemokine/cytokine RT-PCR analyses clearly demonstrated that 
curcumin treatment selectively downregulated pro-inflammatory 
chemokines/cytokines such as MIP-1α, TNF-α and IL-1β expression levels in 
p25Tg mice. In contrast, TGF-β levels were found unaltered between the two 
groups (Figure 5.3). TGF-β, an anti-inflammatory cytokine, was found to be 
elevated in AD as a regulatory response to maintain homeostasis in brain 
(Chao et al., 1994; Rota et al., 2006). Moreover, studies reported that TGF-β 
164 
 
was involved in the regulation of alternate activation of microglia which could 
be a protective adaption against chronic inflammation (Zhou et al., 2012). A 
number of studies have already reported that curcumin negatively regulated 
pro-inflammatory cytokine production especially that of TNF-α (Paul et al., 
2006; Jain et al., 2009). Studies have also indicated that curcumin mediated 
this function through the inhibition of various inflammatory signaling 
pathways including NF-κB and Janus kinase-STAT (Kim et al., 2003; Park et 
al., 2012). 
The main sources for chemokines/cytokines production are activated 
astrocytes and microglia. In light of this, experiments were then focused on 
analyzing the effect of curcumin on p25-mediated microglial activation. 
Different markers for microglial activation were used in immunostaining 
analyses and results demonstrated that the total activation of microglia was 
effectively reduced in curcumin-treated 4-week induced groups compared to 
non-treated groups. However, this curcumin-induced reduction in microglial 
activation was only moderate in 12-week induced curcumin-treated groups 
(Figure 5.5). Similarly, Iba-1 and F4/80 staining results were found identical 
to the Cd11b results (data not shown). In contrast, pro-inflammatory 
cytokines/chemokines expression levels were dramatically reduced in 12 
induced curcumin-treated p25Tg mice (Figure 5.3). Moreover, CNS 
infiltration of peripheral immune cells was not significantly reduced in 12-
week induced curcumin-treated group compared to the non-treated p25Tg 
mice (Figure 5.7). Hence, these results collectively suggested that curcumin 
selectively targeted the release of pro-inflammatory mediators without 
affecting microgliosis or CNS infiltration rate of peripherally-derived immune 
cells especially at the late time point of 12-week induction of p25 expression 
in p25Tg mice. This finding is supported by evidence from a previous study 
where curcumin effectively suppressed microglial activation in neuronal 
layers, but failed to prevent microgliosis near amyloid deposits. Furthermore, 
it has been suggested that curcumin might induce microglial-mediated 




In general, resident microglial cells become activated during the early phase of 
neuroinflammation and this is followed by the recruitment of peripherally 
derived macrophages. In the later stage, these macrophages are subsequently 
transformed into microglial cells (Krause and Muller, 2010). In addition, 
studies also suggested that these newly recruited microglial cells have 
increased phagocytic ability compared to the intrinsic microglia (Majumdar et 
al., 2007). However, the phagocytic ability of this newly recruited microglia 
may be dampened by the expression of pro-inflammatory cytokines especially 
TNF-α (Koenigsknecht-Talboo and Landreth, 2005). It has also been 
demonstrated previously that TGF-β expression might promote the microglial-
mediated clearance of Aβ (Wyss-Coray et al., 2001). Hence, results from this 
chapter and previous evidence indicated that curcumin treatment might inhibit 
the early activation of microglial cells that were committed to an inflammatory 
response in 4-week induced p25Tg mice via the regulation of NF-κB signaling 
pathways. On the other hand, curcumin facilitated the later recruitment and 
activation of peripherally-derived macrophages/leukocytes in 12-week 
induced p25Tg mice by regulating the pro- and anti-inflammatory cytokines 
signal mechanisms (Jobin et al., 1999; Koenigsknecht-Talboo and Landreth, 
2005; Bisht et al., 2009). Moreover, this curcumin-mediated temporal 
regulation of microglial activation and subsequent CNS infiltration of immune 
cells resulted in the reduction of detrimental pro-inflammatory response and at 
the same time ameliorated amyloid pathology in p25Tg mice.   
In addition, p25-induced upregulation of tissue plasminogen activator (tPA) 
was completely abolished by curcumin in both 4 and 12-week induced p25Tg 
mice (Figure 5.6). It has been reported previously that tPA is a potent 
stimulator of the conversion of microglial cells into a pro-inflammatory 
phenotype (Siao and Tsirka, 2002; Pineda et al., 2012). Thus, these results 
demonstrated that curcumin selectively changed the pro-inflammatory state of 
microglia into a beneficial anti-inflammatory phenotype via multiple ways. A 
recent report supported our finding and their microarray results indicated that 
curcumin can trigger a change in microglial phenotype from pro-inflammatory 
to anti-inflammatory with neuroprotective properties (Karlstetter et al., 2011). 
Furthermore, their transcriptomic analyses identified that curcumin inhibited 
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the gene expression of NF-κB, STAT3 and complement factor 3 which are 
main factors inducing the conversion of microglial cells to the pro-
inflammatory state. In addition, curcumin was found to increase the gene 
expression of peroxisome proliferator-activated receptor-gamma (PPARγ), a  
primary inhibitor of  the pro-inflammatory activation of the microglia 
(Karlstetter et al., 2011).  
5.4.3 Curcumin attenuates p25-induced tau and amyloid pathology in 
p25Tg mice 
Hyperphosphorylation of tau and amyloid accumulations are prominent events 
in p25-mediated neurodegeneration of p25Tg mice (Chapter 3 results and 
(Cruz et al., 2003; Cruz et al., 2006)). However, significant reduction in tau 
phosphorylation and clearance of amyloid accumulations were observed after 
treatment with curcumin in p25Tg mice (Figure 5.9, 5.10 and 5.11). 
Interestingly, these observations strongly supported the hypothesis of this 
study that early inhibition of neuroinflammation can slow down the 
progression of later pathological events. The finding of curcumin-mediated 
reduction in tau pathology in p25Tg mice was supported by a recent study 
using 3xTg-AD mice. Oral administration of 500 ppm curcumin decreased tau 
phosphorylation and mice showed improvement in Y-maze performance (Ma 
et al., 2009). In another study, approximately 80% reduction in tau 
phosphorylation was observed in curcumin-treated Tg2576 AD mice (Shytle 
et al., 2012). In addition, significant reductions in Cdk5 hyperactivation were 
observed after curcumin treatment in p25Tg mice (Figure 5.4). Hence, this 
suggested that curcumin-mediated reduction of neurodegenerative pathology 
may be achieved via multiple diverse mechanisms. Although, it has already 
been reported that curcumin inhibits GSK-3β (Bustanji et al., 2009), there was 
no previous evidence concerning curcumin-mediated inhibition of Cdk5 
hyperactivity. Hence, further investigation is required to fully understand the 
actual mechanism behind the curcumin-mediated specific reduction in Cdk5 
hyperactivity. However, previous reports showed that there was a feed-
forward loop mechanism between amyloid and p25/Cdk5 hyperactivity (Lee et 
al., 2000; Lee et al., 2003; Cruz et al., 2006). Thus, curcumin-mediated 
reduction in neurotoxicity including oxidative stress and amyloid 
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accumulation might reduce the feed-forward mechanism-based upregulation 
of Cdk5 activity in p25Tg mice.  
Numerous studies have determined that curcumin was a potent anti-
amyloidogenic agent that inhibited Aβ aggregation, conferring protecting 
against Aβ-induced cell death (Yang et al., 2005; Zhang et al., 2010). 
Curcumin has been shown to reduce the amyloid-β burden in Tg2576 AD 
mice (Lim et al., 2001). Moreover, intravenous administration of curcumin 
cleared senile plaques in APPswe/PS1dE9 mice (Garcia-Alloza et al., 2007). 
In another study, Aβ infusion-induced cognitive deficits were corrected by 
curcumin treatment in Sprague-Dawley rats (Frautschy et al., 2001). In 
addition, it was reported recently that curcumin reduced amyloid production 
via inhibition of the BACE expression and activity (Shimmyo et al., 2008). 
Studies are now focused on finding out the mechanism behind the curcumin-
mediated clearance of amyloid aggregations and it has been reported that 
curcumin cleared amyloid aggregates via the induction of phagocytosis by 
brain macrophages and microglia. It has been found that curcumin even at low 
doses effectively stimulates robust microglial phagocytosis both in vitro and in 
vivo (Cole et al., 2007). In addition, it has been reported that curcumin cleared 
amyloid burden via monocytic gene expression regulation (Gagliardi et al., 
2011). In general, peripheral blood mononuclear cells (PBMC) from AD 
patients were found to be defective in Aβ phagocytosis (Cashman et al., 2008). 
However, curcumin treatment was shown to restore the amyloid phagocytic 
ability of AD PBMCs via the upregulation of some of the key genes that 
regulate macrophage activation including TLRs (Toll-like receptors) and 
MGAT3 (β-1, 4-mannosyl-glycoprotein-4-β-N-acetylglucosaminyltransferase) 
(Gagliardi et al., 2011; Cashman et al., 2012). Therefore, based on evidences 
from previous reports, one can hypothesize that curcumin enhanced the 
phagocytic ability of p25-induced brain recruited PBMCs to clear the p25-
mediated amyloid accumulations. However, more studies are needed to further 
support this theory. Thus, the results collectively suggested that curcumin-
mediated selective activation of microglia/monocytes into a beneficial anti-
inflammatory phenotype would be a valuable therapeutic tool to fight against 
the neuroinflammation-associated neurodegenerative diseases.  
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5.4.4 Curcumin rescues against p25-induced apoptosis and restores 
neurocognitive abilities in p25Tg mice 
Results from immunostaining with cleaved caspase-3 antibody showed that 
p25-mediated neuronal apoptosis was reduced after curcumin treatment in 
p25Tg mice. In addition, radial arm maze task results clearly demonstrated 
that the p25-induced spatial memory deficits were corrected almost back to 
normal by curcumin treatment in p25Tg mice (Figure 5.12). Curcumin-
mediated reductions in the p25-mediated pathologies including aberrant glial 
activation, upregulated pro-inflammatory cytokines especially TNF-α, and 
intraneuronal tau/amyloid accumulations could be the reasons behind this 
curcumin-mediated reversal of neuronal apoptosis and cognitive deficits. 
Moreover, previous studies reported that curcumin, a potent anti-oxidant 
prevented neuronal apoptosis through reduction in ROS production and 
oxidative damage (Zhu et al., 2004). Collectively, results confirmed that 
curcumin offered neuroprotection against p25-mediated neurotoxicity via its 















The results from this chapter collectively showed that curcumin, a potent 
natural anti-inflammatory agent, effectively counteracted the p25-mediated 
glial activation and pro-inflammatory chemokines/cytokines production in 
p25Tg mice. In addition, curcumin significantly reduced p25/Cdk5 
hyperactivation-mediated tau hyperphosphorylation, amyloid accumulations, 
neuronal apoptosis and neurocognitive deficits. Thus, results from this chapter 
strongly suggested that curcumin, a multipotent natural compound, could be a 
valuable tool to prevent the progression of neuroinflammation-associated 































                        





















CHAPTER 6: Final discussion, conclusions and future work 
6.1 Discussion and conclusions 
Although there are numerous AD intervention strategies currently being 
investigated, none of them have effectively translated into disease 
modification and clinical success. To date, drugs marketed for the treatment of 
AD are acetylcholinesterase (AChE) inhibitors (donepezil, galantamine, 
rivastigmine) and the glutamate receptor antagonist (memantine) (Noetzli and 
Eap, 2013). Despite this, these treatment strategies in AD do not have 
neuroprotective properties and even symptomatic relief is only temporary. 
Moreover, recent studies suggested that cholinergic deficit occur fairly late in 
the disease (Frolich, 2002), while it has also been acknowledged that to treat 
AD, one must target the early-stage pathological changes and protect neurons 
from irreversible damage (Sperling et al., 2011). Although epidemiological 
evidence suggested that NSAIDs have beneficial effects in AD treatment 
(McGeer et al., 1996), increasing failures in clinical trials for AD with 
NSAIDs clearly indicate that they are either not effective in late stage patients 
or not able to combat the multifactorial nature of AD pathology (Aisen et al., 
2003; Imbimbo, 2009). Moreover, recent failures reported in clinical trials 
with anti-Aβ immunization strategies have brought the Aβ hypothesis into 
some question. In a recent clinical trial, bapineuzimab (initially co-developed 
by Elan/Wyeth and then acquired by Johnson & Johnson/Pfizer) has been 
reported to be effective in decreasing the amyloid burden. However, primary 
clinical endpoints (improved cognitive ability) were not met in the phase II 
clinical trial (Salloway et al., 2009). Hence, it is evident that a better 
understanding of the initiation and progression of AD, a complex and 
multifactorial syndrome, is needed to allow future treatments to be developed 
with novel drug targets. Moreover, finding a multi-target approach that can hit 
the early events of neuropathology may be more important in AD therapeutics 
(Figure 6.1). Hence, targeting the pathological hallmarks such as amyloid-β 




   
Figure 6.1: Schematic description showing key points behind the development of 
effective drugs to treat AD 
 
The Alzheimer’s Disease Research Summit 2012 strongly recommended the 
use of experimental models that better simulate the multifactorial nature of 
AD to more accurately identify disease modifying pathways and to assess 
effective treatment strategies (National Institute on Aging, 2013). Although 
there are numerous available AD mouse models based on genetic mutations 
found in AD patients (Hall and Roberson, 2012), not all the models develop 
pathological features reminiscent of AD. Some models develop amyloid 
plaques without tau hyperphosphorylation and some exhibit only tau 
pathology (Duff and Suleman, 2004). Very few models exist that recapitulate 
most of the AD pathologic features and one such mouse model is the p25 
transgenic mouse model which exhibits robust astrogliosis, substantial tau 
hyperphosphorylation, intraneuronal amyloid accumulations, and extensive 
neuronal loss especially in the forebrain. Moreover, these mice exhibit 
cognitive defects in addition to the pathology (Cruz et al., 2003; Fischer et al., 
2005; Cruz et al., 2006; Sundaram et al., 2013). Deregulation of Cdk5 activity 
has previously been shown to be a contributory factor in the pathogenesis of 





Better understanding of 
biological mechanisms 
behind the formation of AD 
MTDL (Multi-target-
directed ligand) design 
strategy 
Finding biomarkers to 




Lee and Tsai, 2003; Smith et al., 2006). Although there have been some 
conflicting data about the elevation of p25 levels in post-mortem samples of 
AD patients (Tandon et al., 2003), subsequent studies have confirmed the 
occurrence of increased p25 expression and altered Cdk5 activity in the human 
AD cases (Patrick et al., 1999; Tseng et al., 2002). Mechanistically, abnormal 
calcium influx-induced, calpain-mediated p25 production and subsequent 
Cdk5 deregulation results in the hyperphosphorylation of microtubule protein 
tau, neurofilaments and amyloid precursor protein (APP), which ultimately 
leads to the production of NFTs and amyloid accumulations (Patrick et al., 
1999; Ahlijanian et al., 2000; Noble et al., 2003). Although there is 
considerable evidence to support the role of Cdk5 in neurodegeneration, there 
has not been a clear demonstration for the actual mechanism behind the 
initiation of p25/Cdk5 hyperactivation-mediated neuroinflammation and its 
role in the progression of neurodegeneration. Finding out this piece of puzzle 
will certainly add more value to the field. Hence, this study was designed to 
investigate p25/Cdk5-mediated neuroinflammatory mechanisms using the 
CamK2a-p25 inducible transgenic (p25Tg) mice and in vitro lentivirus-based 
overexpression of p25 in cortical neurons.  
Experiments were initially focused to gain more information about the onset 
of major inflammatory events like astrogliosis, microgliosis and 
chemokines/cytokines production in p25Tg mice. Results from multi-platform 
experiments such as immunohistochemistry, Western blots and RT-PCR 
clearly indicated that astrogliosis was an early event in p25-mediated 
neuroinflammation where GFAP expression and pro-inflammatory 
chemokines/cytokines such as TNF-α, MIP-1α, TGF-β and IL-1β levels were 
significantly elevated even in 1 week induced p25Tg mice (Figures 3.1 and 
3.2). In addition, the finding of astrogliosis preceding microgliosis in the p25-
mediated inflammatory paradigm suggested that microglial activation may 
possibly be dependent on chemokine/cytokine release by activated astrocytes 
(Figure 3.3). Moreover, results showed that this early event of astrogliosis 
occurred prior to any neuropathological changes such as tau and amyloid 
pathology (Figure 3.5). Hence, results collectively suggested that targeting 
astrocytes could be a potential early intervention strategy for AD therapeutics. 
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For some time, astrocytes were just considered as the “brain glue” and the role 
of astrocytes during AD progression have not received as much attention as 
the role of microglia (Miller, 2005; Ralay Ranaivo et al., 2006). Earlier studies 
indicated that the development of a drug that is able to specifically target glia 
and reduce inflammation in the brain without weakening the immune system 
may be extremely valuable in AD therapeutics (Miller, 2005).  
Furthermore, immunostaining results in Chapter 3 identified the presence of 
brain infiltration of peripherally-derived CD4+ and CD8+ T cells in p25Tg 
mice especially after 4 weeks of induction of p25 expression (Figure 3.4). 
However, the role and significance of these CNS infiltrating T cells are 
unclear in these mice. Recent studies demonstrated that leukocytes 
translocating into the CNS could be detrimental (in multiple sclerosis) or 
beneficial (in ALS) depending upon the disease state (Chiu et al., 2008; 
Fletcher et al., 2010). Detection of CNS infiltration of leukocytes in p25Tg 
mice suggested that further investigation into this field might provide new 
ways to elucidate the complex mechanisms and consequences of 
neuroinflammation. Subsequently, results from in vitro co-cultures as well as 
conditioned media transfer systems in Chapter 3 showed that there was a 
soluble signal secreted by the p25 expressing neurons (via both overexpression 
and endogenous production) that caused the activation of glial cells (Figures 
3.6, 3.7 and 3.8). Together, results in Chapter 3 showed that astrogliosis was a 
principal event in the p25-mediated neuroinflammation that began very early 
in the absence of microgliosis, tau and amyloid pathology. Further findings 
indicated that there was a soluble trigger behind this p25-induced astrocyte 
activation. Hence, these results have emphasized the importance of further 
characterization of this soluble trigger and experiments in Chapter 4 aimed to 
uncover the mechanism behind the production of this soluble trigger.  
Results from factor removal experiments and high performance mass 
spectrometry lipidomics in Chapter 4 identified that lysophosphatidylcholine 
(LPC) was the soluble lipid signal secreted from the p25 expressing neurons 
that mediated astrogliosis (Figures 4.1, 4.2, 4.3 and 4.4). Gradual increases in 
LPC levels from 1 to 12-week expression of p25 in p25Tg mice clearly 
showed that production of LPC could be a critical event in the initiation and as 
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well as progression of p25-mediated neuroinflammation (Figure 4.4C). Further 
characterization using in vitro experiments identified the particular LPC 
species that most effectively induced the astrocyte activation as LPC 18:0 and 
18:1 (Figure 4.5). Moreover, this exciting finding is supported by considerable 
evidence from previous studies where LPC was found to be involved in the 
regulation of astrocyte activation, T cell migration and transcriptional 
activation of genes relevant to inflammation (Cieslik et al., 1998; Radu et al., 
2004; Sheikh et al., 2009).  
Real-time PCR, enzyme activity assays and cPLA2 inhibitor experiments were 
carried out to trace this pathway back into the neurons and results identified 
that cytosolic Phospholipase A2 (cPLA2) was the enzyme responsible for this 
lipid signal production (Figure 4.6). Furthermore, gene silencing experiments 
indicated that cPLA2 upregulation was crucial for the production of LPC and 
subsequent astrocyte activation during p25 overexpression (Figures 4.7 and 
4.8). cPLA2 expression has been reported previously in neurons and the 
activation of cPLA2 under normal conditions resulted in the generation of 
arachidonic acid and lysophospholipids which in turn regulated membrane 
dynamics, signal transduction and cell proliferation. However, prolonged 
activation of cPLA2 under pathological conditions may contribute to 
neurodegeneration via neuronal membrane degradation and overproduction of 
inflammatory mediators including LPC, platelet-activating factors and 4-
hydroxynonenal. Thus, cPLA2 activity must be tightly regulated in order to 
maintain cellular homeostasis (Katsuki and Okuda, 1995; Farooqui et al., 
2006; Sun et al., 2010). Moreover, there are data demonstrating an obvious 
change in cPLA2 mRNA expression as well as cPLA2 immunoreactivity in 
the AD brain as compared to age-matched controls  (Stephenson et al., 1996; 
Colangelo et al., 2002).  
In addition, it is crucial to find out the link between p25 overexpression and 
cPLA2 elevation. It has been reported previously that p25/Cdk5 activity may 
act on nuclear machinery to regulate gene transcription (Patrick et al., 1999; 
O'Hare et al., 2005; Saito et al., 2007) and recent reports showed that cPLA2 
gene expression can be regulated by the transcription factors p300 and NF-κB 
(Luo et al., 2006; Lee et al., 2010; Lee et al., 2011). Adding on to that, it was 
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reported that p25/Cdk5 interacts with CREB1 binding protein (CBP), the co-
activator protein for p300, through the binding with C53. Moreover, evidence 
from various studies have led to a hypothesis that p25/Cdk5 might regulate 
NF-κB activity via AKT-mediated phosphorylation (Kane et al., 2002; Huang 
and Chen, 2005; Liu et al., 2008). Furthermore, the hypothesis of Cdk5-
mediated regulation of NF-κB activity is further supported by the Western blot 
results in this thesis where NF-κB expression was noticeably increased in both 
4-week and 12-week expression of p25 in p25Tg mice compared to the 
controls (Figure 5.8). However, further studies would be needed to fully 
understand the mechanism behind the p25-mediated cPLA2 elevation. 
Subsequently, results from Chapter 4 also determined that the inflammatory 
mediators released during the p25-mediated neuroinflammation might trigger 
the progression of neuropathological changes including hyperphosphorylation 
of tau and amyloid production. Of further significance, reducing LPC 
production by silencing cPLA2 attenuated glial activation and subsequent 
development of tau and amyloid pathology (Figure 4.9). Previous studies have 
shown that cPLA2 activity mediated amyloid-β-induced mitochondrial 
dysfunction and neuronal apoptosis (Kriem et al., 2005; Shelat et al., 2008). 
Moreover, the pathological breakdown of phosphatidylcholine and production 
of LPC by cPLA2 could induce neuronal sheath demyelination, axonal 
degeneration and neuronal apoptosis (Hall, 1972; Jean et al., 2002). In 
addition, reports have shown the direct effect of LPC on Aβ-induced neuronal 
apoptosis to be occurring through signal pathways of orphan G protein-
coupled receptors (Hall, 1972; Kabarowski et al., 2001; Qin et al., 2009). 
Hence, this study strongly suggested that cPLA2 activity may be a viable 
molecular target to halt the progression of neurodegeneration caused by 
p25/Cdk5 hyperactivation. Indeed, the novel findings from this study will 
assist the identification of early detection and possible therapeutic targets for 
various neurodegenerative diseases especially AD. Key findings from Chapter 




Figure 6.2: Schematic representation of the mechanism behind the p25/Cdk5-
mediated neuroinflammation  
Neurotoxic insults-induced Ca2
+ 
influx and subsequent intense calpain activation 
cause Cdk5 hyperactivation via the abnormal production of p25 from p35. 
Successively, p25/Cdk5 hyperactivation causes increase in cytosolic phospholipase 
A2 (cPLA2) production/activation which in turn releases extracellular soluble 
lysophosphatidylcholine (LPC) from phosphatidylcholine (PC). LPC activates 





CD8+ lymphocytes infiltration which are the main indicators for severe 
neuroinflammation. Subsequently, these inflammatory mediators induce progression 
of neurodegeneration in neurons expressing p25. 
 
 
Results from in vitro studies in chapter 4 showed that inhibiting early events 
of neuroinflammation during p25 overexpression could prevent the 
progression of p25-mediated neuropathology. Therefore, extension of this 
study using in vivo experiments is vital to further support the research in AD 
therapy development. Moreover, it is important to select a compound that is 
chronically active against the sustained neuroinflammation and can cross the 
BBB without any adverse side effects. One such candidate is curcumin, a 
naturally available multipotent polyphenol present in turmeric, a spice 
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commonly found in the Indian diet. Various clinical trials with curcumin have 
been conducted for inflammation-associated diseases and curcumin was found 
to be effective against cancer, diabetes, stroke, atherosclerosis and brain 
trauma (Aggarwal et al., 2007; Begum et al., 2008; Jagtap et al., 2009; Basnet 
and Skalko-Basnet, 2011). Therefore, experiments in Chapter 5 aimed to 
determine the effects of early intervention of p25-mediated neuroinflammation 
in the progression of neurodegeneration in p25Tg mice by using a special 
formulation of curcumin (“LONGVIDA”) prepared under a novel SLCP (solid 
lipid curcumin particle preparation) technology. Studies with this new 
formulation have shown increased free curcumin levels in plasma as well as in 
brain in both human and mice models (Begum et al., 2008; Gota et al., 2010; 
Dadhaniya et al., 2011). 
Results from Chapter 5 showed that curcumin attenuated the p25-mediated 
neuroinflammatory events, in particular astrocyte activation and pro-
inflammatory chemokines/cytokines production, in p25Tg mice (Figures 5.2 
and 5.3). Results also suggested that the actual mechanism behind this 
curcumin effect might be through the inhibition of p25-mediated cPLA2 
upregulation and LPC production (Figure 5.8). In addition, curcumin 
efficiently reduced p25-mediated over-production of NF-κB, the master 
regulator for various inflammatory events including cPLA2 expression (Figure 
5.8). Furthermore, experiments were next focused on examining whether this 
curcumin-mediated attenuation of p25-induced neuroinflammatory triggers 
has any effect on the neurodegenerative progression in p25Tg mice. 
Interestingly, there was a marked reduction in tau hyperphosphorylation and 
amyloid accumulations after curcumin treatment in 12-week induced p25Tg 
mice (Figures 5.9, 5.10 and 5.11). Curcumin treatment might mediate these 
effects via multiple ways and should be investigated carefully. This thesis 
proposed a few hypotheses. Firstly, curcumin might inhibit the 
neuroinflammation-triggered initiation of neurodegeneration. Secondly, results 
in Chapter 5 showed that curcumin may act directly at the level of Cdk5 and 
reduce its hyperactivation (Figure 5.4). Curcumin-mediated reduction in 
neurotoxicity could lead to the decrease in feed-forward mechanism-based 
elevation of Cdk5 activity in p25Tg mice. Furthermore, results in Chapter 5 
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also indicated that curcumin altered the microglia/macrophage phenotype from 
a pro-inflammatory to an anti-inflammatory state (Figures 5.5, 5.6 and 5.7). 
Previous studies reported that curcumin clears amyloid burden via the 
regulation of phagocytic ability of microglia, macrophages and monocytes 
(Cole et al., 2007; Gagliardi et al., 2011) and hence one hypothesis could be 
that curcumin treatment may alter or improve the phagocytic ability of 
microglia and CNS-infiltrating immune cells in p25Tg mice. However, further 
investigation should be undertaken to fully validate this concept. Results in 
Chapter 5 also showed that curcumin effectively reversed the p25-mediated 
neuronal apoptosis and memory deficits in p25Tg mice via its anti-
inflammatory, anti-amyloidogenic and anti-oxidant properties (Figure 5.12). 
The neuroprotective effects of curcumin against the p25-mediated 
neuroinflammation and subsequent neurodegeneration is summarized in 
Figure 6.3. Collectively, results in Chapter 5 demonstrated that curcumin; a 
multipotent natural compound, could be a promising tool to treat 
neuroinflammation-associated neurodegenerative diseases including AD.  
 
Figure 6.3: Summary of effects of curcumin on p25/Cdk5-mediated 
neuroinflammation and subsequent neurodegeneration 
Red indicator symbolizes the inhibitory effect of curcumin and green arrow 
represents the positive effect of curcumin 
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6.2 Caveats and Future works 
Results from this thesis identified that cPLA2 overexpression is a crucial event 
in p25/Cdk5-associated neurodegeneration and inhibition of cPLA2 activity 
could be a viable therapeutic approach in AD. However, further experimental 
investigations in this area are necessary in order to achieve a clear 
understanding of the mechanism behind neuroinflammation. Firstly, it is 
essential to extend the investigation to study the effects of specific inhibition 
of cPLA2 on the progression of neurodegeneration in p25Tg mice. However, 
cPLA2 gene silencing using shRNA lentiviruses in p25Tg mice would be 
challenging and would probably require many injections with shRNA virus to 
achieve extended in vivo knock-down of cPLA2 overexpression caused by p25 
elevation. Therefore, another possible way to do this in vivo investigation 
could be to use a cPLA2 inhibitor with adequate potency to inhibit the early 
inflammatory changes during p25 overexpression in p25Tg mice. However, 
currently there are no chronically active and brain-penetrant specific inhibitors 
of cPLA2 (Farooqui et al., 2006). Hence, it is critical to develop small 
molecule inhibitors specific to cPLA2 and investigate the effect of those 
compounds in p25Tg mice. Our laboratory has recently been involved in the 
development of such small molecule specific inhibitors for cPLA2 based on 
the knowledge of the structure of commercially available cPLA2 inhibitors 
and a cPLA2 X-ray structure. Molecules will be tested in vitro (p25-LV 
transduced cortical neurons) and then in vivo in various AD mouse models 
including p25Tg mice and results from this future project will certainly pave 
the way to the discovery of an effective drug against the neuroinflammation-
associated neurodegenerative diseases.     
The next key area that requires further investigation is the link between p25 
overexpression and cPLA2 upregulation. Although Western blot results from 
this thesis supported the hypothesis that p25 might regulate cPLA2 expression 
via the NF-κB pathway, it is important to delineate the exact interaction 
between p25/Cdk5 hyperactivation and the NF-kB pathway. In addition, it 
would be interesting to find out the possibility of involvement and interaction 
of other major transcription factors in the p25/Cdk5-mediated cPLA2 
upregulation. One possible way to do this investigation could be to perform 
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chromatin immunoprecipitation assay coupled with DNA microarrays (ChIP-
on-chip assay) using RNA samples from p25 overexpressing neurons. Results 
from this study will certainly add more value to the future development of 
effective biomarkers for the early detection and prevention of AD.    
The aberrant p25/Cdk5 complex which is involved in the formation of major 
AD pathological hallmarks such as Aβ plaques, NFTs, and neuroinflammatory 
changes, can be a good candidate for the disease modifying therapies. 
Therefore, targeting either the Cdk5 hyperactivation directly or the secondary 
events mediated by Cdk5 hyperactivation could be a viable avenue for 
developing effective treatment strategies to combat the early events of 
pathological changes in various neurodegenerative diseases. More recently, 
studies have shown that silencing Cdk5 using lentiviral or adeno-associated 
viral vectors markedly reduced the formation of neurofibrillary tangles in AD 
mouse models (Piedrahita et al., 2010). Furthermore, the effects of Cdk5 
kinase inhibitors that target ATP binding sites have also been studied recently 
(Helal et al., 2004; Helal et al., 2009). However, these compounds not only do 
not specifically target p25/Cdk5, but they also inhibit p35/Cdk5 activity, 
interfering with normal Cdk5 activity and causing deleterious side effects. In 
recent years, Dr. Harish C. Pant and his colleagues have successfully 
generated truncated peptides of p35 including Cdk5 inhibitor peptide (CIP) (a 
125-residue peptide) and p5 (a 24-residue peptide) and previous in vitro 
studies demonstrated that both CIP and p5 were specific inhibitors against 
p25/Cdk5-mediated neuropathological developments, without affecting 
normal p35/Cdk5 activity (Zheng et al., 2002; Zheng et al., 2005; Kesavapany 
et al., 2007; Zheng et al., 2010). Moreover, a recent in vivo study by our group 
further supported the above in vitro findings using transgenic mice that 
overexpress both CIP and p25 in the forebrain. Results confirmed a 
remarkable reduction in hyperphosphorylated tau, amyloid accumulations and 
brain atrophy in these mice (Sundaram et al., 2013). However, 
neuroinflammation was not completely reversed as compared to the amyloid 
pathology in these mice. Therefore, it would be interesting to investigate 
whether curcumin can be additive to this protection in addition to the CIP 
effect to bring about a complete reversal of p25-mediated neurotoxicity. 
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Furthermore, this combinational therapy could be effective against multi-
factorial neurodegenerative diseases. Since p5, the further truncated product of 
CIP was also found to be effective specifically against p25/Cdk5 
hyperactivation, it would be interesting to extend the investigation with the 
combination of p5 peptide and curcumin in p25 transgenic mice. Together, 
consistent progress in the investigation of independent treatment strategies 
such as specific inhibition of p25/Cdk5 hyperactivation, and early inhibition of 
neuroinflammation using curcumin in the field of Cdk5-associated 
neurodegenerative diseases strongly recommend the use of combinational 
therapy to target both events simultaneously so as to promote an improved 
therapeutic approach. Furthermore, careful and stringent evaluation of these 
promising candidates in other AD transgenic mouse models or in other 
neurodegenerative disease models would afford the necessary pre-clinical 
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Supplementary Figures   
 
Supplementary Figure 1: 
 
Astrogliosis in p25 transgenic mice  
Representative immunofluorescence images of hippocampus (CA3 region) 
from 1, 4, 8 and 12-week induced p25Tg and their respective age-matched 
control (Ctrl) mice brain sections stained with anti-GFAP antibody (red) and 
nuclei were stained with DAPI (blue). Scale bars represent 50µm and images 















Supplementary Figure 2: 
 
 
Endogenous p35 expression and exogenous p25 expression levels in p25Tg 
mice 
Western blot results of brain lysates from the (A) 4-week  and  (B) 12-week 
induced p25Tg mice with normal feed (NFBT), p25Tg mice with curcumin 
feed (CFBT), respective age-matched WT mice with normal feed (NFWT) and 
WT mice with curcumin feed (CFWT) using anti-C19 antibody (n=3). 
Membranes were re-probed with anti-tubulin antibody which acts as a loading 
control. 
